Patent Application
20190315716
Compounds of formula (I) and methods for inhibiting Mer kinases are disclosed. Additionally, the present disclosure relates to compositions containing compounds of the present disclosure and methods for their use.
Receptor tyrosine kinases (RTKs) are enzymes that can phosphorylate specific tyrosine residues in target proteins, using ATP and share a highly conserved catalytic domain. The conservation makes it hard to develop a selective tyrosine kinase inhibitor (TKI). The TAM receptor family consists of Tyro3, Axl, and Mer, which play important roles in hemostasis and inflammation. Mer is, especially, a key regulator of macrophage activation and promotes apoptotic cell clearance. Moreover, Mer is abnormally expressed and activated in human cancers such as pituitary adenomas, mantle cell lymphomas, and T-cell acute lymphoblastic leukemia.
Since ATP-binding site is similar for all protein kinases, it is challenging to find an inhibitor that is specific for the Mer. Compound-52, a 2,6,9-trisubstituted purine that competitively binds to the ATP binding pocket, was actually the first molecule that was found to be successful in inhibiting Mer (J Struct Biol. 2009 February; 165(2): 88-96). This inhibitor has, however, limited potency and lack of selectivity. Lately, several compounds have been discovered mostly by modifying Compound-52 including UNC-569, UNC-1062, and UNC-2025 (ACS Med Chem Lett. 2012 Feb. 9; 3(2):129-134, Eur J Med Chem. 2013 July; 65:83-93, J Med Chem. 2014 Aug. 28; 57(16):7031-41). And quite recently, highly potent and selective Mer kinase inhibitors were disclosed based on aminopyridine or aminopyrimidine scaffolds (US20170066742, Ser. No. 15/253,773).
It is an object of the invention to provide reagents and methods of regulating a receptor tyrosine kinase Mer. This and other objects of the invention are provided by one or more of the embodiments described below.
The present invention provides novel compounds capable of selectively inhibiting Mer kinase, which compounds are useful for the prevention and/or the treatment of cancer and other immune-related disease such as infection and sepsis. Highly potent and selective receptor tyrosine kinase Mer inhibitors based on several heteroaryl scaffolds, including aminopyridine and 7-azaindole are described. Such compounds have the following formula (I).
The present disclosure is directed to compounds having a structure of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is
X is —C(═O)O—, —C(═O)N(R8)—, —C(═O)N(R8)CH2—, —SO2N(R8)—, —N(R8)—, —O—, or —S—;
n is 1 or 2;
p is 1, 2, or 3;
L is none, C1-3 alkyl, C2-3 alkenyl, C1-3 alkyl-O—, C1-3 alkyl-O—C1-3alkyl, —C(═O)—, —C(═O)—C(═O)—, —C(═O)O—, —C(═O)N(R8)—, —C(═S)N(R8)—(CR12R13)m—, —C(═S)—, —C(═S)O—, —SO2—, —SO2—(CH2)m—, —(CR12R13)m—C(═O)(CR12R13)m—, —C(═O)O(CR12R13)m—, —C(═O)—CR1═CR13—, or —CHR14;
R1 is H, halogen, C1-3 alkyl, —NH(R8), —OR8 or —(CH2)l—NR12R13;
R2 is —Br, —Cl, —CN, cycloalkenyl, C2-6 alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocycle, C1-2 alkylaryl, C1-2 alkylheteroaryl, or C1-2 alkylheterocycle, which aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle may optionally be substituted with one or more R18;
R3 is halogen, cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle which cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle, may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are the same as or different from each other, and are each independently H, halogen, C1-3 alkyl, —OR21; —OCH2R21; —C(═O)NHR21, —C(═O)OR21, —C(═O)SR21; —C(═O)S—SR21, —CH2OR21, or —CH2NHR21;
R8 is H, C1-6 alkyl, C1-3 alkylaryl, or C1-3 alkylheteroaryl which C1-6 alkyl, C1-3 alkylaryl or C1-3 alkylheteroaryl may optionally be substituted with one or more R9;
when R1 is —NH(R8)— and X is —C(═O)N(R8)—, the R8 groups together may be —CH2—, forming a ring with the nitrogen atoms to which they are attached;
R9 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, -J9-NR10R11, -J9-COOR8, -J9-alkyl, -J9-C3-10 cycloalkyl, -J9-cycloalkenyl, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl, which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J9-alkyl, -J9-C3-10 cycloalky, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl, may be substituted with one or more R16;
R10 and R11 each independently is H, C1-6 alkyl, C3-10 cycloalkyl or SO2R8;
R12 and R13 each independently is H, C1-6 alkyl, or C3-10 cycloalkyl;
R12 and R13 together with the carbon atom to which they are attached may form a C3-6 cycloalkyl;
R14 is —C(═O)NHR15, —C(═O)OR15, —CH2OR15, or —CH2NHR15;
R15 is H, or C1-3 alkyl;
R16 is halogen, hydroxyl, —CN, —CHO, —NR10R11, —NO2, C1-6 alkyl, (═O), C3-10 cycloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, aryl, heterocycle, -J16-alkyl, -J16-aryl, -J16-heterocycle, —(CH2)l—NR10R11, —(CH2)l—COOR8, or —(CH2)l—C(═O)—NR10R11, which -J16-heterocycle may be substituted with one or more R17;
R17 is C1-6 alkyl, C1-4 hydroxyalkyl, or C1-4 aminoalkyl;
R18 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, J18-NR10R11, -J18-COOR8, -J18-alkyl, -J18-C3-10 cycloalkyl, -J18-cycloalkenyl, -J18-heterocycle, -J18-heteroaryl, or -J18-aryl, which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J18-alkyl, -J18-C3-10 cycloalky, -J18-heterocycle, -J18-heteroaryl, or -J18-aryl, may be substituted with one or more R19;
R19 is halogen, hydroxyl, —CN, —CHO, —NR10R11, —NO2, C1-6 alkyl, (═O), C3-10 cycloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, aryl, heterocycle, -J19-alkyl, -J19-aryl, -J19-heterocycle, —(CH2)l—NR10R11, —(CH2)l—COOR8, or —(CH2)l—C(═O)—NR10R11, which -J19 heterocycle may be substituted with one or more R20;
R20 is —NO2, C1-6 alkyl, C1-4 hydroxyalkyl, or C1-4 aminoalkyl;
R21 is H, halogen, C1-6 alkyl, cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle which cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle, may optionally be substituted with one or more R22;
R22 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, -J22-NR10R11, -J22-COOR8, -J22 alkyl, -J22-C3-10 cycloalkyl, -J22-cycloalkenyl, -J22-heterocycle, -J22-heteroaryl, or -J22-aryl, which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J22-alkyl, -J22-C3-10 cycloalkyl, -J22-heterocycle, -J22-heteroaryl, or -J22-aryl, may be substituted with one or more R23;
R23 is C1-6 alkyl;
R24 is —CN, —(CH2)l—OR8, —(CH2)l—N(R)2, or C1-3 alkyl;
J9 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2—;
J16 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, or —SO2—;
J18 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2—;
J19 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, or —SO2—;
J22 is C1-3 alkyl, C1-3 alkyl-O—, or —O—; and
l and m each independently is an integer of 0 to 3;
with the proviso that when Ring A is
then R2 is not
Another aspect of the present disclosure relates to pharmaceutical compositions comprising compounds of the present disclosure or pharmaceutically acceptable salts thereof, and a pharmaceutical carrier.
Moreover, the compounds of the present disclosure or pharmaceutically acceptable salts thereof, useful in the pharmaceutical compositions and treatment methods disclosed herein, are pharmaceutically acceptable as prepared and used.
In embodiments, the present disclosure relates to a method of modulating the Mer tyrosine kinase receptor activity. This method is useful for the prevention and/or the treatment of cancer and other immune-related disease such as infection and sepsis. Accordingly, the compounds and compositions of the present disclosure are useful as a medicament for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions.
These and other objects of the present disclosure are described in the following paragraphs. These objects should not be deemed to narrow the scope of the present disclosure.
Disclosed herein are compounds of formula (I), or a pharmaceutically acceptable salt thereof,
wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are defined above in the Summary and below in the Detailed Description. Further, compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also described.
Compounds included herein may contain one or more variable(s) that occur more than one time in any substituent or in the formulae herein. Definition of a variable on each occurrence is independent of its definition at another occurrence. Further, combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds, which can be isolated from a reaction mixture.
It is noted that, as used in this specification and the intended claims, the singular form “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes a single compound as well as one or more of the same or different compounds, reference to “optionally a pharmaceutically acceptable carrier” refers to a single optional pharmaceutically acceptable carrier as well as one or more pharmaceutically acceptable carriers, and the like.
As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:
The term “alkenyl” as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to buta-1,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.
The term “alkoxy” as used herein, means a C1-C6 alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative, non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
The term “alkyl” as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term “lower alkyl” or “C1-C6alkyl” means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms. The term “C1-3alkyl” or “C1-C3alkyl” means a straight or branched chain hydrocarbon containing from 1 to 3 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
The term “alkylene” or “alkylenyl” denotes a divalent group derived from a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkylene include, but are not limited to, —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, and —CH2CH(CH3)CH2—.
The term “alkynyl” as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term “aminoalkyl” as used herein, means a C1-C6 alkyl group, as defined herein, which is substituted by a —NH2 group substituent. Representative, non-limiting examples of alkoxy include aminomethyl, 1-aminoethyl, 2-aminoethyl, 1-aminopropyl, 2-aminopropyl, 3-aminopropyl.
The term “aryl” as used herein, means phenyl or a bicyclic aryl. The bicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl, or a phenyl fused to a monocyclic cycloalkenyl. Representative examples of the aryl groups include, but are not limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl. The bicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the bicyclic ring system. The aryl groups of the present disclosure can be unsubstituted or substituted.
The term “biaryl” as used herein, means a group comprising two aryl groups joined by a single bond. The aryl group may be phenyl or a bicyclic aryl.
The term “carbonyl” as used herein means a —C(═O)— group.
The term “cyano” as used herein, means a —CN group.
The term “cycloalkenyl” or “cycloalkene” as used herein, means a monocyclic or a bicyclic hydrocarbon ring system. The monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five- or six-membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two or three double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. The bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group, or a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge containing one, two, three, or four carbon atoms. Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl and 1,6-dihydro-pentalene. The monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems, and can be unsubstituted or substituted.
The term “cycloalkyl” or “cycloalkane” as used herein, means a monocyclic, a bicyclic, a tricyclic, or a spirocyclic cycloalkyl. The monocyclic cycloalkyl is a carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bicyclic cycloalkyl is a monocyclic cycloalkyl fused to a monocyclic cycloalkyl ring, or a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge containing one, two, three, or four carbon atoms. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Tricyclic cycloalkyls are exemplified by a bicyclic cycloalkyl fused to a monocyclic cycloalkyl, or a bicyclic cycloalkyl in which two non-adjacent carbon atoms of the ring systems are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.03,7]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.13,7]decane (adamantane). The monocyclic, bicyclic, and tricyclic cycloalkyls can be unsubstituted or substituted, and are attached to the parent molecular moiety through any substitutable atom contained within the ring system. Spirocyclic cycloalkyl is exemplified by a monocyclic or a bicyclic cycloalkyl, wherein two of the substituents on the same carbon atom of the ring, together with said carbon atom, form a 4-, 5-, or 6-membered monocyclic cycloalkyl. An example of a spirocyclic cycloalkyl is spiro[2.5]octane. The spirocyclic cycloalkyl groups of the invention can be appended to the parent molecular moiety through any substitutable carbon atom of the groups. In a bridged cycloalkyl, the rings share at least two non-adjacent atoms. Examples of bridged cycloalkyls include, but are not limited to, bicyclo[1.1.1]pentanyl, bicyclo[2.2.2]octanyl, bicyclo[3.2.1]octanyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, tricyclo[3.3.1.03,7]nonyl (octahydro-2,5-methanopentalenyl or noradamantyl), tricyclo[3.3.1.13,7]decyl (adamantyl), and tricyclo[4.3.1.13,8]undecyl (homoadamantyl). In a fused ring cycloalkyl, the rings share one common bond. Example of fused-ring cycloalkyl include, but not limited to, decalin (decahydronaphthyl).
The term “halo” or “halogen” as used herein, means Cl, Br, I, and F.
The term “haloalkyl” as used herein, means an alkyl group, as defined herein, in which one, two, three, four, five, six, seven or eight hydrogen atoms are replaced by halogen. Representative examples ofhaloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and trifluoropropyl such as 3,3,3-trifluoropropyl.
The term “heteroaryl” as used herein, means a monocyclic heteroaryl or a bicyclic heteroaryl. The monocyclic heteroaryl is a five- or six-membered hydrocarbon ring wherein at least one carbon ring atom is replaced by heteroatom independently selected from the group consisting of O, N, and S. The five-membered ring contains two double bonds. The five-membered ring may contain one heteroatom selected from O, N, or S; or one, two, three, or four nitrogen atoms and optionally one oxygen or sulfur atom. The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms. Representative examples of monocyclic heteroaryl include, but are not limited to, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle. Representative examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, 6,7-dihydro-1,3-benzothiazolyl, imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, naphthyridinyl, pyridoimidazolyl, quinolinyl, thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-d]pyrimidin-2-yl, and 5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and bicyclic heteroaryl groups of the invention can be substituted or unsubstituted and are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the ring systems.
The term “heterobiaryl” as used herein, means a group comprising two heteroaryl groups joined by a single bond, or a group comprising one aryl and one heteroaryl group joined by a single bond. The aryl group may be phenyl or a bicyclic aryl. The heteroaryl group may be a monocyclic heteroaryl or a bicyclic heteroaryl
The term “heterocycle” or “heterocyclic” or “heterocyclyl” as used herein, means a monocyclic heterocycle, a bicyclic heterocycle, a tricyclic heterocycle, or a spirocyclic heterocycle. The monocyclic heterocycle is a three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The three- or four-membered ring contains zero or one double bond, and one heteroatom selected from the group consisting of O, N, and S. The five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The six-membered ring contains zero, one or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. The seven- and eight-membered rings contains zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Representative examples of monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, 1,2-thiazinanyl, 1,3-thiazinanyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non-adjacent atoms of the ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms. Representative examples of bicyclic heterocycles include, but are not limited to, benzopyranyl, benzothiopyranyl, chromanyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, 2,3-dihydroisoquinoline, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl), 2,3-dihydro-1H-indolyl, isoindolinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolopyridinyl, and tetrahydroisoquinolinyl. Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle, or a bicyclic heterocycle in which two non-adjacent atoms of the bicyclic ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms. Examples of tricyclic heterocycles include, but not limited to, octahydro-2,5-epoxypentalene, hexahydro-2H-2,5-methanocyclopenta[b]furan, hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-adamantane (1-azatricyclo[3.3.1.13,7]decane), oxa-adamantane (2-oxatricyclo[3.3.1.13,7]decane), and octahydro-1H-4,7-epiminoisoindole. The spirocyclic heterocycles are exemplified by a monocyclic heterocycle as defined herein wherein one carbon atom of the monocyclic heterocycle is bridged by two ends of an alkylene chain. In the spirocyclic heterocycle, one or more carbon atoms in the bridging alkylene chain may be replaced with a heteroatom. Examples of spirocyclic heterocycles include, but are not limited to, 4,7-diazaspiro[2.5]octane, 2-oxa-6-azaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2-oxa-5,8-diazaspiro[3.5]nonane, 2,7-diazaspiro[3.5]nonane, 1,4-dioxa-8-azaspiro[4.5]decane, 1,6-diazaspiro[3.3]heptane, 1-azaspiro[4.4]nonane, 7-azaspiro[3.5]nonane, 1,4-dioxa-7-azaspiro[4.4]nonane, 5,8-diazaspiro[3.5]nonane, 5,8-dioxa-2-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 6-oxa-1-azaspiro[3.3]heptane, 6-oxa-2-azaspiro[3.4]octane, 6-oxa-2-azaspiro[3.5]nonane, and 7-oxa-2-azaspiro[3.5]nonane. The monocyclic, bicyclic, tricyclic, and spirocyclic heterocycles are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the rings, and can be unsubstituted or substituted.
The term “heteroatom” as used herein, means a nitrogen, oxygen, and sulfur.
The term “hydroxyl” or “hydroxy” as used herein, means an —OH group.
The term “hydroxyalkyl” as used herein, means a C1-C6 alkyl group, as defined herein, which is substituted by an —OH group substituent. Representative, non-limiting examples of alkoxy include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, and 3-hydroxypropyl.
The term “oxo” as used herein, means a═O group.
In some instances, the number of carbon atoms in a hydrocarbyl substituent (e.g., alkyl, alkenyl, alkynyl, or cycloalkyl) is indicated by the prefix “Cx-Cy” or “Cx-y”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, “C1-C6alkyl” refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C3-C6cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms.
Where a group is a divalent group, the group may be attached in any order to the two groups to which it is attached. By way of example, when W and V are attached by the divalent group —CH2O— this will be understood to include W—CH2O—V and V—CH2O—W.
As used herein, the term “radiolabel” refers to a compound of the invention in which at least one of the atoms is a radioactive atom or radioactive isotope, wherein the radioactive atom or isotope spontaneously emits gamma rays or energetic particles, for example alpha particles or beta particles, or positrons. Examples of such radioactive atoms include, but are not limited to, 3H (tritium), 14C, 11C, 15O, 18F, 35S, 123I, and 125I.
If a moiety is described as “substituted”, a non-hydrogen radical is in the place of hydrogen radical of any substitutable atom of the moiety. Thus, for example, a substituted heterocycle moiety is a heterocycle moiety in which at least one non-hydrogen radical is in the place of a hydrogen radical on the heterocycle. It should be recognized that if there are more than one substitution on a moiety, each non-hydrogen radical may be identical or different (unless otherwise stated).
If a moiety is described as being “optionally substituted,” the moiety may be either (1) not substituted or (2) substituted. If a moiety is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that moiety may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the moiety, whichever is less. Thus, for example, if a moiety is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.
The terms “treat”, “treating”, and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms. In certain embodiments, “treat,” “treating,” and “treatment” refer to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treat”, “treating”, and “treatment” refer to modulating the disease or disorder, either physically (for example, stabilization of a discernible symptom), physiologically (for example, stabilization of a physical parameter), or both. In a further embodiment, “treat”, “treating”, and “treatment” refer to slowing the progression of the disease or disorder.
The terms “prevent”, “preventing”, and “prevention” refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, “prevent”, “preventing” and “prevention” also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring or developing a disease or disorder.
The phrase “therapeutically effective amount” means an amount of a compound, or a pharmaceutically acceptable salt thereof, sufficient to prevent the development of or to alleviate to some extent one or more of the symptoms of the condition or disorder being treated when administered alone or in conjunction with another therapeutic agent or treatment in a particular subject or subject population. For example in a human or other mammal, a therapeutically effective amount can be determined experimentally in a laboratory or clinical setting, or may be the amount required by the guidelines of the United States Food and Drug Administration, or equivalent foreign agency, for the particular disease and subject being treated.
The term “subject” is defined herein to refer to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, pigs, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human. The terms “human”, “patient”, and “subject” are used interchangeably herein.
In one embodiment, compounds of the present disclosure are represented by formula (I) as described in the Summary.
In one embodiment, compounds of the present disclosure are represented by formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is
X is —C(═O)O—, —C(═O)N(R8)—, —C(═O)N(R8)CH2—, —SO2N(R8)—, —N(R8)—, —O—, or —S—;
L is none, C1-3 alkyl, C2-3 alkenyl, C1-3 alkyl-O—, C1-3 alkyl-O—C1-3alkyl, —C(═O)—, —C(═O)—C(═O)—, —C(═O)O—, —C(═O)N(R8)—, —C(═S)N(R8)—(CR12R13)m—, —C(═S)—, —C(═S)O—, —SO2—, —SO2—(CH2)m—, —(CR12R13)m—C(═O)—(CR12R13)m—, —C(═O)O(CR12R13)m—, —C(═O)—CR12═CR13—, or —CHR14;
R1 is H, halogen, C1-3 alkyl, —NH(R8)—, —OR8 or —(CH2)l—NR12R13;
R2 is —Br, —Cl, —CN, cycloalkenyl, C2-6 alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocycle, C1-2 alkylaryl, C1-2 alkylheteroaryl, or C1-2 alkylheterocycle which aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle may optionally be substituted with one or more R18;
R3 is halogen, cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle which cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle, may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are the same as or different from each other, and are each independently H, halogen, C1-3 alkyl, —OR21; —OCH2R21; —C(═O)NHR21, —C(═)OR21, —C(═O)SR21; —C(═O)S—SR21, —CH2OR21, or —CH2NHR21;
R8 is H, C1-6 alkyl, C1-3 alkylaryl, or C1-3 alkylheteroaryl which C1-6 alkyl, C1-3 alkylaryl or C1-3 alkylheteroaryl may optionally be substituted with one or more R9;
when R1 is —NH(R8)— and X is —C(═O)N(R8)—, the R8 groups together may be —CH2—, forming a ring with the nitrogen atoms to which they are attached;
R9 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, -J9-NR10R11, -J9-COOR8, -J9-alkyl, -J9-C3-10 cycloalkyl, -J9-cycloalkenyl, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J9-alkyl, -J9-C3-10 cycloalky, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl, may be substituted with one or more R16;
R10 and R11 each independently is H, C1-6 alkyl, C3-10 cycloalkyl or SO2R8;
R12 and R13 each independently is H, C1-6 alkyl, or C3-10 cycloalkyl;
R12 and R13 together with the carbon atom to which they are attached may form a C3-6 cycloalkyl;
R14 is —C(═O)NHR15, —C(═O)OR15, —CH2OR15, or —CH2NHR15;
R15 is H, or C1-3 alkyl;
R16 is halogen, hydroxyl, —CN, —CHO, —NR10R11, —NO2, C1-6 alkyl, (═O), C3-10 cycloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, aryl, heterocycle, -J16-alkyl, -J16-aryl, -J 6-heterocycle, —(CH2)l—NR10R11, —(CH2)l—COOR8, or —(CH2)l—C(═O)—NR10R11, which -J16-heterocycle may be substituted with one or more R17;
R17 is C1-6 alkyl, C1-4 hydroxyalkyl, or C1-4 aminoalkyl;
R18 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, J18-NR10R11, -J18-COOR8, -J18-alkyl, -J18-C3-10 cycloalkyl, -J18-cycloalkenyl, -J18-heterocycle, -J18-heteroaryl, or -J18-aryl which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J18-alkyl, -J18-C3-10 cycloalky, -J18-heterocycle, -J18-heteroaryl, or -J18-aryl may be substituted with one or more R19;
R19 is halogen, hydroxyl, —CN, —CHO, —NR10R11, —NO2, C1-6 alkyl, (═O), C3-10 cycloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, aryl, heterocycle, -J19-alkyl, -J19-aryl, -J19-heterocycle, —(CH2)l—NR10R11, —(CH2)l—COOR8, or —(CH2)l—C(═O)—NR10R11, which -J19-heterocycle may be substituted with one or more R20;
R20 is C1-6 alkyl, C1-4 hydroxyalkyl, or C1-4 aminoalkyl;
R21 is H, halogen, C1-6 alkyl, cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle which cycloalkyl, cycloalkenyl, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle, may optionally be substituted with one or more R22;
R22 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, -J22-NR10R11, -J22-COOR8, -J22-alkyl, -J22-C3-10 cycloalkyl, -J22-cycloalkenyl, -J22-heterocycle, -J22-heteroaryl, or -J22-aryl, which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J22-alkyl, -J22-C3-10 cycloalky, -J22-heterocycle, -J22-heteroaryl, or -J22-aryl may be substituted with one or more R23;
R23 is C1-6 alkyl;
R24 is —CN, —(CH2)l—OR8, —(CH2)l—N(R8)2, or C1-3 alkyl;
J9 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2;
J16 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, or —SO2—;
J18 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2—;
J19 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, or —SO2—;
J22 is C1-3 alkyl, C1-3 alkyl-O—, or —O—; and
l and m each independently is an integer of 0 to 3;
with the proviso that when Ring A is
then R2 is not
In one embodiment, compounds of the present disclosure are represented by formula (III):
or a pharmaceutically acceptable salt thereof; wherein:
R9 is F or Cl; and
q is 1, 2, or 3.
In another embodiment, the present disclosure relates to a heterocyclic compound represented by the following formula A, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof:
wherein
Ring A is a monocyclic or bicyclic ring selected from a 5 to 10-membered heteroaryl; wherein said heteroaryl contains from 0 to 3 ring heteroatoms independently selected from N, O, or S;
X is —C(═O)O—, —C(═O)N(R8)—, —SO2N(R8)—, —N(R8)—, —O—, or —S—;
n is 0, 1, 2, or 3;
p is 1, 2, or 3;
L is none, C1-3 alkyl, C2-3 alkenyl, C1-3 alkyl-O—, C1-3 alkyl-O—C1-3alkyl, —C(═O)—, —C(═O)O—, —C(═O)N(R8)—, C(═S)N(R8)—, —C(═S)—, —C(═S)O—, —SO2—(CH2)m—, —C(═O)—(CH2)m—, or —C(═O)—CH═CH—;
R1 is H, halogen, C1-3 alkyl, —NH(R8)—, or —OR8;
R2 is H, halogen, —CN, C1-3 alkyl, cycloalkenyl, C2-6 alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocycle, C1-2 alkylaryl, C1-2 alkylheteroaryl, or C1-2 alkylheterocycle which aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle may optionally be substituted with one or more R9;
R3 is H, halogen, aryl, biaryl, heteroaryl, heterobiaryl, or heterocycle, which aryl, biaryl, heteroaryl, heterobiaryl or heterocycle may optionally be substituted with one or more R9;
R4 to R7 are the same as or different from each other, and are each independently H, halogen, —C(═O)NHR3, —C(═O)OR3, —CH2OR3, or —CH2NHR3;
R8 is H, C1-6 alkyl, C1-3 alkylaryl, or C1-3 alkylheteroaryl which C1-6 alkyl, C1-3 alkylaryl or C1-3 alkylheteroaryl may optionally be substituted with one or more R9;
R9 is halogen, hydroxyl, —CN, —NO2, —COOH, —(C═O)H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, -J-NR10R11, -J-COOR8, -J-alkyl, -J-C3-10 cycloalkyl, -J-heterocycle, -J-heteroaryl, or -J-aryl which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, or aryl may be substituted with halogen, hydroxyl, —CN, —NR10R11, C1-6 alkyl, C3-10 cycloalkyl, C1-4 hydroxyalkyl, C2-6 alkenyl, aryl, heterocycle, -J-alkyl, -J-aryl, -J-heterocycle, or —(CH2)l—C(═O)—NR10R11;
R10 and R11 each independently is H, C1-6 alkyl, C3-10 cycloalkyl or SO2R8;
J is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CH2)l—NR8—(CH2)m—, —NH—C(═O)—CR10R11—NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, or —SO2—; and
l and m each independently is an integer of 0 to 3.
Particular values of variable groups in compounds of formula (I), (II), or (III) are as follows. Such values can be used where appropriate with any of the other values, definitions, claims or embodiments defined hereinbefore or hereinafter.
In one embodiment of formula (I), R4, R5, and R24 are H; n is 1; and A, X, R1, R2, R3, R6, R7, R24, L, and p are as defined for formula (I); with the proviso that when Ring A is
then R2 is not
In one embodiment of formula (I),
R4, R5, and R24 are H;
n is 1;
R6, and R7 are the same as or different from each other, and are each independently H, halogen, —OR 21; —OCH2R21; —C(═O)NHR21, —C(═O)OR21, —C(═O)SR21; —C(═O)S—SR21, —CH2OR21 or —CH2NHR21;
J9 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CH2)l—NR—(CR10R11)m—, —NH—C(═O)—CR10R11NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2—; and
A, X, R1, R2, R3, L, and p are as defined for formula (I);
with the proviso that when Ring A is
then R is not
In one embodiment of formula (II), R4, R5, and R24 are H; and A, X, R1, R2, R3, R6, R7, R24, and L, are as defined for formula (I); with the proviso that when Ring A is
then R2 is not
In one embodiment of formula (II),
R4, R5, and R24 are H;
R6, and R7 are the same as or different from each other, and are each independently H, halogen, —OR21; —OCH2R21; —C(═O)NHR21, —C(═O)OR21, —C(═O)SR21; —C(═O)S—SR21, —CH2OR21, or —CH2NHR21;
J9 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CH2)l—NHC(═O)—(CH2)m—, —(CH2)l—NR—(CR10R11)m—, —NH—C(═O)—CR10R11NH—C(═O)—, —NHC(═O)—, —O—, —O(C═O)—, —S—, —S(═O)—, —SO2—, or —NHSO2—; and
A, X, R1, R2, R3, and L, are as defined for formula (I);
with the proviso that when Ring A is
then R2 is not
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—; and
R1, R2, R3, R4, R5, R6, R7, R24, and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is —Br, —Cl, aryl, heteroaryl, or heterocycle, which aryl, heteroaryl, or heterocycle may optionally be substituted with one or more R1; and
R3, R4, R5, R6, R7, R8, R24 and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
R3, R4, R5, R6, R7, R24, and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—; and
R3, R4, R5, R6, R7, and R24, are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—;
R3 is aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R9; and
R4, R5, R6, R7, R9, and R24, are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1_3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—;
R3 is aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R9;
R9 is halogen, C1-6 alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl which alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl may be substituted with may be substituted with one or more R16;
R16 is —NR10R11, C1-6 alkyl, C1-4 hydroxyalkyl, or heterocycle; and
R4, R5, R6, R7, R10, R11, R24, and -J9 are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is —C(═O)—;
R3 is biphenyl substituted with one, two, or three R9;
R9 is halogen; and
R4, R5, R6 and R7 are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is phenyl, pyridyl, or pyrazole, which phenyl, pyridyl, or pyrazole may optionally be substituted with one or more R18;
R3 is biphenyl which may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are each independently H;
R8 is H;
R9 is halogen, or -J9-aryl which -J9-aryl, may be substituted with one or more R16;
R16 is —(CH2)l—NR10R11;
R18 is C1-6 alkyl, heterocycle, or -J18-heterocycle, which heterocycle, or -J18-heterocycle may be substituted with R19;
R19 is C1-6 alkyl;
R24 is H; and
J9 is —C(═O)NH—.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl which may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are each independently H;
R8 is H;
R9 is halogen, or -J9-aryl which -J9-aryl, may be substituted with one or more R16;
R16 is —(CH2)l—NR10R11;
R18 is C1-6 alkyl, heterocycle, or -J18-heterocycle, which heterocycle, or -J18-heterocycle may be substituted with R19;
R19 is C1-6 alkyl;
R24 is H; and
J9 is —C(═O)NH—.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)— or —N(R8)—;
L is —C(═O)—, —C(═O)O—, —C(═O)N(R8)—;
R1 is H or —NH2;
R2 is phenyl, pyridyl, or pyrazole which phenyl, pyridyl, or pyrazole may optionally be substituted with one or more R18;
R3 is phenyl or biphenyl which may optionally be substituted with one or more R9;
R4, R5, and R6, are each independently H;
R7 is H, halogen, —OR21; —C(═O)NHR21, —C(═O)OR21, or —CH2OR21;
R8 is H, or C1-6 alkyl;
R21 is H, C1-6 alkyl, aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R22;
R22 is halogen, C1-6 alkyl, heterocycle, -J22-NR10R11, -J22-heterocycle, or -J22-aryl, which alkyl, heterocycle, -J22-heterocycle or -J22-aryl, may be substituted with one or more R23;
R23 is C1-6 alkyl;
R24 is H; and
J22 is C1-3 alkyl, C1-3 alkyl-O—, or —O—.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl substituted with 1-3 R9;
R4, R5, R6 and R7 are each independently H;
R8 is H;
R9 is halogen; and
R24 is H.
In one embodiment of formula (II), Ring A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl substituted with 1-3 R9;
R4, R5, R6 and R7 are each independently H;
R8 is H;
R9 is halogen; and
R24 is H.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—; and
R1, R2, R3, R4, R5, R6, R7, R24, and L are as defined for formula (II);
with the proviso that R2 is not
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is —Br, —Cl, aryl, heteroaryl, or heterocycle, which aryl, heteroaryl, or heterocycle may optionally be substituted with one or more R18;
with the proviso that R2 is not
and
R3, R4, R5, R6, R7, R8, R24 and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
R3, R4, R5, R6, R7, R24, and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—; and
R3, R4, R5, R6, R7, and R24, are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—;
R3 is aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R9; and
R4, R5, R6, R7, R9, and R24, are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—;
R3 is aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R9;
R9 is halogen, C1-6 alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl which alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl may be substituted with may be substituted with one or more R16;
R16 is —NR10R11, C1-6 alkyl, C1-4 hydroxyalkyl, or heterocycle; and
R4, R5, R6, R7, R10, R11, R24, and -J9 are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
R1 is —NH2;
R2 is
L is —C(═O)—;
R3 is biphenyl substituted with one, two, or three R9;
R9 is halogen; and
R4, R5, R6, R7, and R24 are as defined for formula (II).
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is phenyl, pyridyl, or pyrazole, which phenyl, pyridyl, or pyrazole may optionally be substituted with one or more R18; with the proviso that R2 is not
R3 is biphenyl which may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are each independently H;
R8 is H;
R9 is halogen, or -J9-aryl which -J9-aryl, may be substituted with one or more R16;
R16 is —(CH2)l—NR10R11;
R18 is C1-6 alkyl, heterocycle, or -J18-heterocycle, which heterocycle, or -J18-heterocycle may be substituted with R19;
R19 is C1-6 alkyl;
R24 is H; and
J9 is —C(═O)NH—.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl which may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are each independently H;
R8 is H;
R9 is halogen, or -J9-aryl which -J9-aryl, may be substituted with one or more R16;
R16 is —(CH2)l—NR10R11;
R18 is C1-6 alkyl, heterocycle, or -J18-heterocycle, which heterocycle, or -J18-heterocycle may be substituted with R19;
R19 is C1-6 alkyl;
R24 is H; and
J9 is —C(═O)NH—.
In one embodiment of formula (II), A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl substituted with 1-3 R9;
R4, R5, R6 and R7 are each independently H;
R8 is H;
R9 is halogen; and
R24 is H.
In one embodiment of formula (II), Ring A is
X is —C(═O)N(R8)—;
L is —C(═O)—;
R1 is NH2;
R2 is
R3 is biphenyl substituted with 1-3 R9;
R4, R5, R6 and R7 are each independently H;
R8 is H;
R9 is halogen; and
R24 is H.
In one embodiment of formula (II), A is
and
A, R1, R2, R3, R4, R5, R6, R7, R24, X, and L are as defined for formula (II).
In one embodiment of formula (II), A is
X is —N(R8)—;
L is —C(═O)—;
R1 is H;
R2 is
R3 is phenyl or biphenyl each of which may optionally be substituted with one or more R9;
R4, R5, R6, and R7 are each independently H;
R8 is H;
R9 is halogen, C1-6 alkyl, heterocycle, -J9-heterocycle, or -J9-aryl which alkyl, heterocycle, or aryl, may be substituted with one or more R16;
R10 and R1 each independently is H, or C1-6 alkyl;
J9 is C1-3 alkyl, or —O—;
R16 is C1-6 alkyl, or —(CH2)l—NR10R11;
R24 is H; and
l and m each independently is an integer of 0 to 3.
In one embodiment of formula (III), q is 1; and R9 is F.
In one embodiment of formula (III), q is 1; and R9 is Cl.
In one embodiment of formula (III), q is 2; and both R9 are F.
In one embodiment of formula (III), q is 2; and both R9 are Cl.
In one embodiment of formula (III), q is 2; and one R9 is F; and the other R9 is Cl.
Particular values of variable groups in compounds of formula (I, II or III) are as follows. Such values can be used where appropriate with any of the other values, definitions, claims or embodiments defined hereinbefore or hereinafter.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), A is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), A is
with the proviso that R2 is not
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), A is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), A is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R1 is H, —NH(R8), or —(CH2)l—NR12R13; where R8, R12, and R13 are as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R1 is NH2.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is phenyl, pyridyl, or pyrazole, which phenyl, pyridyl, or pyrazole may optionally be substituted with one or more R18; where R18 is as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is —Br, aryl, heteroaryl, heterocycle, which aryl, heteroaryl, or heterocycle may optionally be substituted with one or more R18; where R18 is as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R2 is
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R3 is aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R9; where R9 is as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R3 is phenyl, naphthyl, biphenyl, phenyl-pyridine, phenyl-pyrazole, or phenyl-thiophene, which phenyl, naphthyl, biphenyl, phenyl-pyridine, phenyl-pyrazole, or phenyl-thiophene, may optionally be substituted with one or more R9; where R9 is as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R3 is biphenyl which may optionally be substituted with one or more R9; where R9 is as defined for formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R3 is biphenyl substituted with one or more halogen.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R3 is biphenyl substituted with one or more R9; where R9 is —F or —Cl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R4 is H and R5 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R4, R5, R6, and R7, are each independently H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R6 is H and R7 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R6 is H and R7 is H, halogen, —OR21; —OCH2R21; —C(═O)NHR21, —C(═O)OR21, —C(═O)SR21; —C(═O)S—SR21, —CH2OR21, or —CH2NHR21; where R21 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R6 is H and R7 is H, halogen, —OR21; —OCH2R21; —C(═O)NHR21, —C(═O)OR21, —C(═O)SR21; —C(═O)S—SR21, or —CH2OR21; where R21 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R8 is H or C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R8 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is halogen, hydroxyl, —CN, —NO2, —CHO, —COOH, C1-6 alkyl, C2-6 alkenyl, C1-6 aminoalkyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, cycloalkenyl, aryl, heterocycle, heteroaryl, —NR10R11, J9-NR10R11, -J9-COOR8, -J9-alkyl, -J9-C3-10 cycloalkyl, -J9-cycloalkenyl, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl, which alkyl, C1-6 alkoxy, C3-10 cycloalkyl, heterocycle, heteroaryl, aryl, -J9-alkyl, -J9-C3-10 cycloalky, -J9-heterocycle, -J9-heteroaryl, or -J9-aryl, may be substituted with one or more R16; where R10, R1, R16 and J9 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is halogen, C1-6 alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl which alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl, may be substituted with may substituted with one or more R16; where R16 and J9 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is halogen, C1-6 alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl which alkyl, aryl, heterocycle, -J9-heterocycle, or -J9-aryl, may be substituted with may substituted with one or more R16; and R16 is —NR10R11, C1-6 alkyl, C1-4 hydroxyalkyl, or heterocycle; where R10, R11, and J9 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is halogen, or -J9-aryl which -J9-aryl may substituted with one or more R16; R16 is —(CH2)l—NR10R11; J9 is —C(═O)NH; where R10 and R11 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is halogen.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R9 is F or Cl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R10 and R11 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R10 is H and R11 is C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R12 and R13 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R12 is H and R13 is C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R14 is —C(═O)NHR15, —C(═O)OR15, —CH2OR15; and R15 is H, or C1-3 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R14 is —C(═O)NHR15, —C(═O)OR15, —CH2OR15; and R15 is C1-3 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R16 is halogen, hydroxyl, —CN, —CHO, —NR10R11, —NO2, C1-6 alkyl, (═O), C1-4 hydroxyalkyl, C1-6 alkoxy, heterocycle, -J16-alkyl, -J16-heterocycle, —(CH2)l—NR10R11, —(CH2)l—COOR8, or —(CH2)l—C(═O)—NR10R11; where R10, R11, and J9 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R16 is —NR10R11, C1-6 alkyl, C1-4 hydroxyalkyl, or heterocycle; where R10 and R11 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R16 is R16 is C1-6 alkyl, or —(CH2)l—NR10R11; where R10, R11, and 1 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R16 is —(CH2)l—NR10R11; where R10, R11, and 1 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R17 is C1-6 alkyl or C1-4 hydroxyalkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R18 is halogen, hydroxyl, —CN, —CHO, —COOH, C1-6 alkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, heterocycle, NR10R11, -J18-NR10R11, -J18-alkyl, -J18-C3-10 cycloalkyl, -J18-heterocycle, which alkyl, C1-6 alkoxy, heterocycle, -J18-alkyl, -J18-C3-10 cycloalky, or -J18-heterocycle, may substituted with one or more R19; where R19 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R18 is C1-6 alkyl, heterocycle, or -J18-heterocycle, which heterocycle, or -J18-heterocycle may be substituted with R19; where R19 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R19 is hydroxyl, C1-6 alkyl, C1-4 hydroxyalkyl, C1-6 alkoxy, -J19-alkyl, -J19-aryl, -J19-heterocycle, which -J19-heterocycle may be substituted with one or more R20; where J19 and R20 are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R19 is C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R20 is —NO2, or C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R20 is C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R21 is H, C1-6 alkyl, aryl, biaryl, or heterobiaryl, which aryl, biaryl, or heterobiaryl, may optionally be substituted with one or more R22; where R22 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R22 is halogen, C1-6 alkyl, heterocycle, -J22-NR10R11, -J22-heterocycle, or -J22-aryl, which alkyl, heterocycle, -J22-heterocycle, or -J22-aryl may substituted with one or more R23; where R23 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R23 is C1-6 alkyl.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R24 is —(CH2)l—OR8.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), R24 is H.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J9 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CR10R11)l—NR—(CR10R11)m—, —NHC(═O)—, —O—, —S—, or —SO2—; where R8, R10, R11, 1 and m are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J9 is —C(═O)NH—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J9 is C1-3 alkyl or —O—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J16 is C1-3 alkyl, C1-3 alkyl-O—, C2-6 alkenyl, C2-6 alkynyl, —(CH2)l—C(═O)—(CH2)m—, —(CH2)l—CH═CH—C(═O)—(CH2)m—, —C(═O)O—, —(CH2)l—C(═O)NH—(CH2)m—, —(CR10R11)l—NR—(CR10R11)m—, —NHC(═O)—, —O—, —S—, or —SO2—; where R8, R10, R11, 1 and m are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J18 is C1-3 alkyl, —C(═O)—, —(CH2)l—C(═O)NH—(CH2)m—, —(CR10R11)l—NR8—(CR10R11)m—, —NHC(═O)—, —SO2—, or —NHSO2—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J19 is C1-3 alkyl, —C(═O)O—, or —SO2—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), J22 is C1-3 alkyl, C1-3 alkyl-O—, or —O—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), X is —C(═O)N(R8)—, —C(═O)N(R8)CH2—, or —N(R8)—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), X is —C(═O)N(R8)—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), X is —N(R8)—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), L is none, C1-3 alkyl, C2-3 alkenyl, C1-3 alkyl-O—, C1-3 alkyl-O—C1-3alkyl, —C(═O)—, —C(═O)—C(═O)—, —C(═O)O—, —C(═O)N(R8)—, —C(═S)N(R8)—(CR12R13)m—, —SO2—, —SO2—(CH2)m—, —(CR12R13)m—C(═O)—(CR13)m—, —C(═O)O(CR12R13)m—, —C(═O)—CR12═CR13—, or —CHR14; where R12, R13, R14, l and m are as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), L is C1-3 alkyl, C1-3 alkyl-O—, —C(═O)—, —C(═O)O—, or —C(═O)N(R8)—; where R8 is as defined in formula (I or II).
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), L is —C(═O)—, —C(═O)O—, —C(═O)N(R8)—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I or II), L is —C(═O)—.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), n is 1.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), n is 2.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), n is 1; and p is 1.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), n is 1; and p is 2.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), n is 1; and p is 3.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), p is 1.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), p is 2.
In one embodiment, in a compound or pharmaceutically acceptable salt of formula (I), p is 3.
Specific embodiments contemplated as part of the present disclosure also include, but are not limited to, compounds or pharmaceutically acceptable salts of formula (I), as defined, for example:
Compound names are assigned by using CHEMDRAW® ULTRA v. 12.0.2.1076 or CHEMDRAW® PROFESSIONAL v. 15.0.0.106.
Compounds of the present disclosure may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom. The terms “R” and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30. The present disclosure contemplates various stereoisomers and mixtures thereof and these are specifically included within the scope of this disclosure. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present disclosure may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by methods of resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Fumrniss, Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns or (3) fractional recrystallization methods.
Compounds of the present disclosure may exist as cis or trans isomers, wherein substituents on a ring may attached in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans). For example, cyclobutane may be present in the cis or trans configuration, and may be present as a single isomer or a mixture of the cis and trans isomers. Individual cis or trans isomers of compounds of the present disclosure may be prepared synthetically from commercially available starting materials using selective organic transformations, or prepared in single isomeric form by purification of mixtures of the cis and trans isomers. Such methods are well-known to those of ordinary skill in the art, and may include separation of isomers by recrystallization or chromatography.
It should be understood that the compounds of the present disclosure may possess tautomeric forms, as well as geometric isomers, and that these also constitute an aspect of the present disclosure.
The present disclosure includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compounds of the disclosure include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S. Certain isotopically-labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Thus, the formula drawings within this specification can represent only one of the possible tautomeric, geometric, or stereoisomeric forms. It is to be understood that the present disclosure encompasses any tautomeric, geometric, or stereoisomeric form, and mixtures thereof, and is not to be limited merely to any one tautomeric, geometric, or stereoisomeric form utilized within the formula drawings.
Present compounds may be used in the form of pharmaceutically acceptable salts. The phrase “pharmaceutically acceptable salt” means those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts have been described in S. M. Berge et al. J. Pharmaceutical Sciences, 1977, 66: 1-19.
Compounds of the present disclosure may contain either a basic or an acidic functionality, or both, and can be converted to a pharmaceutically acceptable salt, when desired, by using a suitable acid or base. The salts may be prepared in situ during the final isolation and purification of the compounds of the present disclosure.
The compounds of the present disclosure can be better understood in connection with the following synthetic schemes and methods which illustrate a means by which the compounds can be prepared.
The compounds of this disclosure can be prepared by a variety of synthetic procedures. Representative procedures are shown in, but are not limited to, Schemes 1 and 2.
One general approach to the compounds of this invention is illustrated in general Scheme 1.
Another general approach to the compounds of this invention is illustrated in general Scheme 2.
The compounds and intermediates of the present disclosure may be isolated and purified by methods well-known to those skilled in the art of organic synthesis. Examples of conventional methods for isolating and purifying compounds can include, but are not limited to, chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups, by recrystallization at high or low temperature with an optional pretreatment with activated carbon, thin-layer chromatography, distillation at various pressures, sublimation under vacuum, and trituration, as described for instance in “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989), by Fumrniss, Hannaford, Smith, and Tatchell, pub. Longman Scientific & Technical, Essex CM20 2JE, England.
Many of the compounds of the present disclosure have at least one basic nitrogen whereby the compound can be treated with an acid to form a desired salt. For example, a compound may be reacted with an acid at or above room temperature to provide the desired salt, which is deposited, and collected by filtration after cooling.
Optimum reaction conditions and reaction times for each individual step can vary depending on the particular reactants employed and substituents present in the reactants used. Unless otherwise specified, solvents, temperatures and other reaction conditions can be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Examples section. Reactions can be worked up in the conventional manner, e.g. by eliminating the solvent from the residue and further purified according to methodologies generally known in the art such as, but not limited to, crystallization, distillation, extraction, trituration and chromatography. Unless otherwise described, the starting materials and reagents are either commercially available or can be prepared by one skilled in the art from commercially available materials using methods described in the chemical literature.
Routine experimentations, including appropriate manipulation of the reaction conditions, reagents and sequence of the synthetic route, protection of any chemical functionality that cannot be compatible with the reaction conditions, and deprotection at a suitable point in the reaction sequence of the method are included in the scope of the present disclosure. Suitable protecting groups and the methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which can be found in PGM Wuts and TW Greene, in Greene's book titled Protective Groups in Organic Synthesis (4th ed.), John Wiley & Sons, NY (2006), which is incorporated herein by reference in its entirety. Synthesis of the compounds of the present disclosure can be accomplished by methods analogous to those described in the synthetic schemes described hereinabove and in specific examples.
Starting materials, if not commercially available, can be prepared by procedures selected from standard organic chemical techniques, techniques that are analogous to the synthesis of known, structurally similar compounds, or techniques that are analogous to the above described schemes or the procedures described in the synthetic examples section.
When an optically active form of a compound of the present disclosure is required, it can be obtained by carrying out one of the procedures described herein using an optically active starting material (prepared, for example, by asymmetric induction of a suitable reaction step), or by resolution of a mixture of the stereoisomers of the compound or intermediates using a standard procedure (such as chromatographic separation, recrystallization or enzymatic resolution).
Similarly, when a pure geometric isomer of a compound of the present disclosure is required, it can be obtained by carrying out one of the above procedures using a pure geometric isomer as a starting material, or by resolution of a mixture of the geometric isomers of the compound or intermediates using a standard procedure such as chromatographic separation.
It can be appreciated that the synthetic schemes and specific examples as illustrated in the Examples section are illustrative and are not to be read as limiting the scope of the present disclosure as it is defined in the appended claims. All alternatives, modifications, and equivalents of the synthetic methods and specific examples are included within the scope of the claims.
This disclosure also provides for pharmaceutical compositions comprising a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
The term “pharmaceutically acceptable carrier” as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
The pharmaceutical composition may be a unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component.
The dose to be administered to a subject may be determined by the efficacy of the particular compound employed and the condition of the subject, as well as the body weight or surface area of the subject to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound in a particular subject. In determining the effective amount of the compound to be administered in the treatment or prophylaxis of the disorder being treated, the physician can evaluate factors such as the circulating plasma levels of the compound, compound toxicities, and/or the progression of the disease, etc.
Novel heterocyclic compounds according to the present invention, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof exhibit the effect of effectively inhibiting Mer kinase.
Novel heterocyclic compounds according to the present invention, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt can be used for the prevention or treatment of cancer or immune-related disease.
The compounds described herein, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, may be administered to a subject suffering from a disorder or condition associated with Mer kinase kinase expression/over-expression or up-regulation and with activating genetic and epigenetic alterations. The term “administering” refers to the method of contacting a compound with a subject.
A “Mer kinase-mediated disorder or condition” is characterized by the participation of Mer kinase in the inception, manifestation of one or more symptoms or disease markers, maintenance, severity, or progression or resistance to therapeutic intervention of a disorder or condition. Accordingly, in embodiments, the present disclosure provides a method for treating cancer. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein with or without a pharmaceutically acceptable carrier.
In embodiments, the present disclosure provides compounds of the disclosure, or pharmaceutical compositions comprising a compound of the disclosure, for use in medicine. In embodiments, the present disclosure provides compounds of the disclosure, or pharmaceutical compositions comprising a compound of the disclosure, for use in the treatment of diseases or disorders as described herein above.
One embodiment is directed to the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof in the preparation of a medicament. The medicament optionally can comprise at least one additional therapeutic agent. In some embodiments the medicament is for use in the treatment of diseases and disorders as described herein above.
This disclosure is also directed to the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of the diseases and disorders as described herein above. The medicament optionally can comprise at least one additional therapeutic agent.
The compounds disclosed herein may be administered as the sole active agent or may be co-administered with other therapeutic agents, including other compounds that demonstrate the same or a similar therapeutic activity and that are determined to be safe and efficacious for such combined administration. The term “co-administered” means the administration of two or more different therapeutic agents or treatments (e.g., radiation treatment) that are administered to a subject in a single pharmaceutical composition or in separate pharmaceutical compositions. Thus co-administration involves administration at the same time of a single pharmaceutical composition comprising two or more different therapeutic agents or administration of two or more different compositions to the same subject at the same or different times.
The compounds of the present disclosure may be co-administered with a therapeutically effective amount of at least one additional therapeutic agent to treat cancer.
Further benefits of Applicants' disclosure will be apparent to one skilled in the art from reading this patent application.
The following Examples may be used for illustrative purposes and should not be deemed to narrow the scope of the present disclosure.
Embodiments of the present invention are described in the following examples, which are meant to illustrate and not limit the scope of this invention. Common abbreviations well known to those with ordinary skills in the synthetic art used throughout.
Abbreviations: atm for atomspheres of gas pressure; BINAP for 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl; CDI for N,N′-carbonyldiimidazole; DCE for 1,2-dichloroethane; DCM for dichloromethane; DIAD for diisopropyl azodicarboxylate; DMAP for 4-dimethyamnino pyridine; DMF for N,N-dimethylformamide; DMAP for dimethylamino pyridine; DMFDMA for N,N-Dimethylformamide dimethyl acetal, DMSO for dimethyl sulfoxide; DPT for di-2-pyridyl thionocarbonate; EA or EtOAc for ethyl acetate; ESI for electrospray ionization; HATU for 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; HPLC for high performance liquid chromatography; KOtBu for potassium tert-butoxide; Lawesson's reagent for 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane; MeOH for methanol; MS for mass spectrum; NMR for nuclear magnetic resonance; psi for pounds per square inch; rt for room temperature; TEA for triethylamine; TFA for trifluoroacetic acid; and THF for tetrahydrofuran.
Flash column chromatography means silica gel chromatography unless specified otherwise, which was performed on Teledyne Combiflash-RF200 System. 1H NMR spectra (6, ppm) are recorded on 400 MHz or 600 MHz instrument. Mass spectroscopy data for a positive ionization method are provided. Preparative HPLC was performed on Agilent technologies G1361A, using a Agilent ZORBAX SB-C18 (21.2×150 mm; 5 m) stationary phase, with 0.1% aqueous TFA/acetonitrile gradients as the mobile phase (typically 10-100% acetonitrile over 10 min) with a flow rate of 20 mL/min.
Reagents and solvents may be obtained from commercial sources such as Seno International (Seoul, Korea) which may source compounds from various manufacturers including WuXi AppTec, J&H Chemical, Chemlin, Angene International, or Leap Labchem. Other reagents and intermediates were prepared according to general methods disclosed herein as detailed in Table 1.
In the general methods disclosed herein, boronic acids may be substituted for boronic acid pinacol esters and boronic acid pinacol esters may be substituted for boronic acids as known to one skilled in the art.
To a mixture of 2-amino-5-bromonicotinic acid (23 g, 100 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (27 g, 130 mmol) in 400 mL of 1,4-dioxane/water (3/1) was added K2CO3 (27.6 g, 200 mmol) followed by Pd(PPh3)4(8.1 g, 7 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. Water layer was separated and adjusted to pH value around 5. The precipitate was collected by filtration and triturated in mixture of methanol and water. The precipitate was filtered. The wet cake was dried to afford 17.5 g of the title compound. The crude product was used for the next step without further purification. 1H NMR (600 MHz, DIMETHYL SULFOXIDE-d6) δ ppm 3.82 (s, 3H), 5.73 (s, 2H), 7.77 (s, 1H), 8.05 (s, 1H), 8.13 (d, J=2.4 Hz, 1H), 8.42 (d, J=2.4 Hz, 1H); MS (ESI, m/z): 219.1 [M+H]+
To a mixture of intermediate 1 (20 mg, 0.09 mmol) and triethylamine (0.038 mL, 0.28 mmol) in 0.5 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (35 mg, 0.09 mmol) followed (R)-3-amino-N-phenylpyrrolidine-1-carboxamide (19 mg, 0.09 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 406.1 [M+H]+
Using (R)-3-amino-N-(3-fluorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 424.2 [M+H]+
Using (R)-3-amino-N-(3,4-difluorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 442.2 [M+H]+
Using (R)-3-amino-N-(3,5-dimethylphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 434.2 [M+H]+
Using (R)-3-amino-N-(3,5-di(trifluoromethyl)phenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 542.2 [M+H]+
Using (R)-3-amino-N-(4-trifluoromethylphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 474.2 [M+H]+
Using (R)-3-amino-N-(4-cyanophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 430.2 [M+H]+
Using (R)-3-amino-N-isopropylpyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 372.2 [M+H]+
Using (4-(morpholine-4-carbonyl)phenyl)boronic acid and (R)-3-amino-N-(3,5-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z):583.2 [M+H]+
Using (4-hydroxymethylphenyl)boronic acid and (R)-3-amino-N-(3,5-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 500.2 [M+H]+
Using (1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester and (R)-3-amino-N-(3,5-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 557.2 [M+H]+
Using (R)-3-amino-N-(1-methyl-1H-pyrazol-3-yl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 410.2 [M+H]+
Using (R)-3-amino-N-(pyridin-3-yl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 407.2 [M+H]+
Using (R)-3-amino-N-(3-chlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 440.2 [M+H]+
Using (R)-3-amino-N-(2,3-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 474.2 [M+H]+
Using (R)-3-amino-N-(3-isopropoxyphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 464.2 [M+H]+
Using (R)-3-amino-N-(3-phenoxyphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 498.2 [M+H]+
Using (R)-3-amino-N-(2-phenoxyphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 498.2 [M+H]+
Using (R)-3-amino-N-(3-ethylphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 434.2 [M+H]+
Using (R)-3-amino-N-(2-ethylphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 434.2 [M+H]+
Using (R)-3-amino-N-(2-chlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 440.2 [M+H]+
Using (R)-3-amino-N-(3,5-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 459.2 [M+H]+
Using (R)-3-amino-N-(3-biphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 482.2 [M+H]+
Using (R)-3-amino-N-(3-bromophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 484.2 [M+H]+
Using (R)-3-amino-N-(4-bromophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 484.2 [M+H]+
Using (R)-3-amino-N-(3-(morpholinomethyl)phenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 505.2 [M+H]+
Using (S)-3-amino-N-phenylpyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 406.2 [M+H]+
Using (R)-(5-amino-3,4-dihydroisoquinolin-2(1H)-yl)(3-aminopyrrolidin-1-yl)methanone, the title compound was obtained as described in general method A. MS (ESI, m/z): 461.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(8-bromo-3,4-dihydroisoquinolin-2(1H)-yl)methanone, the title compound was obtained as described in general method A. MS (ESI, m/z): 524.2 [M+H]+
Using (R)-3-amino-N-cyclohexylpyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 412.2 [M+H]+
Using (R)-3-amino-N-((1R,2S)-2-hydroxycyclohexyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 428.2 [M+H]+
Using (R)-3-amino-N-((1R,2R)-2-hydroxycyclohexyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 428.2 [M+H]+
Using (R)-3-amino-N-(2,4,6-trichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 508.07 [M+H]+
Using (R)-3-amino-N-(3,5-dichlorophenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 474.11 [M+H]+
Using (R)-3-amino-N-(3,4,5-trimethoxyphenyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 496.22 [M+H]+
Using (R)—N-([1,1′-biphenyl]-2-yl)-3-aminopyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 482.22 [M+H]+
Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid and (R)—N-([1,1′-biphenyl]-3-yl)-3-aminopyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 590.2 [M+H]+
Using (4-(morpholinomethyl)phenyl)boronic acid and (R)—N—([1,1′-biphenyl]-3-yl)-3-aminopyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 577.2 [M+H]+
Using (4-((4-hydroxypiperidin-1-yl)methyl)phenyl)boronic acid and (R)—N-([1,1′-biphenyl]-3-yl)-3-aminopyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 591.2 [M+H]+
Using (R)-3-amino-N-((1 S,2S)-2-(benzyloxy)cyclopentyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 504.26 [M+H]+
Using (3R)-3-amino-N-(3-(benzyloxy)cyclopentyl)pyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 504.26 [M+H]+
Using (R)-3-amino-N-(4-fluorophenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 440.2 [M+H]+
Using (R)-3-amino-N-benzylpyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 436.2 [M+H]+
Using (R)-3-amino-N-(3,4-dichlorophenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 490.2 [M+H]+
Using (R)-3-amino-N-(4-methoxyphenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 452.2 [M+H]+
Using (R)-3-amino-N-(4-bromophenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 500.2 [M+H]+
Using (R)-3-amino-N-(4-nitorphenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 467.2 [M+H]+
Using (R)-3-amino-N-(4-dimethylaminophenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 465.2 [M+H]+
Using (R)-3-amino-N-(4-(1-morpholino)phenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 507.2 [M+H]+
Using (R)-3-amino-N-(3,5-dichlorohenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 490.2 [M+H]+
Using (R)-3-amino-N-(3-biphenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 498.2 [M+H]+
Using (R)-3-amino-N-(3-bromophenyl)pyrrolidine-1-carbothioamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 500.2 [M+H]+
Using 3-bromophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 485.2/487.2 [M+H]+
Using phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 407.2 [M+H]+
Using 3-(piperidine-1-carbonyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 518.2 [M+H]+
Using 5,6,7,8-tetrahydronaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 461.2 [M+H]+
Using 3-isopropyl-5-methylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 463.2 [M+H]+
Using 2-benzyloxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 513.2 [M+H]+
Using 3-benzyloxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 513.2 [M+H]+
Using 2,3-dichlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 475.2 [M+H]+
Using 2,5-dichlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 475.2 [M+H]+
Using 2-cyanophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 432.2 [M+H]+
Using 4-bromo-2-methoxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 515.2 [M+H]+
Using 3-(methoxycarbonyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 465.2 [M+H]+
Using 5-methoxy-2-(methoxycarbonyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 495.2 [M+H]+
Using cyclohexyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 413.2 [M+H]+
Using 6-bromonaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 535.2 [M+H]+
Using naphthalen-1-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 457.2 [M+H]+
Using 1-aminonaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 472.2 [M+H]+
Using 2-aminophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 422.2 [M+H]+
Using 2-hydroxymethylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 437.2 [M+H]+
Using quinolin-6-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 458.2 [M+H]+
Using quinolin-8-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 458.2 [M+H]+
Using 3-(ethylamino)-4-methylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 464.2 [M+H]+
Using 4-chloro-2-cyclohexylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z):523.2 [M+H]+
Using 3-acetamidophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 464.2 [M+H]+
Using 4-(methylsulfonyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 485.2 [M+H]+
Using 2-(N,N-dimethylaminomethyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 464.2 [M+H]+
Using 3,5-dimethylcyclohexyl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 441.2 [M+H]+
Using benzyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 421.2 [M+H]+
Using 4-hydroxymethylphenylboronic acid and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 509.2 [M+H]+
Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 591.2 [M+H]+
Using (4-(morpholine-4-carbonyl)phenyl)boronic acid and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z):592.2 [M+H]+
Using 3,4-difluorophenylboronic acid and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 515.2 [M+H]+
Using 2-amino-5-bromonicotinic acid and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 481.2 [M+H]+
Using 4-chloro-3-methylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 455.2 [M+H]+
Using 3-cyanophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 432.2 [M+H]+
Using 3,4-dichlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 475.2 [M+H]+
Using 4-amino-3-chlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 456.2 [M+H]+
Using 3,5-difluorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 443.2 [M+H]+
Using 3,5-dimethylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 435.2 [M+H]+
Using 2-(methoxycarbonyl)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 465.2 [M+H]+
Using 4-ethylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 435.2 [M+H]+
Using 3,4-dimethylphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 435.2 [M+H]+
Using 7-hydroxynaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 473.2 [M+H]+
Using (1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester and [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 566.2 [M+H]+
Using 3-hydroxynaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 473.2 [M+H]+
Using 2-hydroxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 423.2 [M+H]+
Using 2-amino-4-chlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 456.2 [M+H]+
Using 2-amino-5-nitrophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 467.2 [M+H]+
Using 3-hydroxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 423.2 [M+H]+
Using 4-phenoxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 499.2 [M+H]+
Using naphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 457.2 [M+H]+
Using 6-hydroxynaphthalen-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 473.2 [M+H]+
Using (1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 425.2 [M+H]+
Using cyclopentyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 399.2 [M+H]+
Using cycloheptyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 427.2 [M+H]+
Using (1R,2S)-2-methylcyclohexyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 427.2 [M+H]+
Using (1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 425.2 [M+H]+
Using 3-phenoxyphenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 499.2 [M+H]+
Using 4-(4-nitrophenoxy)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 544.2 [M+H]+
Using 4-(4-aminophenoxy)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 514.2 [M+H]+
Using 4-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 611.2 [M+H]+
Using 4-(4-(hydroxymethyl)phenoxy)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 529.2 [M+H]+
Using 4-(4-(N,N-dimethylaminomethyl)phenoxy)phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 556.2 [M+H]+
Using 3,5-dichlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 475.10 [M+H]+
Using [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 483.21 [M+H]+
Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester and phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 515.27 [M+H]+
Using (1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester and phenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 490.25 [M+H]+
Using (1S,2S)-2-(benzyloxy)cyclopentyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 505.25 [M+H]+
Using 3-phenylcyclopentyl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 475.24 [M+H]+
Using 1-benzylpiperidin-3-yl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 504.26 [M+H]+
Using 1-(4-formylphenyl)piperidin-3-yl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 518.24 [M+H]+
Using 1-(4-((4-methylpiperazin-1-yl)methyl)phenyl)piperidin-3-yl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 602.35 [M+H]+
Using 4-phenylcyclohexyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 489.25 [M+H]+
Using 1-phenylpyrrolidin-3-yl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 476.23 [M+H]+
Using (R)-1-phenylpyrrolidin-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 476.23 [M+H]+
Using (S)-1-phenylpyrrolidin-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 476.23 [M+H]+
Using 3-phenylcyclohexyl (3R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 489.25 [M+H]+
Using [1,1′-biphenyl]-3-yl (R)-3-(methylamino)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 497.25 [M+H]+
Using (R)-1-benzyl-N-methylpyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 391.22 [M+H]+
Using (R)-1-(2-chlorobenzyl)-N-methylpyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 425.18 [M+H]+
Using (R)-1-(1H-benzo[d]imidazol-2-yl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 403.2 [M+H]+
Using (R)-1-(p-tolyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 377.2 [M+H]+
Using (R)-1-(pyridin-2-yl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 364.2 [M+H]+
Using (R)-1-(5-ethylpyrimidin-2-yl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 393.2 [M+H]+
Using (R)-1-(quinazolin-2-yl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 415.2 [M+H]+
Using (R)-1-(5-nitrothiazol-2-yl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 415.2 [M+H]+
Using ethyl (R)-2-(3-aminopyrrolidin-1-yl)thiazole-4-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z):442.2 [M+H]+
Using (R)-1-(benzylsulfonyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 441.16 [M+H]+
Using (R)-1-(phenylsulfonyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 427.15 [M+H]+
Using (R)-1-((2,4-dichlorophenyl)sulfonyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 495.07 [M+H]+
Using (R)-1-((3-chloropropyl)sulfonyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 427.07 [M+H]+
Using (3S,5S)-1-(methylsulfonyl)-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 471.17 [M+H]+
Using (3S,5S)-1-methyl-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 407.21 [M+H]+
Using 4-hydroxymethylphenylboronic acid and (R)—N-([1,1′-biphenyl]-3-yl)-3-aminopyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 508.2 [M+H]+
Using SS-methyl (2S,4R)-4-amino-1-benzylpyrrolidine-2-carbo(dithioperoxoate) (BB Library), the title compound was obtained as described in general method A. MS (ESI, m/z): 483.2 [M+H]+
Using SS-methyl (2S,4R)-4-amino-1-(2-chlorobenzyl)pyrrolidine-2-carbo(dithioperoxoate) (BB Library), the title compound was obtained as described in general method A. MS (ESI, m/z):517.1 [M+H]+
Using (R)-1-benzyl-N-methylpyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 391.2 [M+H]+
Using (R)-1-(2-chlorobenzyl)-N-methylpyrrolidin-3-amine, the title compound was obtained as described in general method A. MS (ESI, m/z): 425.2 [M+H]+
Using (R)-3-amino-N-methyl-N-phenylpyrrolidine-1-carboxamide, the title compound was obtained as described in general method A. MS (ESI, m/z): 420.2 [M+H]+
Using (S)-1-(3-((4-methylpiperazin-1-yl)methyl)phenyl)pyrrolidin-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 588.3 [M+H]+
Using 3-bromo-5-chlorophenyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method A. MS (ESI, m/z): 519.0 [M+H]+
To a mixture of 2-amino-5-bromonicotinic acid (1 g, 4.61 mmol) and (1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester (2.6 g, 6.91 mmol) in 25 mL of 1,4-dioxane/water (3/1) was added K2CO3 (1.9 g, 13.8 mmol) followed by Pd(PPh3)4 (0.26 g, 0.23 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. Water layer was separated and adjusted to pH value around 5. The precipitate was collected by filtration and triturated in mixture of methanol and water. The precipitate was filtered. The wet cake was dried to afford 1.5 g of the title compound. The crude product was used for the next step without further purification. MS (ESI, m/z): 388.1 [M+H]+
To a mixture of Intermediate 2 (20 mg, 0.05 mmol) and triethylamine (0.022 mL, 0.15 mmol) in 0.5 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (20 mg, 0.05 mmol) followed (R)-3-amino-N-3,5-dichlorophenylpyrrolidine-1-carboxamide (14 mg, 0.05 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was dissolved in 0.5 mL of dichloromethane/trifluoroacetic acid (4/1) and stirred at room temperature for 3 h. After concentration in vacuo, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 543.2 [M+H]+
Using [1,1′-biphenyl]-3-yl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method B. MS (ESI, m/z): 552.2 [M+H]+
Using (3R)-1-(1-(2-chlorophenyl)ethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 494.24 [M+H]+
Using (3R)-1-(1-(3-chlorophenyl)ethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 494.24 [M+H]+
Using (3R)-1-(1-(3,4-dichlorophenyl)ethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 528.20 [M+H]+
Using (R)-1-benzylpyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 446.26 [M+H]+
Using 1-benzylpyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 446.26 [M+H]+
Using (R)-1-(4-fluorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 464.25 [M+H]+
Using (R)-1-(3-methoxybenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 476.27 [M+H]+
Using (R)-1-(2-chlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 480.22 [M+H]+
Using (R)-1-(4-nitrobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 491.24 [M+H]+
Using (R)-1-(2,4,5-trifluorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 500.23 [M+H]+
Using (R)-1-(3-chloro-4-fluorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 498.21 [M+H]+
Using (R)-1-(2,6-dichlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 514.18 [M+H]+
Using (R)-1-(3,4-difluorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 482.24 [M+H]+
Using (R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 514.18 [M+H]+
Using (R)-1-(2,3,6-trifluorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 500.23 [M+H]+
Using (R)-1-((2,4-dimethylthiazol-5-yl)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 481.24 [M+H]+
Using (R)-1-(2,3-dichlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 514.18 [M+H]+
Using (R)-1-(2,4-dichlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 514.18 [M+H]+
Using (R)-1-(2,5-dimethylbenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 474.29 [M+H]+
Using (R)-1-(2-methoxybenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 476.27 [M+H]+
Using (R)-1-(2-trifluoromethylbenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 514.25 [M+H]+
Using (3R)-1-(cyclohex-3-en-1-ylmethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 450.29 [M+H]+
Using (R)-1-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 490.32 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (2S,4R)-4-amino-1-boc-N-phenylpyrrolidine-2-carboxamide, the title compound was obtained as described in general method B. MS (ESI, m/z): 406.19 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (2S,4R)-4-amino-1-boc-N-(4′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-3-yl)pyrrolidine-2-carboxamide, the title compound was obtained as described in general method B. MS (ESI, m/z): 594.32 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (2S,4S)-4-amino-1-boc-N-phenylpyrrolidine-2-carboxamide and trifluoroacetic acid, the title compound was obtained as described in general method B. MS (ESI, m/z): 406.19 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (2S,4S)-4-amino-1-boc-N-(4′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-3-yl)pyrrolidine-2-carboxamide, the title compound was obtained as described in general method B. MS (ESI, m/z): 594.32 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and phenyl (2S,4S)-4-amino-1-boc-pyrrolidine-2-carboxylate, the title compound was obtained as described in general method B. MS (ESI, m/z): 407.18 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 393.20 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5R)-1-boc-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 393.20 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3R,5S)-1-boc-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 393.20 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(((3′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-3-yl)oxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 581.33 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(((4′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-3-yl)oxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 581.33 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(((3′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-4-yl)oxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 581.33 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(((4′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-4-yl)oxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 581.33 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3R,5R)-1-boc-5-(phenoxymethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 393.20 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((2-(sec-butyl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 449.26 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((2,6-dimethylphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 421.23 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((2,3-dichlorophenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 461.12 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((2,4-dichlorophenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 461.12 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-chloro-2-methylphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 441.17 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-(tert-butyl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 449.26 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-phenoxyphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 485.22 [M+H]+
Using (1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-benzylphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 483.24 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(([1,1′-biphenyl]-2-yloxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 469.23 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(([1,1′-biphenyl]-4-yloxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 469.23 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-(benzyloxy)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 499.24 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-((dimethylamino)methyl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 450.25 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and tert-butyl 4-(4-(4-(((2S,4S)-4-amino-1-boc-pyrrolidin-2-yl)methoxy)phenyl)pyridin-2-yl)piperazine-1-carboxylate, the title compound was obtained as described in general method B. MS (ESI, m/z): 554.29 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 530.29 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-(2-phenylpropan-2-yl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 511.27 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(([1,1′-biphenyl]-3-yloxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 469.23 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-(((2,6-dimethyl-[1,1′-biphenyl]-4-yl)oxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 497.26 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((3,4-dimethylphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 421.2 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((3,5-dimethylphenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 421.2 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((2-chlorophenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 428.2 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and (3S,5S)-1-boc-5-((4-((4-methylpiperazin-1-yl)methyl)phenoxy)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 505.3 [M+H]+
Using 2-((R)-3-aminopyrrolidin-1-yl)-N-methyl-2-phenylacetamide, the title compound was obtained as described in general method B. MS (ESI, m/z): 503.3 [M+H]+
Using methyl 2-((R)-3-aminopyrrolidin-1-yl)-2-phenylacetate, the title compound was obtained as described in general method B. MS (ESI, m/z): 504.3 [M+H]+
Using 2-((R)-3-aminopyrrolidin-1-yl)-2-phenylethan-1-ol, the title compound was obtained as described in general method B. MS (ESI, m/z): 476.3 [M+H]+
Using (R)-1-(pyridin-3-ylmethyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 447.2 [M+H]+
Using (R)-1-((2-chloropyridin-4-yl)methyl)pyrrolidin-3-amine, the title compound was obtained as described in general method B. MS (ESI, m/z): 481.2 [M+H]+
To a mixture of 2-amino-5-bromonicotinic acid (23 g, 100 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (27 g, 130 mmol) in 400 mL of 1,4-dioxane/water (3/1) was added K2CO3 (27.6 g, 200 mmol) followed by Pd(PPh3)4(8.1 g, 7 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. Water layer was separated and adjusted to pH value around 5. The precipitate was collected by filtration and triturated in mixture of methanol and water. The precipitate was filtered. The wet cake was dried to afford 17.5 g of the title compound. The crude product was used for the next step without further purification. 1H NMR (600 MHz, DIMETHYL SULFOXIDE-d6) δ ppm 3.82 (s, 3H), 5.73 (s, 2H), 7.77 (s, 1H), 8.05 (s, 1H), 8.13 (d, J=2.4 Hz, 1H), 8.42 (d, J=2.4 Hz, 1H); MS (ESI, m/z): 219.1 [M+H]+
To a mixture of Intermediate 1 (1.0 g, 4.58 mmol) and triethylamine (0.958 mL, 6.87 mmol) in 12 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.7 g, 4.58 mmol) followed by tert-butyl (R)-3-aminopyrrolidine-1-carboxylate (0.853 g, 4.58 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silicagel column chromatography (5% methanol/CH2Cl2) to give off-white solid. To a mixture of product in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL) and stirred at room temperature for overnight. After removing volatiles, the crude product was diluted with diethylether and the precipitate was collected by filtration and dried to afford 1.3 g of the title compound. 1H NMR (600 MHz, DIMETHYL SULFOXIDE-d6) δ ppm 2.01 (br d, J=5.87 Hz, 1H) 2.20 (dd, J=13.50, 7.63 Hz, 1H) 3.14-3.19 (m, 1H) 3.26 (br d, J=6.46 Hz, 1H) 3.35 (br dd, J=7.04, 4.70 Hz, 1H) 3.43 (br dd, J=11.74, 5.28 Hz, 1H) 4.47 (br d, J=5.87 Hz, 1H) 7.83 (s, 1H) 8.07 (s, 1H) 8.29 (d, J=1.76 Hz, 1H) 8.36 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 287.1 [M+H]+
To a mixture of Intermediate 3 (20 mg, 0.05 mmol) in 0.4 mL of dichloroethane was added benzaldehyde (0.011 mL, 0.10 mmol) followed by NaBH(OAc)3 (33 mg, 0.16 mmol). The mixture was stirred at room temperature for 4 h and then water was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 377.20 [M+H]+
Using tert-butyl 3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method C. MS (ESI, m/z): 377.20 [M+H]+
Using tert-butyl (S)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method C. MS (ESI, m/z): 377.20 [M+H]+
Using 2-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 411.2 [M+H]+
Using 3-methoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 407.2 [M+H]+
Using 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 411.2 [M+H]+
Using 4-ethylbenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 405.2 [M+H]+
Using 4-isopropylbenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 419.2 [M+H]+
Using 3,4-dichlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 445.2 [M+H]+
Using 3,4-dimethylbenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 405.2 [M+H]+
Using 2-oxo-2-phenylacetaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 405.2 [M+H]+
Using 3,5-dimethoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 437.2 [M+H]+
Using 2,3-dimethoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 437.2 [M+H]+
Using 2,5-dimethoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 437.2 [M+H]+
Using 2-hydroxy-5-methylbenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 423.2 [M+H]+
Using 2,4-dimethoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 437.2 [M+H]+
Using 3-phenoxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 469.2 [M+H]+
Using 3-benzyloxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 483.2 [M+H]+
Using 3,5-dichloro-2-hydroxybenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 461.2 [M+H]+
Using 3,5-dichlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 445.2 [M+H]+
Using [1,1′-biphenyl]-2-carbaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 453.2 [M+H]+
Using [1,1′-biphenyl]-4-carbaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 453.2 [M+H]+
Using 3-phenylpropanal, the title compound was obtained as described in general method C. MS (ESI, m/z): 405.23 [M+H]+
Using cinnamaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 403.22 [M+H]+
Using 2-(benzyloxy)acetaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 421.23 [M+H]+
Using phenylacetaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 391.23 [M+H]+
Using 3-bromobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 455.2/457.2 [M+H]+
Using 2-bromobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 455.2/457.2 [M+H]+
Using 3-bromo-4-fluorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 473.2/475.2[M+H]+
Using 2-(3-bromophenyl)acetaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 469.2/471.2 [M+H]+
Using (4-(morpholine-4-carbonyl)phenyl)boronic acid and 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 520.2 [M+H]+
Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid, pinacol ester and 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 519 [M+H]+
Using (4-hydroxymethyl)phenylboronic acid and 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 437.2 [M+H]+
Using 4-cyanophenylboronic acid and 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 432.2 [M+H]+
Using quinolin-3-ylboronic acid and 4-chlorobenzaldehyde, the title compound was obtained as described in general method C. MS (ESI, m/z): 458.2 [M+H]+
Using 1-(1-acetyl-4-piperidyl)pyrazole-4-boronic acid pinacol ester, the title compound was obtained as described in general method C. MS (ESI, m/z): 488.27 [M+H]+
Using 1-(1-methylsulfonyl-4-piperidyl)pyrazole-4-boronic acid pinacol ester, the title compound was obtained as described in general method C. MS (ESI, m/z): 524.24 [M+H]+
Using (1-(1-((3,4,5-trimethoxyphenyl)carbamoyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method C. MS (ESI, m/z): 655.33 [M+H]+
Using 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and (R)-1-(2-chlorobenzyl)pyrrolidin-3-amine, the title compound was obtained as described in general method C. MS (ESI, m/z): 453.2 [M+H]+
To a mixture of Example 231 (20 mg, 0.04 mmol) and (3-hydroxymethyl)phenylboronic acid (10 mg, 0.07 mmol) in 0.4 mL of 1,4-dioxane/water (3/1) was added K2CO3 (18 mg, 0.13 mmol) followed by Pd(PPh3)4(3 mg, 0.002 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, the mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 483.2 [M+H]+
Using (4-hydroxymethyl)phenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 483.2 [M+H]+
Using (3-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 565.2 [M+H]+
Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 565.2 [M+H]+
Using Example 232, the title compound was obtained as described in general method D. MS (ESI, m/z): 483.2 [M+H]+
Using Example 232 and (4-hydroxymethyl)phenylboronic aicd, the title compound was obtained as described in general method D. MS (ESI, m/z): 483.2 [M+H]+
Using Example 233 and phenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 471.2 [M+H]+
Using Example 233, the title compound was obtained as described in general method D. MS (ESI, m/z): 501.2 [M+H]+
Using Example 233 and (3-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 583.2 [M+H]+
Using Example 233 and (1,2,3,6-tetrahydropyridin-4-yl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 476.2 [M+H]+
Using Example 234 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 579.2 [M+H]+
Using Example 024 and (3-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.2 [M+H]+
Using Example 024 and (4-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.2 [M+H]+
Using Example 024 and 3-aminophenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 497.2 [M+H]+
Using Example 024 and 4-aminophenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 497.2 [M+H]+
Using Example 024 and 4-hydroxymethylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 512.2 [M+H]+
Using Example 024 and (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 555.2 [M+H]+
Using Example 024 and (6-(piperazin-1-yl)pyridin-3-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 567.2 [M+H]+
Using Example 024 and 4-(N-methylamino)phenylboronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.2 [M+H]+
Using Example 024 and 4-(N,N-dimethylamino)phenylboronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 583.2 [M+H]+
Using Example 024 and 3-hydroxy methylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 512.2 [M+H]+
Using Example 024 and (3-(N,N-dimethylaminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 539.2 [M+H]+
Using Example 024 and (4-(N,N-dimethylaminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 539.2 [M+H]+
Using Example 024 and (3-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 594.32 [M+H]+
Using Example 024 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 594.32 [M+H]+
Using Example 025 and (3-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.2 [M+H]+
Using Example 025 and (4-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.2 [M+H]+
Using Example 025 and phenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 482.2 [M+H]+
Using Example 025 and (3-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 594.32 [M+H]+
Using Example 025 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 594.32 [M+H]+
Using Example 052 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 610.2 [M+H]+
Using Example 053 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 595.31 [M+H]+
Using Example 053 and 3-(4-boronophenyl)propanoic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 555.23 [M+H]+
Using Example 053 and (3-((2-cyanoethyl)carbamoyl)phenyl)boronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 579.24 [M+H]+
Using Example 053 and 4-carboxyphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 527.20 [M+H]+
Using Example 053 and 4-hydroxyphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 499.20 [M+H]+
Using Example 053 and 4-hydroxymethylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 513.22 [M+H]+
Using Example 053 and 4-formylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.20 [M+H]+
Using Example 053 and 4-formylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 511.20 [M+H]+
Using Example 053 and (1-benzyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 563.24 [M+H]+
Using Example 053 and (1-(2-hydroxyethyl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 517.22 [M+H]+
Using Example 053 and (1-(4-piperidinyl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 556.27 [M+H]+
Using Example 053 and (1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 570.29 [M+H]+
Using Example 053 and (1-(2-morpholinoethyl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 586.28 [M+H]+
Using Example 053 and (1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 599.31 [M+H]+
Using Example 053 and isoquinolin-4-ylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 534.22 [M+H]+
Using Example 053 and (2-(4-methylpiperazin-1-yl)pyridin-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 582.29 [M+H]+
Using Example 846 and 4-hydroxymethylphenylboronic acid, the title compound was obtained as described in general method D. MS (ESI, m/z): 547.18 [M+H]+
Using Example 846 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 629.27 [M+H]+
Using Example 067 and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described in general method D. MS (ESI, m/z): 645.2 [M+H]+
Using Example 233 and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described in general method D. MS (ESI, m/z): 583.3 [M+H]+
A mixture of Example 095 (20 mg, 0.04 mmol), tert-butyl 4-bromopiperidine-1-carboxylate (17 μL, 0.08 mmol) and K2CO3 (29 mg, 0.21 mmol) in N,N-dimethylformamide (0.5 mL) was heated at 60° C. for 12 h, cooled to room temperature, and extracted with ethyl acetate, dried over anhydrous MgSO4 and concentrated under vacuum. The crude residue was dissolved in 0.5 mL of dichloromethane/trifluoroacetic acid (4/1) and stirred at room temperature for 3 h. After concentration in vacuo, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 556.2 [M+H]+
Using 3-(N,N-dimethylamino)propyl chloride hydrochloride, the title compound was obtained as described in general method E. MS (ESI, m/z): 558.2 [M+H]+
Using 2-dimethylaminoethyl chloride hydrochloride, the title compound was obtained as described in general method E. MS (ESI, m/z): 544.2 [M+H]+
Using 4-bromo-1-methylpiperidine, the title compound was obtained as described in general method E. MS (ESI, m/z): 570.2 [M+H]+
Using tert-butyl 4-(bromomethyl)piperidine-1-carboxylate, the title compound was obtained as described in general method E. MS (ESI, m/z): 570.2 [M+H]+
Using 2-bromoethanol, the title compound was obtained as described in general method E. MS (ESI, m/z): 517.2 [M+H]+
Using Example 104, the title compound was obtained as described in general method E. MS (ESI, m/z): 544.2 [M+H]+
Using Example 104 and 3-(N,N-dimethylamino)propyl chloride hydrochloride, the title compound was obtained as described in general method E. MS (ESI, m/z): 558.2 [M+H]+
Using Example 104 and tert-butyl 4-bromopiperidine-1-carboxylate, the title compound was obtained as described in general method E. MS (ESI, m/z): 556.2 [M+H]+
Using Example 104 and tert-butyl 4-(bromomethyl)piperidine-1-carboxylate, the title compound was obtained as described in general method E. MS (ESI, m/z): 570.2 [M+H]+
Using Example 101 and tert-butyl 4-(bromomethyl)piperidine-1-carboxylate, the title compound was obtained as described in general method E. MS (ESI, m/z): 520.2 [M+H]+
Using Example 101 and tert-butyl ((1R,4R-4-(chloromethyl)cyclohexyl)carbamate, the title compound was obtained as described in general method E. MS (ESI, m/z): 570.2 [M+H]+
To a mixture of Example 281 (20 mg, 0.04 mmol) in 0.4 mL of dichloroethane was added tert-butyl 3-aminoazetidine-1-carboxylate (13 mg, 0.08 mmol) followed by NaBH(OAc)3 (25 mg, 0.12 mmol). The mixture was stirred at 80° C. for 4 h and then water was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was dissolved in 0.5 mL of dichloromethane/trifluoroacetic acid (4/1) and stirred at room temperature for 3 h. After concentration in vacuo, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound. MS (ESI, m/z): 567.28 [M+H]+
Using 2-aminoethylamine, the title compound was obtained as described in general method F. MS (ESI, m/z): 555.28 [M+H]+
Using 2-dimethylaminoethylamine, the title compound was obtained as described in general method F. MS (ESI, m/z): 583.31 [M+H]+
Using tert-butyl 3-(aminomethyl)azetidine-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using (R)-1-methylpyrrolidin-3-amine, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using 3-dimethylaminopyrrolidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 609.32 [M+H]+
Using tert-butyl (S)-2-(aminomethyl)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using tert-butyl (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using (R)-(1-ethylpyrrolidin-2-yl)methanamine, the title compound was obtained as described in general method F. MS (ESI, m/z): 623.34 [M+H]+
Using tert-butyl (S)-3-aminopiperidine-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using tert-butyl (R)-piperidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using tert-butyl piperidin-4-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using 1-methylpiperidin-4-amine, the title compound was obtained as described in general method F. MS (ESI, m/z): 609.32 [M+H]+
Using 3-hydroxypiperidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 596.29 [M+H]+
Using 3-hydroxymethylpiperidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 610.31 [M+H]+
Using 4-hydroxymethylpiperidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 610.31 [M+H]+
Using (3aR,6aR)-1-methyloctahydropyrrolo[3,4-b]pyrrole, the title compound was obtained as described in general method F. MS (ESI, m/z): 621.32 [M+H]+
Using tert-butyl 1,4-diazepane-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using (R)-2-hydroxymethylpyrrolidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 596.29 [M+H]+
Using (S)-2-carbamoylpyrrolidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 609.29 [M+H]+
Using glycine, the title compound was obtained as described in general method F. MS (ESI, m/z): 570.24 [M+H]+
Using (R)-2-aminopropan-1-ol, the title compound was obtained as described in general method F. MS (ESI, m/z): 570.24 [M+H]+
Using 3-aminopropan-1-ol, the title compound was obtained as described in general method F. MS (ESI, m/z): 570.24 [M+H]+
Using pyrrolidine-3-carboxylic acid, the title compound was obtained as described in general method F. MS (ESI, m/z): 610.27 [M+H]+
Using tert-butyl (R)-pyrrolidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using tert-butyl (S)-pyrrolidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using tert-butyl (S)-piperidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using pyrrolidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 566.28 [M+H]+
Using piperidine, the title compound was obtained as described in general method F. MS (ESI, m/z): 580.30 [M+H]+
Using morpholine, the title compound was obtained as described in general method F. MS (ESI, m/z): 582.28 [M+H]+
Using Example 282, tert-butyl (R)-pyrrolidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using Example 282, tert-butyl (S)-pyrrolidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 581.29 [M+H]+
Using Example 282, tert-butyl (R)-piperidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using Example 282, tert-butyl (S)-piperidin-3-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using Example 282, tert-butyl piperidin-4-ylcarbamate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using Example 282, tert-butyl 1,4-diazepane-1-carboxylate, the title compound was obtained as described in general method F. MS (ESI, m/z): 595.31 [M+H]+
Using Example 811 and ammonia, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.44 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.73 (m, 1H) 3.73-3.81 (m, 1H) 3.81-3.89 (m, 0.5H) 3.93 (d, J=4.70 Hz, 3H) 3.95-4.04 (m, 1H) 4.09 (s, 2H) 4.51-4.59 (m, 0.5H) 4.66-4.73 (m, 0.5H) 7.05-7.19 (m, 4H) 7.46 (dd, J=8.80, 1.76 Hz, 1H) 7.60-7.78 (m, 7H) 7.89 (d, J=18.19 Hz, 1H) 8.05 (d, J=15.85 Hz, 1H) 8.23 (dd, J=18.78, 2.35 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 588.3 [M+H]+
It was isolated as a side product of Example 634. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.26-2.45 (m, 1H) 3.56 (br dd, J=11.15, 5.28 Hz, 1H) 3.67 (br d, J=9.98 Hz, 1H) 3.71-3.79 (m, 1H) 3.81-3.89 (m, 1H) 3.93 (d, J=5.28 Hz, 2H) 3.94-4.03 (m, 1H) 4.52-4.56 (m, 1H) 4.58 (s, 1H) 4.65-4.71 (m, 1H) 5.65-5.65 (m, 1H) 6.97-7.17 (m, 3H) 7.31-7.40 (m, 1H) 7.41-7.55 (m, 2H) 7.56-7.72 (m, 6H) 7.89 (d, J=19.37 Hz, 1H) 8.03 (d, J=18.19 Hz, 1H) 8.18-8.25 (m, 1H) 8.60-8.74 (m, 1H); MS (ESI, m/z): 589.3 [M+H]+
Using Example 811 and dimethylamine, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.11-2.26 (m, 1H) 2.30-2.46 (m, 1H) 2.88 (s, 6H) 3.60 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.74 (m, 1H) 3.75-3.84 (m, 1H) 3.86-3.92 (m, 0.5H) 3.96 (d, J=5.28 Hz, 3H) 3.98-4.06 (m, 1H) 4.31 (s, 2H) 4.55-4.60 (m, 0.5H) 4.69-4.75 (m, 0.5H) 7.10-7.20 (m, 4H) 7.52 (br d, J=8.22 Hz, 2H) 7.64-7.79 (m, 6H) 7.92 (d, J=17.61 Hz, 1H) 8.07 (d, J=15.85 Hz, 1H) 8.26 (br d, J=18.78 Hz, 1H) 8.65-8.76 (m, 1H); MS (ESI, m/z): 616.3 [M+H]+
Using Example 844 and ammonia, the title compound was obtained as described in general method F. MS (ESI, m/z): 622.2 [M+H]+
Using Example 844 and dimethylamine, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.25 (m, 1H) 2.29-2.45 (m, 1H) 2.86-2.90 (s, 6H) 3.59 (dd, J=11.15, 5.28 Hz, 0.5H) 3.70 (br dd, J=12.62, 4.99 Hz, 1H) 3.74-3.82 (m, 1H) 3.84-3.91 (m, 0.5H) 3.94 (d, J=4.11 Hz, 3H) 3.96-4.06 (m, 1H) 4.30-4.34 (s, 2H) 4.55-4.61 (m, 0.5H) 4.65-4.74 (m, 0.5H) 7.08 (ddd, J=8.07, 5.43, 2.35 Hz, 1H) 7.16-7.22 (m, 3H) 7.40-7.45 (m, 1H) 7.50-7.57 (m, 4H) 7.65 (dd, J=13.50, 8.22 Hz, 2H) 7.90 (d, J=17.02 Hz, 1H) 8.06 (d, J=15.26 Hz, 1H) 8.25 (dd, J=18.49, 2.05 Hz, 1H) 8.63-8.73 (m, 1H); MS (ESI, m/z): 650.3 [M+H]+
It was isolated as a side product of Example 637. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.24 (m, 1H) 2.30-2.45 (m, 1H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.70 (br dd, J=12.33, 4.70 Hz, 1H) 3.78 (br dd, J=12.33, 6.46 Hz, 1H) 3.87 (br s, 0.5H) 3.95 (d, J=4.70 Hz, 3H) 3.97-4.05 (m, 1H) 4.54-4.60 (m, 0.5H) 4.62 (s, 2H) 4.67-4.76 (m, 0.5H) 7.00 (ddd, J=8.22, 5.28, 2.35 Hz, 1H) 7.04-7.10 (m, 2H) 7.10-7.23 (m, 1H) 7.33-7.40 (m, 1H) 7.42 (br d, J=6.46 Hz, 2H) 7.50-7.55 (m, 2H) 7.64 (br dd, J=13.50, 8.22 Hz, 2H) 7.91 (d, J=17.61 Hz, 1H) 8.06 (d, J=16.43 Hz, 1H) 8.25 (dd, J=19.37, 1.76 Hz, 1H) 8.63-8.76 (m, 1H); MS (ESI, m/z): 623.2 [M+H]+
Using Example 841 and 1-methylpiperazine, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.25-2.42 (m, 1H) 2.91 (d, J=4.11 Hz, 3H) 3.20 (br s, 4H) 3.40 (br s, 4H) 3.49 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.58-3.76 (m, 2H) 3.79-3.86 (m, 0.5H) 3.88-3.92 (m, 0.5H) 3.94 (d, J=2.93 Hz, 3H) 3.96-4.04 (m, 2.5H) 4.51-4.56 (m, 0.5H) 4.65-4.72 (m, 0.5H) 7.50-7.56 (m, 2H) 7.56-7.63 (m, 2H) 7.90 (d, J=16.43 Hz, 1H) 8.05 (d, J=12.91 Hz, 1H) 8.24 (dd, J=13.50, 2.35 Hz, 1H) 8.61-8.76 (m, 1H); MS (ESI, m/z): 503.3 [M+H]+
Using Example 841 and 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.25-2.45 (m, 1H) 3.20 (br s, 4H) 3.28-3.31 (m, 2H) 3.41-3.57 (m, 4.5H) 3.58-3.78 (m, 2H) 3.82-3.92 (m, 3H) 3.94 (d, J=2.93 Hz, 3H) 4.00 (dd, J=12.91, 7.04 Hz, 0.5H) 4.09 (d, J=11.15 Hz, 2H) 4.50-4.57 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.50-7.57 (m, 2H) 7.57-7.65 (m, 1H) 7.89 (d, J=15.85 Hz, 1H) 8.05 (d, J=13.50 Hz, 1H) 8.24 (dd, J=13.21, 2.05 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 533.3 [M+H]+
Using Example 845 and (1r,4r)-4-aminocyclohexan-1-ol, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.22-1.33 (m, 2H) 1.42 (br dd, J=12.33, 9.98 Hz, 2H) 1.51-1.63 (m, 1H) 1.98-2.02 (m, 1H) 2.03-2.11 (m, 2H) 2.14-2.21 (m, 1H) 2.26-2.40 (m, 1H) 3.01-3.11 (m, 1H) 3.62-3.68 (m, 1.5H) 3.70-3.76 (m, 1H) 3.79 (br t, J=7.34 Hz, 1H) 3.92-4.01 (m, 1H) 4.23 (d, J=17.61 Hz, 2H) 4.25 (d, J=17.61 Hz, 1H) 4.53-4.59 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.17 (td, J=8.36, 2.64 Hz, 1H) 7.34 (d, J=8.65 Hz, 1H) 7.38-7.47 (m, 2H) 7.47-7.51 (m, 2H) 7.53-7.63 (m, 4H) 7.64-7.69 (m, 1H) 8.05-8.13 (m, 1H) 8.36-8.48 (m, 1H); MS (ESI, m/z): 642.3 [M+H]+
Using Example 807 and formaldehyde, the title compound was obtained as described in general method F. MS (ESI, m/z): 578.3 [M+H]+
Using Example 818 and formaldehyde, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.03 (br d, J=11.15 Hz, 2H) 2.06-2.15 (m, 2H) 2.06-2.22 (m, 1H) 2.26-2.44 (m, 1H) 2.89 (s, 3H) 2.97 (br d, J=8.80 Hz, 3H) 3.14-3.26 (m, 2H) 3.51 (br d, J=11.15 Hz, 0.5H) 3.57-3.65 (m, 2H) 3.65-3.83 (m, 2H) 3.85-3.90 (m, 0.5H) 3.93 (d, J=7.04 Hz, 3H) 3.96-4.06 (m, 1H) 4.15-4.24 (m, 1H) 4.49-4.55 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.24 (br d, J=14.09 Hz, 1H) 7.42 (br t, J=9.68 Hz, 1H) 7.48-7.59 (m, 1H) 7.72-7.79 (m, 1H) 7.83 (br dd, J=16.43, 8.80 Hz, 1H) 7.86-7.91 (m, 1H) 7.91-7.97 (m, 1H) 7.99-8.08 (m, 1H) 8.16-8.28 (m, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 567.3 [M+H]+
Using Example 818 and acetone, the title compound was obtained as described in general method F. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.38 (br s, 6H) 2.02-2.10 (m, 2H) 2.10-2.26 (m, 3H) 2.27-2.45 (m, 1H) 2.97 (br s, 3H) 3.21-3.28 (m, 2H) 3.55 (br d, J=11.15 Hz, 2H) 3.62 (br d, J=11.15 Hz, 0.5H) 3.68-3.92 (m, 3.5H) 3.94 (br s, 3H) 4.02 (br s, 1H) 4.24 (br s, 1H) 4.54 (br s, 0.5H) 4.71 (br s, 0.5H) 7.22 (br d, J=7.63 Hz, 1H) 7.42 (br s, 1H) 7.54 (br s, 1H) 7.75 (br s, 1H) 7.82 (br t, J=9.32 Hz, 1H) 7.87-7.93 (m, 1H) 7.95 (br d, J=17.02 Hz, 1H) 8.02-8.13 (m, 1H) 8.19-8.29 (m, 1H) 8.61-8.75 (m, 1H); MS (ESI, m/z): 595.3 [M+H]+
To a mixture of 2-amino-5-bromonicotinic acid (4.48 g, 20.6 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (5.5 g, 26.8 mmol) in 100 mL of 1,4-dioxane/water (3/1) was added K2CO3 (8.5 g, 61.9 mmol) followed by Pd(PPh3)4(1.19 g, 1.03 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. Water layer was separated and adjusted to pH value between 4 and 5. The precipitate was collected by filtration and dried to afford 4.1 g of the title compound. The crude product was used for the next step without further purification. 1H NMR (600 MHz, DIMETHYL SULFOXIDE-d6) δ ppm 3.82 (s, 3H), 5.73 (s, 2H), 7.77 (s, 1H), 8.05 (s, 1H), 8.13 (d, J=2.4 Hz, 1H), 8.42 (d, J=2.4 Hz, 1H); MS (ESI, m/z): 219.1 [M+H]+
To a mixture of intermediate 1 (1.0 g, 4.58 mmol) and triethylamine (0.958 mL, 6.87 mmol) in 12 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.7 g, 4.58 mmol) followed by tert-butyl (R)-3-aminopyrrolidine-1-carboxylate (0.853 g, 4.58 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silica gel column chromatography (5% methanol/CH2Cl2) to give off-white solid. To a mixture of product in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL) and stirred at room temperature for overnight. After removing volatiles, the crude product was diluted with diethylether and the precipitate was collected by filtration and dried to afford 1.3 g of the title compound. 1H NMR (600 MHz, DIMETHYL SULFOXIDE-d6) δ ppm 2.01 (br d, J=5.87 Hz, 1H) 2.20 (dd, J=13.50, 7.63 Hz, 1H) 3.14-3.19 (m, 1H) 3.26 (br d, J=6.46 Hz, 1H) 3.35 (br dd, J=7.04, 4.70 Hz, 1H) 3.43 (br dd, J=11.74, 5.28 Hz, 1H) 4.47 (br d, J=5.87 Hz, 1H) 7.83 (s, 1H) 8.07 (s, 1H) 8.29 (d, J=1.76 Hz, 1H) 8.36 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 287.1 [M+H]+
To a mixture of 4-bromobenzoic acid (0.262 g, 1.3 mmol) and triethylamine (0.545 mL, 3.91 mmol) in 3 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.496 g, 1.3 mmol) followed by Intermediate 3 (0.5 g, 1.3 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silicagel column chromatography (5% methanol/CH2Cl2) to give 0.5 g off-white solid. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.21 (m, 1H) 2.26-2.42 (m, 1H) 3.49 (br dd, J=10.76, 4.89 Hz, 0.5H) 3.58-3.77 (m, 1.5H) 3.77-4.03 (m, 1H) 3.95 (d, J=1.96 Hz, 3H) 4.51-4.58 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.49 (t, J=8.02 Hz, 2H) 7.60-7.69 (m, 2H) 7.91 (d, J=10.17 Hz, 1H) 8.05 (d, J=9.78 Hz, 1H) 8.25 (dd, J=10.56, 1.96 Hz, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 469.1/471.1 [M+H]+
To a mixture of Example 342 (15 mg, 0.03 mmol) and phenylboronic acid (5 mg, 0.04 mmol) in 0.4 mL of 1,4-dioxane/water (3/1) was added K2CO3 (13 mg, 0.1 mmol) followed by Pd(PPh3)4(2 mg, 0.001 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and extracted with ethyl acetate, dried over anhydrous MgSO4 and concentrated under vacuum. The crude residue was purified by preparative HPLC to afford 10 mg of the title compound. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.23 (m, 1H) 2.27-2.46 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.69 (br dd, J=12.52, 5.09 Hz, 1H) 3.73-3.81 (m, 1H) 3.81-3.90 (m, 0.5H) 3.94 (d, J=3.52 Hz, 3H) 3.96-4.07 (m, 1H) 4.50-4.63 (m, 0.5H) 4.63-4.76 (m, 0.5H) 7.32-7.41 (m, 1H) 7.45 (td, J=7.53, 3.33 Hz, 2H) 7.54-7.67 (m, 4H) 7.67-7.76 (m, 2H) 7.90 (d, J=12.52 Hz, 1H) 8.04 (d, J=11.74 Hz, 1H) 8.23 (dd, J=13.89, 2.15 Hz, 1H) 8.63 (br d, J=1.96 Hz, 1H); MS (ESI, m/z): 467.2 [M+H]+
Using tert-butyl 3-aminoazetidine-1-carboxylate, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 3.93 (s, 3H) 4.25 (br dd, J=10.56, 5.28 Hz, 1H) 4.43 (br dd, J=9.10, 4.99 Hz, 1H) 4.53-4.60 (m, 1H) 4.80 (br t, J=8.80 Hz, 1H) 4.83-4.86 (m, 1H) 7.36-7.39 (m, 1H) 7.44-7.48 (m, 2H) 7.63-7.67 (m, 2H) 7.72-7.78 (m, 4H) 7.89 (s, 1H) 8.03 (s, 1H) 8.26 (d, J=2.35 Hz, 1H) 8.67 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 453.2 [M+H]+
Using (S)-3-aminopyrrolidine-1-carboxylate and 3-bromobenzoic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.25-2.46 (m, 1H) 3.56 (dd, J=11.35, 5.09 Hz, 0.5H) 3.64-3.81 (m, 2H) 3.85-3.91 (m, 0.5H) 3.93 (d, J=4.30 Hz, 3H) 3.94-4.05 (m, 1H) 4.51-4.59 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.33-7.39 (m, 1H) 7.39-7.46 (m, 2H) 7.46-7.51 (m, 1H) 7.51-7.56 (m, 1H) 7.56-7.61 (m, 1H) 7.61-7.66 (m, 1H) 7.70-7.77 (m, 1H) 7.78 (s, 1H) 7.88 (d, J=18.78 Hz, 1H) 8.02 (d, J=18.39 Hz, 1H) 8.18-8.26 (m, 1H) 8.58-8.71 (m, 1H); MS (ESI, m/z): 467.2 [M+H]+
Using (R)-3-aminopyrrolidine-1-carboxylate, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.28-2.46 (m, 1H) 3.54-3.60 (m, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.84 (br d, J=7.04 Hz, 0.5H) 3.95 (d, J=3.91 Hz, 3H) 3.96-4.06 (m, 1H) 4.55 (br d, J=5.48 Hz, 0.5H) 4.72 (br d, J=5.48 Hz, 0.5H) 7.32-7.41 (m, 1H) 7.41-7.50 (m, 2H) 7.61-7.69 (m, 4H) 7.69-7.77 (m, 2H) 7.91 (d, J=12.13 Hz, 1H) 8.05 (d, J=11.74 Hz, 1H) 8.25 (dd, J=13.30, 1.96 Hz, 1H) 8.60-8.73 (n, 1H); MS (ESI, m/z): 467.2 [M+H]+
Using tert-butyl (R)-3-aminopiperidine-1-carboxylate, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.55-1.88 (m, 2H) 1.93-2.05 (m, 1H) 2.11-2.20 (m, 1H) 3.09-3.28 (m, 2H) 3.70 (brs, 0.5H) 3.89-3.99 (m, 3.5H) 4.00-4.18 (m, 1H) 4.33 (br s, 0.5H) 4.52 (br s, 0.5H) 7.37 (br d, J=5.87 Hz, 1H) 7.45 (br s, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.63 (br s, 2H) 7.70 (br d, J=18.78 Hz, 2H) 7.87 (br d, J=18.78 Hz, 1H) 8.01 (br d, J=9.39 Hz, 1H) 8.22 (br d, J=11.74 Hz, 1H) 8.46-8.56 (m, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using tert-butyl (S)-3-aminopiperidine-1-carboxylate, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.55-1.87 (m, 2H) 1.91-2.06 (m, 1H) 2.11-2.20 (m, 1H) 3.09-3.27 (m, 2H) 3.70 (br s, 0.5H) 3.86-3.99 (m, 3.5H) 4.00-4.18 (m, 1H) 4.33 (br s, 0.5H) 4.50 (br s, 0.5H) 7.36 (br s, 1H) 7.45 (br s, 2H) 7.49-7.55 (m, 2H) 7.63 (br s, 2H) 7.70 (br d, J=17.61 Hz, 2H) 7.87 (br d, J=18.19 Hz, 1H) 8.01 (br d, J=12.33 Hz, 1H) 8.22 (br d, J=11.74 Hz, 1H) 8.46-8.58 (m, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using (2-hydroxymethylphenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 497.2 [M+H]+
Using (2-isopropylphenyl)boronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.10 (br d, J=6.65 Hz, 6H) 1.93-2.22 (m, 1H) 2.35 (br s, 1H) 2.86 (br s, 1H) 3.65-3.85 (m, 2H) 3.90-3.95 (m, 3H) 3.97 (br s, 1H) 4.10 (br s, 1H) 4.79 (br s, 1H) 6.98-7.08 (m, 1H) 7.19 (br s, 1H) 7.37 (br s, 2H) 7.50 (br d, J=7.83 Hz, 1H) 7.66 (br s, 1H) 7.76 (br s, 1H) 8.12 (br s, 1H) 8.46 (br s, 1H) 8.62 (br d, J=10.17 Hz, 1H) 8.80 (br s, 1H) 8.96 (br s, 1H); MS (ESI, m/z): 509.3 [M+H]+
Using (2-phenoxyphenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 559.3 [M+H]+
Using (2-biphenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 543.2 [M+H]+
Using (2-ethylphenyl)boronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.01 (t, J=7.43 Hz, 3H) 1.97-2.17 (m, 1H) 2.30-2.45 (m, 1H) 2.48 (q, J=7.43 Hz, 2H) 3.63-3.86 (m, 2H) 3.91 (s, 3H) 3.97 (br s, 1H) 4.13 (br s, 1H) 4.79 (br s, 1H) 6.98-7.11 (m, 1H) 7.20 (br s, 2H) 7.27-7.36 (m, 2H) 7.49 (br d, J=7.04 Hz, 1H) 7.62 (br d, J=11.74 Hz, 1H) 7.66-7.77 (m, 1H) 8.04 (br d, J=19.95 Hz, 1H) 8.62 (br s, 1H) 8.73 (br s, 1H) 8.82 (br s, 1H); MS (ESI, m/z): 495.2 [M+H]+
Using (2-methoxylphenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 497.2 [M+H]+
Using (2-formylphenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 495.2 [M+H]+
Using 3-pyridineboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.10-2.26 (m, 1H) 2.28-2.45 (m, 1H) 3.53-3.67 (m, 1H) 3.68-3.82 (m, 2H) 3.87 (br d, J=5.87 Hz, 0.5H) 3.94 (d, J=3.13 Hz, 3H) 4.00-4.07 (m, 0.5H) 4.52-4.59 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.74-7.81 (m, 1H) 7.86-7.95 (m, 2H) 7.97 (dd, J=7.43, 5.48 Hz, 2H) 8.06 (d, J=10.17 Hz, 1H) 8.10-8.16 (m, 1H) 8.25 (dd, J=11.15, 2.15 Hz, 1H) 8.65-8.71 (m, 1H) 8.85 (dd, J=5.48, 1.17 Hz, 2H) 9.18 (d, J=1.57 Hz, 1H); MS (ESI, m/z): 468.2 [M+H]+
Using 2-fluoropyridine-5-boronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.25-2.46 (m, 1H) 3.55 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.80 (m, 2H) 3.80-3.91 (m, 0.5H) 3.95 (d, J=2.74 Hz, 3H) 3.97-4.06 (m, 1H) 4.51-4.59 (m, 0.5H) 4.66-4.74 (m, 0.5H) 7.18 (br d, J=8.22 Hz, 1H) 7.48 (br t, J=8.22 Hz, 0.5H) 7.56-7.66 (m, 0.5H) 7.66-7.79 (m, 3H) 7.91 (d, J=12.13 Hz, 1H) 8.06 (br d, J=11.35 Hz, 1H) 8.24 (br d, J=10.56 Hz, 2H) 8.49 (br s, 1H) 8.62-8.74 (m, 1H); MS (ESI, m/z): 486.2 [M+H]+
Using 3-thiopheneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.04-2.19 (m, 1H) 2.23-2.40 (m, 1H) 3.57-3.67 (m, 1H) 3.67-3.90 (m, 2H) 3.91 (d, J=3.91 Hz, 3H) 3.94-4.02 (m, 1H) 4.51 (br dd, J=11.74, 5.87 Hz, 0.5H) 4.59-4.76 (m, 0.5H) 7.44-7.49 (m, 1H) 7.51-7.60 (m, 2H) 7.68-7.75 (m, 2H) 7.84-7.90 (m, 1H) 8.01 (br d, J=12.13 Hz, 1H) 8.16-8.20 (m, 1H) 8.20-8.23 (m, 1H) 8.60 (br d, J=1.96 Hz, 1H) 8.64-8.70 (m, 1H); MS (ESI, m/z): 473.2 [M+H]+
Using 2-chlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.25 (m, 1H) 2.27-2.46 (m, 1H) 3.58 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.66-3.82 (m, 2H) 3.82-3.91 (m, 0.5H) 3.94 (d, J=2.74 Hz, 3H) 3.95-4.05 (m, 1H) 4.54-4.61 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.33-7.43 (m, 3H) 7.46-7.58 (m, 3H) 7.60-7.69 (m, 2H) 7.90 (d, J=11.35 Hz, 1H) 8.05 (d, J=10.56 Hz, 1H) 8.24 (dd, J=12.91, 1.96 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 501.2 [M+H]+
Using 3-chlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.25-2.46 (m, 1H) 3.52-3.61 (m, 0.5H) 3.64-3.81 (m, 2H) 3.81-3.90 (m, 0.5H) 3.94 (d, J=3.91 Hz, 3H) 3.95-4.07 (m, 1H) 4.51-4.58 (m, 0.5H) 4.66-4.73 (m, 0.5H) 7.34-7.41 (m, 1H) 7.44 (td, J=7.83, 3.91 Hz, 1H) 7.58 (br t, J=6.46 Hz, 1H) 7.61-7.68 (m, 3H) 7.68-7.75 (m, 2H) 7.90 (d, J=12.91 Hz, 1H) 8.04 (d, J=12.13 Hz, 1H) 8.23 (dd, J=14.09, 1.96 Hz, 1H) 8.61-8.73 (m, 1H); MS (ESI, m/z): 501.2 [M+H]+
Using 2,4-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.27-2.46 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.81 (m, 2H) 3.81-3.90 (m, 0.5H) 3.94 (d, J=2.35 Hz, 3H) 3.96-4.06 (m, 1H) 4.53-4.61 (m, 0.5H) 4.64-4.74 (m, 0.5H) 7.34-7.46 (m, 2H) 7.52 (dd, J=7.83, 5.87 Hz, 2H) 7.58 (br s, 1H) 7.61-7.70 (m, 2H) 7.90 (d, J=11.35 Hz, 1H) 8.05 (d, J=10.56 Hz, 1H) 8.24 (dd, J=12.52, 1.96 Hz, 1H) 8.63-8.74 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using 3,4-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.25-2.45 (m, 1H) 3.55 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.80 (m, 2H) 3.86 (br d, J=7.43 Hz, 0.5H) 3.94 (d, J=3.91 Hz, 3H) 4.00 (td, J=12.13, 6.65 Hz, 1H) 4.50-4.58 (m, 0.5H) 4.65-4.72 (m, 0.5H) 7.59 (br d, J=3.91 Hz, 2H) 7.62-7.69 (m, 2H) 7.69-7.75 (m, 2H) 7.82 (br d, J=5.87 Hz, 1H) 7.90 (d, J=12.91 Hz, 1H) 8.05 (d, J=12.13 Hz, 1H) 8.23 (dd, J=13.69, 1.96 Hz, 1H) 8.61-8.72 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using 3,5-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.25-2.45 (m, 1H) 3.55 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.62-3.80 (m, 2H) 3.81-3.91 (m, 0.5H) 3.94 (d, J=3.91 Hz, 3H) 3.96-4.06 (m, 1H) 4.50-4.59 (m, 0.5H) 4.63-4.74 (m, 0.5H) 7.45 (br s, 1H) 7.58-7.75 (m, 6H) 7.90 (d, J=12.52 Hz, 1H) 8.05 (d, J=11.74 Hz, 1H) 8.23 (dd, J=13.30, 1.96 Hz, 1H) 8.61-8.72 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using 2,6-difluorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.09-2.24 (m, 1H) 2.29-2.46 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.82 (m, 2H) 3.86 (br dd, J=13.30, 6.65 Hz, 0.5H) 3.95 (d, J=2.74 Hz, 3H) 3.96-4.06 (m, 1H) 4.55-4.62 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.05-7.16 (m, 2H) 7.37-7.50 (m, 1H) 7.52-7.60 (m, 2H) 7.64-7.72 (m, 2H) 7.91 (d, J=11.35 Hz, 1H) 8.06 (d, J=10.56 Hz, 1H) 8.24 (dd, J=13.30, 1.96 Hz, 1H) 8.63-8.74 (m, 1H); MS (ESI, m/z): 503.2 [M+H]+
Using 2,4-difluorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.26-2.46 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.81 (m, 2H) 3.85 (br t, J=7.24 Hz, 0.5H) 3.94 (d, J=3.13 Hz, 3H) 3.96-4.05 (m, 1H) 4.57 (br t, J=5.67 Hz, 0.5H) 4.67-4.74 (m, 0.5H) 7.05-7.13 (m, 2H) 7.51-7.58 (m, 1H) 7.58-7.72 (m, 4H) 7.90 (d, J=11.74 Hz, 1H) 8.05 (d, J=10.96 Hz, 1H) 8.24 (dd, J=13.30, 1.96 Hz, 1H) 8.63-8.75 (m, 1H); MS (ESI, m/z): 503.2 [M+H]+
Using 2-chloro-4-fluorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.45 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.86 (dt, J=12.03, 7.48 Hz, 0.5H) 3.93 (d, J=4.11 Hz, 3H) 3.95-4.03 (m, 1H) 4.53-4.60 (m, 0.5H) 4.66-4.73 (m, 0.5H) 7.13-7.20 (m, 1H) 7.31-7.36 (m, 1H) 7.40 (dt, J=8.80, 6.46 Hz, 1H) 7.50 (t, J=8.22 Hz, 2H) 7.63 (dd, J=12.91, 8.22 Hz, 2H) 7.89 (d, J=16.43 Hz, 1H) 8.04 (d, J=15.26 Hz, 1H) 8.23 (dd, J=18.19, 1.76 Hz, 1H) 8.62-8.72 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using 2,5-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.25 (m, 1H) 2.29-2.45 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.73-3.81 (m, 1H) 3.83-3.90 (m, 0.5H) 3.93 (d, J=4.70 Hz, 3H) 3.95-4.04 (m, 1H) 4.54-4.60 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.33-7.43 (m, 2H) 7.46-7.56 (m, 3H) 7.65 (dd, J=12.91, 8.22 Hz, 2H) 7.89 (d, J=16.43 Hz, 1H) 8.04 (d, J=15.85 Hz, 1H) 8.23 (dd, J=18.19, 2.35 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using 2,6-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 536.2 [M+H]+
Using 2,3-dichlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.29-2.46 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.67-3.73 (m, 1H) 3.77 (dt, J=11.30, 6.97 Hz, 1H) 3.83-3.89 (m, 0.5H) 3.94 (d, J=4.11 Hz, 3H) 3.96-4.04 (m, 1H) 4.55-4.59 (m, 0.5H) 4.68-4.72 (m, 0.5H) 7.30-7.34 (m, 1H) 7.37 (td, J=7.78, 4.40 Hz, 1H) 7.49-7.53 (m, 2H) 7.57 (ddd, J=7.92, 3.23, 1.76 Hz, 1H) 7.62-7.69 (m, 2H) 7.90 (d, J=16.43 Hz, 1H) 8.05 (d, J=15.26 Hz, 1H) 8.24 (dd, J=17.61, 2.35 Hz, 1H) 8.62-8.74 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using 2-fluorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.28-2.46 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.73-3.82 (m, 1H) 3.82-3.90 (m, 0.5H) 3.94 (d, J=5.28 Hz, 3H) 3.95-4.04 (m, 1H) 4.52-4.59 (m, 0.5H) 4.67-4.74 (m, 0.5H) 7.15-7.24 (m, 1H) 7.24-7.29 (m, 1H) 7.34-7.45 (m, 1H) 7.45-7.57 (m, 1H) 7.64 (s, 2H) 7.66 (s, 2H) 7.88 (s, 1H) 7.91 (s, 1H) 8.03 (s, 1H) 8.06 (s, 1H) 8.20-8.27 (m, 1H) 8.71 (d, J=2.35 Hz, 1H) 8.63 (d, J=1.76 Hz, 1H); MS (ESI, m/z): 485.2 [M+H]+
Using 4-trifluoromethylbenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.45 (m, 1H) 3.55 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.81-3.90 (m, 0.5H) 3.93 (d, J=4.50 Hz, 3H) 3.94-4.05 (m, 1H) 4.50-4.62 (m, 0.5H) 4.63-4.79 (m, 0.5H) 7.65-7.72 (m, 2H) 7.74-7.80 (m, 4H) 7.82-7.87 (m, 2H) 7.89 (d, J=18.78 Hz, 1H) 8.06 (s, 1H) 8.19-8.28 (m, 1H) 8.60-8.73 (m, 1H); MS (ESI, m/z): 535.2 [M+H]+
Using 4-phenoxylbenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.24-2.42 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.71 (m, 1H) 3.71-3.79 (m, 1H) 3.80-3.89 (m, 0.5H) 3.93 (d, J=5.87 Hz, 3H) 3.94-4.02 (m, 1H) 4.48-4.57 (m, 0.5H) 4.64-4.72 (m, 0.5H) 5.11 (d, J=4.11 Hz, 2H) 7.07 (dd, J=8.51, 6.16 Hz, 2H) 7.26-7.33 (m, 1H) 7.36 (td, J=7.63, 1.76 Hz, 2H) 7.43 (dd, J=7.92, 2.05 Hz, 2H) 7.53-7.62 (m, 4H) 7.62-7.68 (m, 2H) 7.89 (d, J=19.96 Hz, 1H) 8.03 (d, J=19.37 Hz, 1H) 8.18-8.25 (m, 1H) 8.54-8.72 (m, 1H); MS (ESI, m/z): 573.2 [M+H]+
Using 2-bromobenzeneboronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 545.2/547.2 [M+H]+
Using 2,4-di(trifluoromethyl)benzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.22 (m, 1H) 2.30-2.44 (m, 1H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.82-3.90 (m, 0.5H) 3.94 (d, J=2.93 Hz, 3H) 3.95-4.04 (m, 1H) 4.55-4.61 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.46 (t, J=7.92 Hz, 2H) 7.62 (t, J=7.04 Hz, 1H) 7.64-7.70 (m, 2H) 7.90 (d, J=16.43 Hz, 1H) 7.99-8.02 (m, 1H) 8.04 (d, J=14.09 Hz, 1H) 8.07 (br d, J=2.35 Hz, 1H) 8.24 (dd, J=16.14, 2.05 Hz, 1H) 8.61-8.71 (m, 1H); MS (ESI, m/z): 603.2 [M+H]+
Using 2-hydroxy benzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.26-2.47 (m, 1H) 3.59 (dd, J=10.96, 5.09 Hz, 0.5H) 3.65-3.82 (m, 2H) 3.82-3.90 (m, 0.5H) 3.94 (d, J=3.52 Hz, 3H) 3.96-4.04 (m, 1H) 4.48-4.62 (m, 0.5H) 4.63-4.74 (m, 0.5H) 6.73-6.81 (m, 0.5H) 6.84-6.92 (m, 1.5H) 7.11-7.22 (m, 1H) 7.27 (br dd, J=7.24, 3.72 Hz, 1H) 7.55-7.63 (m, 2H) 7.63-7.72 (m, 2H) 7.90 (d, J=12.52 Hz, 1H) 8.05 (d, J=11.74 Hz, 1H) 8.23 (dd, J=14.28, 2.15 Hz, 1H) 8.62-8.76 (m, 1H); MS (ESI, m/z): 483.2 [M+H]+
Using 3-amino-2-methylbenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.11-2.23 (m, 1H) 2.26 (d, J=3.13 Hz, 3H) 2.29-2.46 (m, 1H) 3.54-3.62 (m, 0.5H) 3.66-3.74 (m, 1H) 3.74-3.83 (m, 1H) 3.83-3.91 (m, 0.5H) 3.94 (d, J=2.35 Hz, 3H) 3.96-4.08 (m, 1H) 4.54-4.62 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.33-7.38 (m, 1H) 7.38-7.47 (m, 4H) 7.68 (t, J=8.41 Hz, 2H) 7.91 (d, J=10.17 Hz, 1H) 8.06 (d, J=8.61 Hz, 1H) 8.25 (dd, J=10.37, 2.15 Hz, 1H) 8.64-8.75 (m, 1H); MS (ESI, m/z): 496.2 [M+H]+
Using 4-chlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.25 (m, 1H) 2.26-2.46 (m, 1H) 3.56 (br dd, J=11.15, 4.89 Hz, 0.5H) 3.69 (td, J=8.61, 4.30 Hz, 1H) 3.73-3.81 (m, 1H) 3.81-3.90 (m, 0.5H) 3.95 (d, J=3.91 Hz, 3H) 3.97-4.05 (m, 1H) 4.50-4.60 (m, 0.5H) 4.65-4.75 (m, 0.5H) 7.47 (dd, J=8.61, 2.74 Hz, 2H) 7.61-7.69 (m, 4H) 7.69-7.78 (m, 2H) 7.91 (d, J=12.52 Hz, 1H) 8.05 (d, J=11.35 Hz, 1H) 8.24 (dd, J=13.30, 1.96 Hz, 1H) 8.60-8.73 (m, 1H); MS (ESI, m/z): 501.2 [M+H]+
Using 4-tert-butylbenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.35 (d, J=2.35 Hz, 9H) 2.07-2.25 (m, 1H) 2.27-2.44 (m, 1H) 3.57 (br dd, J=11.15, 4.89 Hz, 0.5H) 3.69 (dt, J=12.81, 4.94 Hz, 1H) 3.73-3.82 (m, 1H) 3.82-3.90 (m, 0.5H) 3.94 (d, J=3.91 Hz, 3H) 3.97-4.04 (m, 1H) 4.49-4.59 (m, 0.5H) 4.67-4.76 (m, 0.5H) 7.46-7.54 (m, 2H) 7.56-7.62 (m, 2H) 7.62-7.67 (m, 2H) 7.67-7.74 (m, 2H) 7.91 (d, J=12.91 Hz, 1H) 8.06 (d, J=12.13 Hz, 1H) 8.24 (dd, J=14.28, 2.15 Hz, 1H) 8.63-8.74 (m, 1H); MS (ESI, m/z): 523.2 [M+H]+
Using 4-dimethylaminobenzeneboronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 510.2 [M+H]+
Using 4-hydroxy benzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.27-2.44 (m, 1H) 3.57 (br dd, J=11.54, 4.89 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.77 (br t, J=6.85 Hz, 1H) 3.84 (br t, J=7.04 Hz, 0.5H) 3.95 (d, J=3.91 Hz, 3H) 3.96-4.04 (m, 1H) 4.51-4.61 (m, 0.5H) 4.66-4.73 (m, 0.5H) 6.87 (dd, J=8.61, 3.13 Hz, 2H) 7.50 (dd, J=8.61, 4.30 Hz, 2H) 7.56-7.70 (m, 4H) 7.91 (d, J=12.52 Hz, 1H) 8.05 (d, J=12.13 Hz, 1H) 8.24 (dd, J=13.89, 2.15 Hz, 1H) 8.63-8.73 (m, 1H); MS (ESI, m/z): 483.2 [M+H]+
Using 4-formylbenzeneboronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 495.2 [M+H]+
Using 3-formylbenzeneboronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 495.2 [M+H]+
Using (4-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 565.2 [M+H]+
Using 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 593.2 [M+H]+
Using 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.26 (m, 1H) 2.28-2.49 (m, 1H) 2.93 (s, 3H) 3.13-3.26 (m, 4H) 3.46 (br s, 4H) 3.54-3.61 (m, 0.5H) 3.63-3.81 (m, 2H) 3.86 (br dd, J=13.89, 6.46 Hz, 0.5H) 3.95 (d, J=3.52 Hz, 3H) 3.97-4.06 (m, 1H) 4.08-4.16 (m, 2H) 4.52-4.60 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.56 (dd, J=8.22, 2.35 Hz, 2H) 7.62-7.70 (m, 2H) 7.70-7.83 (m, 4H) 7.91 (d, J=12.13 Hz, 1H) 8.06 (d, J=10.96 Hz, 1H) 8.25 (dd, J=12.72, 2.15 Hz, 1H) 8.64-8.75 (m, 1H); MS (ESI, m/z): 579.2 [M+H]+
Using 1-methyl-4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 607.2 [M+H]+
Using 2-(4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 607.2 [M+H]+
Using 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 579.2 [M+H]+
Using 2-(4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 609.2 [M+H]+
Using 3-bromobenzoic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 579.2 [M+H]+
Using 4-bromo-2-methylbenzoic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.22 (m, 1H) 2.26-2.51 (m, 1H) 2.90 (d, J=1.57 Hz, 3H) 3.12 (br s, 4H) 3.33-3.46 (m, 4H) 3.48 (br dd, J=6.85, 4.11 Hz, 0.5H) 3.62-3.70 (m, 1H) 3.70-3.82 (m, 1H) 3.87 (br s, 0.5H) 3.95 (d, J=5.09 Hz, 3H) 4.01 (d, J=2.74 Hz, 2H) 4.07 (dd, J=12.72, 7.24 Hz, 1H) 4.48-4.58 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.30-7.38 (m, 1H) 7.45-7.61 (m, 4H) 7.68 (dd, J=8.22, 5.48 Hz, 2H) 7.86-7.93 (m, 1H) 8.05 (br d, J=9.78 Hz, 1H) 8.24 (dd, J=9.59, 2.15 Hz, 1H) 8.61-8.71 (m, 1H); MS (ESI, m/z): 593.2 [M+H]+
Using 4-bromo-3-methylbenzoic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 593.2 [M+H]+
Using 2-amino-4-bromobenzoic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.18 (br d, J=11.35 Hz, 1H) 2.26-2.47 (m, 1H) 3.59 (br s, 0.5H) 3.63-3.74 (m, 1H) 3.78 (br s, 1H) 3.86 (br d, J=7.43 Hz, 0.5H) 3.94 (s, 3H) 3.97-4.10 (m, 1H) 4.56 (br s, 0.5H) 4.70 (br s, 0.5H) 7.28-7.42 (m, 3H) 7.45 (br t, J=7.63 Hz, 2H) 7.52 (br d, J=12.91 Hz, 1H) 7.62 (br d, J=7.04 Hz, 2H) 7.90 (br d, J=7.04 Hz, 1H) 8.05 (br d, J=8.22 Hz, 1H) 8.24 (br d, J=7.83 Hz, 1H) 8.64-8.76 (m, 1H); MS (ESI, m/z): 482.2 [M+H]+
Using 4-bromo-3-chlorobenzoic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.04 (br dd, J=12.52, 5.48 Hz, 0.5H) 2.28 (br d, J=6.65 Hz, 0.5H) 2.32-2.54 (m, 1H) 3.60 (br d, J=11.74 Hz, 0.5H) 3.65-3.77 (m, 1H) 3.77-3.89 (m, 1H) 3.93 (s, 3H) 3.95 (br d, J=6.65 Hz, 1H) 4.31 (br d, J=9.78 Hz, 0.5H) 4.79 (br d, J=16.43 Hz, 1H) 7.13 (br d, J=8.61 Hz, 1H) 7.30-7.45 (m, 4H) 7.58-7.68 (m, 1H) 7.68-7.80 (m, 1H) 7.99-8.17 (m, 1H) 8.52 (s, 1H) 8.67 (br d, J=6.26 Hz, 1H) 8.72-8.83 (m, 1H) 8.88 (br s, 1H); MS (ESI, m/z): 482.2 [M+H]+
Using 5-bromopicolinic acid and 2-chlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.14-2.23 (m, 1H) 2.31-2.43 (m, 1H) 3.79 (d, J=4.30 Hz, 0.5H) 3.80-3.92 (m, 2H) 3.94 (d, J=2.35 Hz, 3H) 4.04 (dd, J=12.52, 7.04 Hz, 1H) 4.18 (dd, J=12.13, 6.26 Hz, 0.5H) 4.60-4.73 (m, 1H) 7.41-7.49 (m, 3H) 7.55-7.60 (m, 1H) 7.88-7.94 (m, 2H) 8.03-8.09 (m, 2H) 8.24 (dd, J=9.00, 2.35 Hz, 1H) 8.67 (d, J=1.96 Hz, 1H) 8.70 (d, J=1.96 Hz, 0.5H) 8.73 (d, J=2.35 Hz, 0.5H); MS (ESI, m/z): 502.2 [M+H]+
Using 5-bromopicolinic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.12-2.22 (m, 1H) 2.36 (td, J=12.13, 6.26 Hz, 1H) 3.78 (d, J=4.30 Hz, 0.5H) 3.79-3.92 (m, 2H) 3.94 (d, J=3.91 Hz, 3H) 3.97-4.08 (m, 1H) 4.17 (dd, J=11.93, 6.06 Hz, 0.5H) 4.59-4.72 (m, 1H) 7.42-7.48 (m, 1H) 7.48-7.56 (m, 2H) 7.67-7.76 (m, 2H) 7.87-7.93 (m, 2H) 8.05 (d, J=11.35 Hz, 1H) 8.20 (ddd, J=8.41, 6.46, 2.35 Hz, 1H) 8.24 (dd, J=9.59, 2.15 Hz, 1H) 8.65-8.75 (m, 1H) 8.88 (dd, J=8.22, 1.96 Hz, 1H); MS (ESI, m/z): 468.2 [M+H]+
Using 6-bromonicotinic acid and 2-chlorobenzeneboronic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.09-2.29 (m, 1H) 2.29-2.48 (m, 1H) 3.61 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.70-3.86 (m, 2H) 3.86-3.93 (m, 0.5H) 3.95 (d, J=3.13 Hz, 3H) 3.98-4.10 (m, 1H) 4.57-4.76 (m, 1H) 7.43-7.51 (m, 2H) 7.53-7.62 (m, 2H) 7.80 (dd, J=8.02, 4.11 Hz, 1H) 7.91 (d, J=11.35 Hz, 1H) 8.06 (d, J=10.56 Hz, 1H) 8.11-8.20 (m, 1H) 8.25 (dd, J=11.93, 2.15 Hz, 1H) 8.63-8.74 (m, 1H) 8.85 (dd, J=6.85, 1.76 Hz, 1H); MS (ESI, m/z): 502.2 [M+H]+
Using 6-bromonicitinic acid, the title compound was obtained as described for the Example 343. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.18 (dt, J=14.38, 7.09 Hz, 1H) 2.31-2.47 (m, 1H) 3.61 (br dd, J=10.76, 4.89 Hz, 0.5H) 3.67-3.86 (m, 2H) 3.86-3.92 (m, 0.5H) 3.95 (d, J=4.30 Hz, 3H) 3.98-4.10 (m, 1H) 4.55-4.64 (m, 0.5H) 4.72 (br d, J=5.48 Hz, 0.5H) 7.47-7.60 (m, 3H) 7.91 (d, J=12.91 Hz, 1H) 7.96-8.09 (m, 4H) 8.12 (td, J=8.31, 2.15 Hz, 1H) 8.24 (dd, J=14.09, 1.96 Hz, 1H) 8.62-8.77 (m, 1H) 8.84 (dd, J=8.41, 1.76 Hz, 1H); MS (ESI, m/z): 468.2 [M+H]+
Using 4-bromo-3-methylbenzoic acid, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 481.2 [M+H]+
Using 4-iodobenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.24-2.44 (m, 1H) 3.45-3.52 (m, 0.5H) 3.57-3.78 (m, 2H) 3.78-3.85 (m, 0.5H) 3.87-4.04 (m, 1H) 3.95 (d, J=1.96 Hz, 3H) 4.50-4.60 (m, 0.5H) 4.64-4.72 (m, 0.5H) 7.33 (t, J=8.41 Hz, 2H) 7.79-7.88 (m, 2H) 7.90 (d, J=10.17 Hz, 1H) 8.05 (d, J=9.39 Hz, 1H) 8.25 (dd, J=10.37, 2.15 Hz, 1H) 8.60-8.71 (m, 1H); MS (ESI, m/z): 517.2 [M+H]+
Using benzofuran-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.15-2.31 (m, 1H) 2.33-2.50 (m, 1H) 3.76-3.82 (m, 1H) 3.88-3.92 (m, 3H) 3.95-4.12 (m, 1H) 4.12-4.25 (m, 1H) 4.37 (br dd, J=11.74, 6.26 Hz, 1H) 4.63-4.77 (m, 1H) 7.27-7.35 (m, 1H) 7.41-7.48 (m, 1H) 7.48-7.53 (m, 1H) 7.53-7.59 (m, 1H) 7.67-7.73 (m, 1H) 7.86 (d, J=6.26 Hz, 1H) 8.00 (d, J=7.43 Hz, 1H) 8.21 (dd, J=5.48, 1.96 Hz, 1H) 8.68 (dd, J=9.78, 1.96 Hz, 1H); MS (ESI, m/z): 431.2 [M+H]+
Using 3-methylbenzofuran-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.09-2.26 (m, 1H) 2.36 (dt, J=16.82, 6.65 Hz, 1H) 2.52 (d, J=2.74 Hz, 3H) 3.70-3.81 (m, 1H) 3.85 (br t, J=7.63 Hz, 0.5H) 3.92 (s, 3H) 3.94-4.02 (m, 1H) 4.04-4.23 (m, 1H) 4.31 (br dd, J=11.93, 6.46 Hz, 0.5H) 4.61-4.71 (m, 1H) 7.27-7.37 (m, 1H) 7.37-7.47 (m, 1H) 7.47-7.53 (m, 1H) 7.63-7.71 (m, 1H) 7.88 (d, J=6.26 Hz, 1H) 8.02 (d, J=6.26 Hz, 1H) 8.18-8.27 (m, 1H) 8.66 (dd, J=14.87, 1.96 Hz, 1H); MS (ESI, m/z): 445.2 [M+H]+
Using 5-chlorobenzofuran-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.14-2.31 (m, 1H) 2.31-2.50 (m, 1H) 3.74-3.90 (m, 1.5H) 3.92 (s, 3H) 3.96-4.11 (m, 1H) 4.18 (br dd, J=16.04, 7.43 Hz, 1H) 4.37 (br dd, J=11.93, 6.06 Hz, 0.5H) 4.64-4.77 (m, 1H) 7.40-7.47 (m, 1H) 7.50 (d, J=5.87 Hz, 1H) 7.58 (dd, J=9.00, 2.35 Hz, 2H) 7.76 (t, J=2.74 Hz, 1H) 7.88 (d, J=5.09 Hz, 1H) 8.02 (d, J=5.48 Hz, 1H) 8.24 (dd, J=3.91, 2.35 Hz, 1H) 8.65 (dd, J=10.76, 2.15 Hz, 1H); MS (ESI, m/z): 465.2 [M+H]+
Using 5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 467.2 [M+H]+
Using 2-naphthoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 441.2 [M+H]+
Using benzo[b]thiophene-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 447.2 [M+H]+
Using 4,5-dibromothiophene-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.10-2.47 (m, 2H) 3.63-3.89 (m, 2H) 3.93 (s, 3H) 3.94-4.03 (m, 1.5H) 4.16-4.26 (m, 0.5H) 4.60-4.77 (m, 1H) 7.50 (br d, J=14.48 Hz, 1H) 7.88 (s, 1H) 8.03 (s, 1H) 8.24 (s, 1H) 8.67 (br d, J=7.83 Hz, 1H); MS (ESI, m/z): 553.0/555.1/557.1 [M+H]+
Using 5-methylthiophene-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.11-2.28 (m, 1H) 2.29-2.42 (m, 1H) 2.49 (s, 3H) 3.70 (br d, J=13.69 Hz, 1H) 3.76-3.89 (m, 1H) 3.92 (s, 3H) 3.95-4.07 (m, 1.5H) 4.21 (br s, 0.5H) 4.65 (br s, 1H) 6.79 (d, J=2.74 Hz, 1H) 7.49 (d, J=3.91 Hz, 1H) 7.88 (s, 1H) 8.03 (s, 1H) 8.22 (s, 1H) 8.68 (br d, J=7.04 Hz, 1H); MS (ESI, m/z): 411.1 [M+H]+
Using 4-methylthiophene-2-carboxylic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.15 (br d, J=5.48 Hz, 1H) 2.26 (s, 3H) 2.29-2.44 (m, 1H) 3.68-3.78 (m, 1H) 3.78-3.88 (m, 1H) 3.92 (s, 3H) 3.93-4.08 (m, 1.5H) 4.18-4.26 (m, 0.5H) 4.66 (br s, 1H) 7.23 (s, 1H) 7.50 (s, 1H) 7.88 (s, 1H) 8.03 (s, 1H) 8.23 (s, 1H) 8.68 (br d, J=11.74 Hz, 1H); MS (ESI, m/z): 411.1 [M+H]+
Using 4-benzyloxybenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.05-2.21 (m, 1H) 2.23-2.44 (m, 1H) 3.56 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.62-3.87 (m, 2.5H) 3.94 (s, 3H) 3.95-4.03 (m, 1H) 4.48-4.60 (m, 0.5H) 4.62-4.72 (m, 0.5H) 5.13 (d, J=3.52 Hz, 2H) 7.06 (dd, J=8.22, 5.48 Hz, 2H) 7.28-7.33 (m, 1H) 7.37 (br t, J=7.43 Hz, 2H) 7.40-7.47 (m, 2H) 7.54 (br t, J=9.59 Hz, 2H) 7.90 (d, J=10.17 Hz, 1H) 8.05 (d, J=9.39 Hz, 1H) 8.24 (dd, J=10.96, 1.96 Hz, 1H) 8.61-8.73 (m, 1H); MS (ESI, m/z): 497.1 [M+H]+
Using 4-(cyclohex-2-en-1-yloxy)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 487.1 [M+H]+
Using 3-phenoxybenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.21 (m, 1H) 2.22-2.42 (m, 1H) 3.48 (dd, J=11.15, 4.89 Hz, 0.5H) 3.57-3.74 (m, 2H) 3.83 (br s, 0.5H) 3.84-3.92 (m, 0.5H) 3.94 (s, 3H) 3.95-4.01 (m, 0.5H) 4.50-4.60 (m, 0.5H) 4.60-4.71 (m, 0.5H) 6.97-7.05 (m, 2H) 7.05-7.18 (m, 3H) 7.27 (dd, J=12.72, 7.63 Hz, 1H) 7.31-7.40 (m, 2H) 7.40-7.48 (m, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.05 (d, J=7.43 Hz, 1H) 8.24 (dd, J=6.85, 2.15 Hz, 1H) 8.60-8.71 (m, 1H); MS (ESI, m/z): 483.1 [M+H]+
Using 4-(2-bromoethyl)benzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.15-2.21 (m, 1H) 2.26-2.43 (m, 1H) 3.21 (br s, 2H) 3.46-3.55 (m, 0.5H) 3.66 (br s, 2H) 3.69-3.88 (m, 2.5H) 3.82 (br s, 3H) 3.97-4.05 (m, 1H) 4.52 (br d, J=18.39 Hz, 0.5H) 4.68 (br s, 0.5H) 6.79 (dd, J=17.61, 10.96 Hz, 2H) 7.33-7.44 (m, 2H) 7.90 (br d, J=10.17 Hz, 1H) 8.05 (br d, J=10.17 Hz, 1H) 8.24 (br d, J=11.35 Hz, 1H) 8.69 (s, 1H); MS (ESI, m/z): 497.1/499.2[M+H]+
Using 4-tert-butylbenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.33 (d, J=3.52 Hz, 9H) 2.03-2.22 (m, 1H) 2.22-2.44 (m, 1H) 3.48-3.58 (m, 0.5H) 3.66 (br dd, J=12.72, 4.89 Hz, 1H) 3.69-3.79 (m, 1H) 3.79-3.87 (m, 0.5H) 3.94 (s, 3H) 3.96-4.03 (m, 1H) 4.46-4.57 (m, 0.5H) 4.63-4.73 (m, 0.5H) 7.50 (br d, J=8.61 Hz, 4H) 7.90 (br d, J=11.35 Hz, 1H) 8.05 (d, J=10.17 Hz, 1H) 8.24 (br d, J=12.91 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 447.1 [M+H]+
Using 3,4-dimethylbenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.04-2.20 (m, 1H) 2.26-2.61 (m, 7H) 3.51 (br dd, J=11.54, 5.28 Hz, 0.5H) 3.58-3.68 (m, 1H) 3.68-3.77 (m, 1H) 3.81-3.86 (m, 0.5H) 3.86-4.04 (m, 1H) 3.94 (s, 3H) 4.47-4.57 (m, 0.5H) 4.63-4.72 (m, 0.5H) 7.17-7.36 (m, 3H) 7.90 (d, J=11.74 Hz, 1H) 8.05 (d, J=10.96 Hz, 1H) 8.23 (dd, J=13.89, 1.76 Hz, 1H) 8.60-8.75 (m, 1H); MS (ESI, m/z): 419.1 [M+H]+
Using 4-(4-methylpiperazin-1-yl)benzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.04-2.22 (m, 1H) 2.22-2.45 (m, 1H) 2.96 (s, 3H) 3.05-3.18 (m, 2H) 3.18-3.27 (m, 2H) 3.55-3.86 (m, 5H) 3.94 (s, 3H) 3.99 (br d, J=14.48 Hz, 2H) 4.51 (br d, J=5.09 Hz, 0.5H) 4.67 (br s, 0.5H) 6.96-7.10 (m, 2H) 7.54 (br t, J=9.59 Hz, 2H) 7.90 (br d, J=9.00 Hz, 1H) 8.05 (br d, J=7.04 Hz, 1H) 8.24 (br d, J=7.43 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 489.1 [M+H]+
Using 4-vinylbenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.04-2.21 (m, 1H) 2.26-2.46 (m, 1H) 3.45-3.59 (m, 0.5H) 3.59-3.69 (m, 1H) 3.69-3.78 (m, 1H) 3.82 (br s, 0.5H) 3.95 (d, J=2.35 Hz, 3H) 4.01 (br d, J=12.91 Hz, 1H) 4.54 (br s, 0.5H) 4.69 (br s, 0.5H) 5.34 (br d, J=10.56 Hz, 1H) 5.84-5.95 (m, 1H) 6.70-6.85 (m, 1H) 7.53 (d, J=7.04 Hz, 4H) 7.91 (br d, J=11.35 Hz, 1H) 8.05 (br d, J=10.17 Hz, 1H) 8.24 (br d, J=12.13 Hz, 1H) 8.61-8.73 (m, 1H); MS (ESI, m/z): 417.1 [M+H]+
Using 4-isopropylbenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.26 (dd, J=7.04, 3.13 Hz, 6H) 1.99-2.23 (m, 1H) 2.23-2.49 (m, 1H) 2.90-3.00 (m, 1H) 3.49-3.58 (m, 0.5H) 3.65 (br dd, J=12.72, 5.28 Hz, 1H) 3.69-3.78 (m, 1H) 3.78-3.87 (m, 0.5H) 3.88-4.02 (m, 1H) 3.95 (d, J=1.96 Hz, 3H) 4.49-4.60 (m, 0.5H) 4.61-4.77 (m, 0.5H) 7.30-7.37 (m, 2H) 7.46-7.55 (m, 2H) 7.90 (d, J=10.96 Hz, 1H) 8.05 (d, J=9.78 Hz, 1H) 8.19-8.29 (m, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 433.1 [M+H]+
Using 4-cyanobenzoic acid, the title compound was obtained as described for the Example 342. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.23 (m, 1H) 2.25-2.48 (m, 1H) 3.42-3.49 (m, 0.5H) 3.55-3.62 (m, 0.5H) 3.62-3.70 (m, 1H) 3.70-3.79 (m, 0.5H) 3.80-3.91 (m, 1H) 3.94 (d, J=1.96 Hz, 3H) 3.96-4.05 (m, 0.5H) 4.52-4.62 (m, 0.5H) 4.63-4.74 (m, 0.5H) 7.68-7.75 (m, 2H) 7.84 (dd, J=8.22, 5.09 Hz, 2H) 7.90 (d, J=10.56 Hz, 1H) 8.05 (d, J=9.39 Hz, 1H) 8.24 (dd, J=10.37, 2.15 Hz, 1H) 8.62-8.78 (m, 1H); MS (ESI, m/z): 416.1 [M+H]+
Using 4-(methylthio)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 437.1 [M+H]+
Using 2-(3-bromophenyl)acetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 483.1/485.1 [M+H]+
Using 2-([1,1′-biphenyl]-4-yl)acetic acid, the title compound was obtained as described for the Example 342. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.01-2.20 (m, 1H) 2.23-2.39 (m, 1H) 3.51-3.60 (m, 1H) 3.66-3.87 (m, 3H) 3.91 (s, 2H) 3.93 (s, 3H) 4.51 (br t, J=4.11 Hz, 0.5H) 4.53-4.59 (m, 0.5H) 7.29-7.42 (m, 5H) 7.43-7.47 (m, 2H) 7.52-7.58 (m, 2H) 7.81 (s, 0.5H) 7.87 (s, 0.5H) 7.94 (s, 0.5H) 8.00 (d, J=2.35 Hz, 0.5H) 8.01 (s, 0.5H) 8.21 (d, J=1.76 Hz, 0.5H) 8.39 (d, J=1.76 Hz, 0.5H) 8.62 (d, J=1.76 Hz, 0.5H); MS (ESI, m/z): 481.1 [M+H]+
Using 2-([1,1′-biphenyl]-3-yl)acetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 481.1 [M+H]+
Using cinnamic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 417.1 [M+H]+
Using (E)-3-(benzo[d][1,3]dioxol-5-yl)acrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 461.1 [M+H]+
Using (E)-2-methyl-3-phenylacrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 431.1 [M+H]+
Using (E)-3-(4-bromophenyl)acrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 495.1/497.2 [M+H]+
Using (E)-3-(3-bromophenyl)acrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 495.1/497.2 [M+H]+
Using (E)-3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)acrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 529.1 [M+H]+
Using (E)-3-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)acrylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 559.1 [M+H]+
Using (E)-3-(3-bromophenyl)acrylic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 605.1 [M+H]+
Using (E)-3-(4-bromophenyl)acrylic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the Example 343. MS (ESI, m/z): 605.1 [M+H]+
Using 2-phenylacetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 405.20 [M+H]+
Using 2-(3-chlorophenyl)acetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 439.16 [M+H]+
Using 2-(2-fluorophenyl)acetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 423.19 [M+H]+
Using 2-(2-methoxyphenyl)acetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 435.21 [M+H]+
Using 2-methyl-2-phenylpropanoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 433.23 [M+H]+
Using benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 391.18 [M+H]+
Using 4-fluoro-2-methylbenzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 423.19 [M+H]+
Using 5-bromo-2-chlorobenzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 503.05 [M+H]+
Using 3,5-dichlorobenzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 459.10 [M+H]+
Using trans-2-phenylcyclopropane-1-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 431.21 [M+H]+
Using 5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1-naphthoic acid the title compound was obtained as described for the Example 342. MS (ESI, m/z): 629.33 [M+H]+
Using (R)-5-(4-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)phenyl)-1-naphthoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 630.31 [M+H]+
Using 5-(4-(((1-(1-methylpiperidin-4-yl)ethyl)amino)methyl)phenyl)-1-naphthoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 671.37 [M+H]+
Using 3-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 595.31 [M+H]+
Using (R)-3-(4-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)phenoxy)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 596.29 [M+H]+
Using 4-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 595.31 [M+H]+
Using (R)-4-(4-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)phenoxy)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 596.29 [M+H]+
Using [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 467.21 [M+H]+
Using 3-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 540.28 [M+H]+
Using 3′-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 607.31 [M+H]+
Using 3′-(2-(4-methylpiperazin-1-yl)ethyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 593.33 [M+H]+
Using 4′-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 607.31 [M+H]+
Using 4′-(2-(4-methylpiperazin-1-yl)ethyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 593.33 [M+H]+
Using [1,1′-biphenyl]-3,3′-dicarboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 511.20 [M+H]+
Using 3′-amino-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 482.22 [M+H]+
Using 2-phenyl-5-(trifluoromethyl)oxazole-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 526.17 [M+H]+
Using 3′-((1H-pyrazol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 547.25 [M+H]+
Using 3′-((1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 547.25 [M+H]+
Using 3′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 566.28 [M+H]+
Using (R)-3′-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 580.30 [M+H]+
Using 3′-(thiomorpholine-4-carbonyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 596.24 [M+H]+
Using 3′-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 579.28 [M+H]+
Using 4′-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 579.28 [M+H]+
Using 3′-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 579.28 [M+H]+
Using 4′-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 579.28 [M+H]+
Using 3-(furan-3-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 457.19 [M+H]+
Using 3-(1,3-dimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 485.23 [M+H]+
Using 3-(1-cyclopentyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 525.26 [M+H]+
Using 3-(1-(phenylsulfonyl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 597.20 [M+H]+
Using 3-(pyridin-3-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 468.21 [M+H]+
Using 3-(pyridin-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 468.21 [M+H]+
Using 3-(benzo[b]thiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 523.18 [M+H]+
Using 2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 471.24 [M+H]+
Using 3′-(4-methylpiperazin-1-yl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 565.30 [M+H]+
Using 3′-(piperidin-1-yl)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 550.29 [M+H]+
Using 2′-chloro-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 501.17 [M+H]+
Using 3′-chloro-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 501.17 [M+H]+
Using 3-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 552.28 [M+H]+
Using 3′-(methylsulfonamido)-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 560.20 [M+H]+
Using 6-methyl-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 481.23 [M+H]+
Using 2′-chloro-6-methyl-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 515.19 [M+H]+
Using 3′-chloro-6-methyl-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 515.19 [M+H]+
Using 2-amino-5-methyl-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 496.24 [M+H]+
Using 4-amino-[1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 482.22 [M+H]+
Using 4-(furan-3-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 457.19 [M+H]+
Using 4-(1,3-dimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 485.23 [M+H]+
Using 4-(pyridin-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 468.21 [M+H]+
Using 4-(benzo[b]thiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 523.18 [M+H]+
Using 4-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 552.28 [M+H]+
Using 4′-morpholino-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 552.26 [M+H]+
Using 4′-(morpholine-4-carbonyl)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 580.26 [M+H]+
Using 2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 471.24 [M+H]+
Using 3-(2,3-dioxoindolin-6-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 536.20 [M+H]+
Using 2,3-dihydro-1H-indene-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 431.21 [M+H]+
Using 3-methyl-1H-indene-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 443.21 [M+H]+
Using 5-chlorobenzo[d]oxazole-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 466.13 [M+H]+
Using 1-methyl-1H-indazole-3-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 445.20 [M+H]+
Using 5-hydroxy-3-phenylisoxazole-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 472.20 [M+H]+
Using dibenzo[b,d]furan-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 481.19 [M+H]+
Using 1-(tert-butoxycarbonyl)-1H-indole-5-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 430.19 [M+H]+
Using 4-(tert-butoxycarbonyl)-1,2,3,4-tetrahydrocyclopenta[b]indole-7-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 470.22 [M+H]+
Using 1-(tert-butoxycarbonyl)-1H-indole-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 430.19 [M+H]+
Using 4′-(4-aminophenoxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 574.25 [M+H]+
Using 4-(1-methyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 471.22 [M+H]+
Using 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 499.25 [M+H]+
Using 4-(1-cyclopentyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 525.26 [M+H]+
Using 4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 541.26 [M+H]+
Using 4-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 540.28 [M+H]+
Using 4-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 640.33 [M+H]+
Using 5-phenylbenzofuran-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 507.21 [M+H]+
Using 1-acetyl-1H-indole-5-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 472.20 [M+H]+
Using 1-acetyl-1H-indole-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 472.20 [M+H]+
Using 3-hydroxybenzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 407.18 [M+H]+
Using 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 525.19 [M+H]+
Using 4-(1,5-dimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 485.23 [M+H]+
Using 4-(3,5-dimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 485.23 [M+H]+
Using 4-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 561.26 [M+H]+
Using 4-(1-(4-aminophenyl)-3,5-dimethyl-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 576.28 [M+H]+
Using 4-(1,3-dimethyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 553.22 [M+H]+
Using 4-(4-bromo-3,5-dimethylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 579.11 [M+H]+
Using 4-(4-methylthiophen-3-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 487.18 [M+H]+
Using 4-(3-methoxythiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 503.18 [M+H]+
Using 4-(4-methylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 487.18 [M+H]+
Using 4-(5-methylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 487.18 [M+H]+
Using 4′-phenoxy-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 559.24 [M+H]+
Using 4′-(4-methoxyphenoxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 589.25 [M+H]+
Using 4′-(4-(dimethylamino)phenoxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 602.28 [M+H]+
Using 4′-(3-aminophenoxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 574.25 [M+H]+
Using 4′-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 566.28 [M+H]+
Using 4′-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)oxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 552.26 [M+H]+
Using 4′-(4-aminophenoxy)-2′-fluoro-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 592.24 [M+H]+
Using 4-(5-chlorothiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 507.13 [M+H]+
Using 3-hydroxy-4-(5-methylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 503.18 [M+H]+
Using 3-methyl-4-(5-methylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 501.20 [M+H]+
Using 4-(5-cyanothiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 498.16 [M+H]+
Using 4-(5-acetylthiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 515.18 [M+H]+
Using 4-(3,5-dimethylisoxazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 486.22 [M+H]+
Using 4-(3-amino-5-methylisoxazol-4-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 487.21 [M+H]+
Using (S)-4′-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)oxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 552.26 [M+H]+
Using 4-(5-(1-hydroxyethyl)thiophen-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 517.19 [M+H]+
Using 4-(5-methylthiazol-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 488.18 [M+H]+
Using 4-(4-methylthiazol-2-yl)benzoic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 488.18 [M+H]+
Using 1H-benzo[d]imidazole-2-carboxylic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 431.2 [M+H]+
Using 2-oxo-2-phenylacetic acid, the title compound was obtained as described for the Example 342. MS (ESI, m/z): 419.2 [M+H]±
Using Example 381 and 1-(tert-butoxycarbonyl)azetidin-3-yl)amine and trifluoroacetic acid, the title compound was obtained as described in general method F. MS (ESI, m/z): 579.1 [M+H]+
Using Example 381 and N-methyl-1-(1-methylpiperidin-3-yl)methanamine, the title compound was obtained as described in general method F. MS (ESI, m/z): 605.1 [M+H]+
Using Example 381 and 1-methylpiperidin-4-amine, the title compound was obtained as described in general method F. MS (ESI, m/z): 593.1 [M+H]+
Using o-tolylboronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.22 (m, 1H) 2.24 (d, J=6.46 Hz, 3H) 2.29-2.45 (m, 1H) 3.60 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.74 (m, 1H) 3.75-3.83 (m, 1H) 3.84-3.91 (m, 0.5H) 3.94 (d, J=3.52 Hz, 3H) 3.97-4.06 (m, 1H) 4.58 (br t, J=5.87 Hz, 0.5H) 4.67-4.74 (m, 0.5H) 7.16-7.20 (m, 1H) 7.20-7.29 (m, 3H) 7.40 (t, J=8.80 Hz, 2 H) 7.63 (dd, J=14.97, 7.92 Hz, 2H) 7.91 (d, J=17.02 Hz, 1H) 8.06 (d, J=15.26 Hz, 1H) 8.24 (dd, J=18.19, 1.76 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using (5-chloro-2-methylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.14-2.24 (br dd, J=12.33, 6.46 Hz, 1H) 2.21 (d, J=6.46 Hz, 3H) 2.29-2.46 (m, 1H) 3.59 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.73-3.83 (m, 1H) 3.83-3.92 (m, 0.5H) 3.95 (d, J=4.11 Hz, 3H) 3.96-4.05 (m, 1H) 4.58 (brt, J=6.16 Hz, 0.5H) 4.67-4.74 (m, 0.5H) 7.19 (d, J=9.98 Hz, 1H) 7.27 (d, J=5.87 Hz, 2H) 7.41 (t, J=8.34 Hz, 2H) 7.65 (dd, J=14.09, 8.22 Hz, 2H) 7.90 (d, J=17.02 Hz, 1H) 8.06 (d, J=15.26 Hz, 1H) 8.24 (dd, J=18.19, 1.76 Hz, 1H) 8.62-8.73 (m, 1H); MS (ESI, m/z): 515.2 [M+H]+
Using (3,5-dimethylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.27-2.40 (br s, 1H) 2.35 (d, J=7.63 Hz, 6H) 3.58 (dd, J=11.15, 4.70 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.82-3.90 (m, 0.5H) 3.94 (d, J=7.04 Hz, 3H) 3.95-4.04 (m, 1H) 4.54 (br t, J=5.87 Hz, 0.5H) 4.65-4.71 (m, 0.5H) 7.01 (br d, J=7.04 Hz, 1H) 7.22 (d, J=12.33 Hz, 2H) 7.60 (dd, J=16.14, 7.92 Hz, 2H) 7.63-7.68 (m, 2H) 7.85-7.93 (m, 1H) 8.00-8.07 (m, 1H) 8.17-8.24 (m, 1H) 8.58-8.71 (m, 1H); MS (ESI, m/z): 495.2 [M+H]+
Using (3,4-dimethylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.23 (m, 1H) 2.29 (d, J=6.46 Hz, 3H) 2.31 (d, J=8.80 Hz, 3H) 2.28-2.39 (br dd, J=13.79, 6.75 Hz, 1H) 3.57 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.83-3.90 (m, 0.5 H) 3.94 (d, J=7.04 Hz, 3H) 3.95-4.03 (m, 1H) 4.50-4.57 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.19 (t, J=8.22 Hz, 1H) 7.34 (t, J=9.31 Hz, 1H) 7.38-7.41 (m, 1H) 7.60 (dd, J=16.43, 8.22 Hz, 2H) 7.63-7.69 (m, 2H) 7.86-7.93 (m, 1H) 8.00-8.07 (m, 1H) 8.18-8.24 (m, 1H) 8.58-8.69 (m, 1H); MS (ESI, m/z): 495.2 [M+H]+
Using (4-fluoro-2-(trifluoromethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.24 (m, 1H) 2.30-2.46 (m, 1H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.73 (m, 1H) 3.74-3.81 (m, 1H) 3.83-3.92 (m, 0.5H) 3.95 (d, J=2.35 Hz, 3H) 3.96-4.06 (m, 1H) 4.59 (br t, J=5.87 Hz, 0.5H) 4.68-4.74 (m, 0.5H) 7.38-7.48 (m, 4H) 7.55-7.60 (m, 1H) 7.64 (dd, J=12.33, 8.22 Hz, 2H) 7.91 (d, J=15.26 Hz, 1H) 8.06 (d, J=14.09 Hz, 1H) 8.25 (dd, J=17.02, 1.76 Hz, 1H) 8.63-8.74 (m, 1H); MS (ESI, m/z): 553.2 [M+H]+
Using (3-(trifluoromethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.26 (m, 1H) 2.30-2.46 (m, 1H) 3.58 (dd, J=10.86, 4.99 Hz, 0.5H) 3.65-3.74 (m, 1H) 3.75-3.83 (m, 1H) 3.83-3.92 (m, 0.5H) 3.93-3.97 (d, J=2.35 Hz, 3H) 3.97-4.06 (m, 1H) 4.57 (br t, J=5.87 Hz, 0.5H) 4.68-4.74 (m, 0.5H) 7.65-7.74 (m, 4H) 7.74-7.81 (m, 2H) 7.88-7.96 (m, 3H) 8.06 (d, J=18.19 Hz, 1H) 8.23 (s, 1H) 8.26 (s, 1H) 8.63-8.74 (m, 1H); MS (ESI, m/z): 535.2 [M+H]+
Using (4-chloro-2-methylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.22 (m, 1H) 2.24 (d, J=5.87 Hz, 3H) 2.30-2.47 (m, 1H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.74-3.83 (m, 1H) 3.84-3.91 (m, 0.5H) 3.95 (d, J=3.52 Hz, 3H) 3.96-4.05 (m, 1H) 4.55-4.61 (m, 0.5H) 4.68-4.73 (m, 0.5H) 7.18 (t, J=7.75 Hz, 1H) 7.22-7.27 (m, 1H) 7.32 (br d, J=3.52 Hz, 1H) 7.41 (t, J=8.51 Hz, 2H) 7.64 (dd, J=14.09, 8.22 Hz, 2H) 7.90 (d, J=16.43 Hz, 1H) 8.05 (d, J=15.26 Hz, 1H) 8.25 (dd, J=17.61, 1.76 Hz, 1H) 8.62-8.73 (m, 1H); MS (ESI, m/z): 515.2 [M+H]+
Using (4-fluoro-3-methylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.24 (m, 1H) 2.31-2.43 (br d, J=7.04 Hz, 1H) 2.34 (br d, J=4.11 Hz, 3H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.73-3.81 (m, 1H) 3.83-3.92 (m, 0.5H) 3.95 (d, J=5.28 Hz, 3H) 3.96-4.05 (m, 1H) 4.53-4.62 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.12 (td, J=8.95, 5.58 Hz, 1H) 7.44-7.50 (m, 1H) 7.53 (br t, J=7.34 Hz, 1H) 7.60-7.66 (m, 2H) 7.66-7.72 (m, 2H) 7.91 (d, J=19.37 Hz, 1H) 8.06 (d, J=18.19 Hz, 1H) 8.20-8.28 (m, 1H) 8.61-8.76 (m, 1H); MS (ESI, m/z): 499.2 [M+H]+
Using (1H-indol-5-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.23 (m, 1H) 2.28-2.43 (m, 1H) 3.61 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.68-3.75 (m, 1H) 3.75-3.83 (m, 1H) 3.85-3.92 (m, 0.5H) 3.94 (d, J=7.63 Hz, 3H) 3.98-4.04 (m, 1H) 4.45-4.60 (m, 0.5H) 4.65-4.73 (m, 0.5H) 6.51 (dd, J=6.16, 3.23 Hz, 1H) 7.28 (br s, 1H) 7.38-7.43 (m, 1H) 7.43-7.49 (m, 1H) 7.62 (dd, J=16.14, 7.92 Hz, 2H) 7.71-7.77 (m, 2H) 7.83 (br d, J=8.80 Hz, 1H) 7.88-7.95 (m, 1H) 8.02-8.11 (m, 1H) 8.19-8.26 (m, 1H) 8.62-8.77 (n, 1H); MS (ESI, m/z): 506.2 [M+H]+
Using indolin-5-ylboronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.27 (m, 1H) 2.29-2.46 (m, 1H) 3.40-3.45 (m, 2H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.67-3.74 (m, 1H) 3.75-3.82 (m, 1H) 3.84-3.90 (m, 1H) 3.92 (td, J=7.78, 3.23 Hz, 1.5H) 3.95 (d, J=5.28 Hz, 3H) 3.97-3.99 (m, 0.5H) 4.04 (br dd, J=12.91, 7.04 Hz, 0.5H) 4.54-4.61 (m, 0.5H) 4.69-4.75 (m, 0.5H) 7.57 (dd, J=8.22, 5.28 Hz, 1H) 7.62-7.78 (m, 5H) 7.81 (br d, J=7.63 Hz, 1H) 7.91 (d, J=17.61 Hz, 1H) 8.07 (d, J=15.85 Hz, 1H) 8.25 (dd, J=17.90, 2.05 Hz, 1H) 8.71 (dd, J=46.37, 1.76 Hz, 1H); MS (ESI, m/z): 508.2 [M+H]+
Using m-tolylboronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.26 (m, 1H) 2.32-2.45 (br dd, J=12.91, 6.46 Hz, 1H) 2.41 (d, J=6.46 Hz, 3H) 3.59 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.73 (m, 1H) 3.74-3.82 (m, 1H) 3.85-3.91 (m, 0.5H) 3.95 (d, J=6.46 Hz, 3H) 3.96-4.05 (m, 1H) 4.51-4.63 (m, 0.5H) 4.66-4.74 (m, 0.5H) 7.20 (br t, J=6.46 Hz, 1H) 7.34 (q, J=7.63 Hz, 1H) 7.43 (t, J=8.42 Hz, 1H) 7.46 (d, J=9.82 Hz, 1H) 7.63 (dd, J=15.85, 8.22 Hz, 2H) 7.67-7.72 (m, 2H) 7.91 (d, J=19.96 Hz, 1H) 8.05 (d, J=19.96 Hz, 1H) 8.19-8.27 (m, 1H) 8.61-8.75 (m, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using (3-ethylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.24-1.30 (m, 3H) 2.09-2.23 (m, 1H) 2.28-2.45 (m, 1H) 2.71 (quin, J=7.19 Hz, 2H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.70 (br dd, J=12.33, 5.28 Hz, 1H) 3.74-3.81 (m, 1H) 3.84-3.91 (m, 0.5H) 3.95 (d, J=5.87 Hz, 3H) 3.96-4.04 (m, 1H) 4.52-4.59 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.23 (br t, J=6.16 Hz, 1H) 7.36 (q, J=7.04 Hz, 1H) 7.40-7.50 (m, 2H) 7.63 (dd, J=15.85, 8.22 Hz, 2H) 7.68-7.74 (m, 2H) 7.91 (d, J=19.96 Hz, 1H) 8.05 (d, J=19.37 Hz, 1H) 8.19-8.27 (m, 1H) 8.62-8.74 (m, 1H); MS (ESI, m/z): 495.2 [M+H]+
Using (3-isopropylphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.26-1.32 (m, 6H) 2.08-2.24 (m, 1H) 2.28-2.44 (m, 1H) 2.92-3.01 (m, 1H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.73 (m, 1H) 3.73-3.81 (m, 1H) 3.81-3.90 (m, 0.5H) 3.94 (d, J=5.87 Hz, 3H) 3.95-4.04 (m, 1H) 4.49-4.58 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.24-7.28 (m, 1H) 7.34-7.39 (m, 1H) 7.43 (t, J=8.10 Hz, 1H) 7.48 (d, J=9.11 Hz, 1H) 7.63 (dd, J=15.26, 8.22 Hz, 2H) 7.66-7.72 (m, 2H) 7.90 (d, J=19.96 Hz, 1H) 8.05 (d, J=19.37 Hz, 1H) 8.19-8.28 (m, 1H) 8.62-8.77 (m, 1H); MS (ESI, m/z): 509.3 [M+H]+
Using (3,4-dimethoxyphenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.27-2.43 (m, 1H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.68 (br dd, J=12.62, 4.99 Hz, 1H) 3.72-3.81 (m, 1H) 3.86 (d, J=5.87 Hz, 3.5H) 3.89 (d, J=8.80 Hz, 3H) 3.94 (d, J=7.04 Hz, 3H) 3.95-4.03 (m, 1H) 4.49-4.57 (m, 0.5H) 4.65-4.71 (m, 0.5H) 6.98-7.06 (m, 1H) 7.16-7.23 (m, 2H) 7.60 (dd, J=16.14, 7.92 Hz, 2H) 7.67 (dd, J=12.91, 8.22 Hz, 2H) 7.85-7.94 (m, 1H) 7.99-8.08 (m, 1H) 8.17-8.25 (m, 1H) 8.60-8.73 (m, 1H); MS (ESI, m/z): 527.2 [M+H]+
Using (4-(azetidin-1-ylsulfonyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.01-2.22 (m, 3H) 2.25-2.44 (m, 1H) 3.45-4.05 (m, 2H) 3.65-3.72 (m, 2H) 3.75-3.80 (m, 2H) 3.93 (s, 3H) 4.51-4.58 (m, 0.5H) 4.63-4.73 (m, 0.5H) 6.97 (d, J=8.80 Hz, 1H) 7.47 (dd, J=12.33, 8.22 Hz, 1H) 7.57-7.67 (m, 2H) 7.70 (dd, J=14.67, 8.22 Hz, 1H) 7.82 (br t, J=8.80 Hz, 1H) 7.87-7.99 (m, 3H) 7.99-8.09 (m, 1H) 8.19-8.28 (m, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 586.6 [M+H]+
Using (4-chloro-3-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.27-2.44 (m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.71 (m, 1H) 3.71-3.79 (m, 1H) 3.81-3.90 (m, 0.5H) 3.93 (d, J=5.28 Hz, 3H) 3.94-4.03 (m, 1H) 4.51-4.61 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.47 (td, J=7.92, 1.76 Hz, 1H) 7.51-7.59 (m, 2H) 7.65 (dd, J=14.67, 8.80 Hz, 2H) 7.69-7.76 (m, 2H) 7.89 (d, J=18.19 Hz, 1H) 8.04 (d, J=17.02 Hz, 1H) 8.16-8.27 (m, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using (4-aminophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.28-2.43 (m, 1H) 3.56 (dd, J=11.15, 4.70 Hz, 1H) 3.64-3.72 (m, 1H) 3.72-3.79 (m, 1H) 3.83-3.89 (m, 1H) 3.92-3.95 (m, 1H) 3.95-4.04 (m, 1H) 4.53-4.58 (m, 1H) 4.67-4.72 (m, 1H) 7.45-7.50 (m, 2H) 7.67 (dd, J=14.09, 8.22 Hz, 2H) 7.72-7.78 (m, 2H) 7.79-7.85 (m, 2H) 7.90 (d, J=17.61 Hz, 1H) 8.05 (d, J=16.43 Hz, 1H) 8.24 (dd, J=18.19, 2.35 Hz, 1H) 8.63-8.75 (m, 1H); MS (ESI, m/z): 482.2 [M+H]+
Using (3-chloro-5-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.27-2.42 (m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.71 (m, 1H) 3.71-3.79 (m, 1H) 3.82-3.89 (m, 0.5H) 3.93 (d, J=5.87 Hz, 3H) 3.94-4.04 (m, 1H) 4.51-4.58 (m, 0.5H) 4.65-4.72 (m, 0.5H) 7.22 (ddt, J=8.44, 4.18, 2.20, 2.20 Hz, 1H) 7.31-7.45 (m, 1H) 7.52 (d, J=8.22 Hz, 1H) 7.62-7.69 (m, 2H) 7.69-7.76 (m, 2H) 7.89 (d, J=18.19 Hz, 1H) 8.04 (d, J=17.61 Hz, 1H) 8.23 (dd, J=19.96, 2.35 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using (3,5-dichloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.27-2.42 (m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.70 (m, 1H) 3.71-3.78 (m, 1H) 3.82-3.88 (m, 0.5H) 3.93 (d, J=5.87 Hz, 3H) 3.94-4.04 (m, 1H) 4.51-4.59 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.62-7.76 (m, 6H) 7.89 (d, J=18.78 Hz, 1H) 8.04 (d, J=17.61 Hz, 1H) 8.23 (dd, J=19.37, 2.35 Hz, 1H) 8.60-8.71 (m, 1H); MS (ESI, m/z): 553.2 [M+H]+
Using (4-(methylthio)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.04-2.22 (m, 1H) 2.25-2.40 (m, 1H) 2.47-2.49 (d, J=4.11 Hz, 3H) 3.52 (dd, J=11.15, 5.87 Hz, 0.5H) 3.60-3.69 (m, 1H) 3.69-3.78 (m, 1H) 3.79-3.87 (m, 0.5H) 3.92 (d, J=3.52 Hz, 3H) 3.93-4.04 (m, 1H) 4.49-4.56 (m, 0.5H) 7.30 (dd, J=8.22, 5.87 Hz, 2H) 7.48-7.54 (m, 2H) 7.54-7.58 (m, 2H) 7.58-7.64 (m, 2H) 7.79 (d, J=15.85 Hz, 1H) 7.91 (d, J=12.33 Hz, 1H) 8.13 (dd, J=16.73, 2.05 Hz, 1H) 8.54-8.65 (m, 1H); MS (ESI, m/z): 513.2 [M+H]+
Using (4-(ethylthio)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.30-1.33 (m, 3H) 2.04-2.22 (m, 1H) 2.25-2.41 (m, 1H) 2.96 (qd, J=7.34, 3.81 Hz, 2H) 3.52 (dd, J=11.15, 5.87 Hz, 0.5H) 3.61-3.69 (m, 1H) 3.71-3.78 (m, 1H) 3.82 (br dd, J=7.63, 5.87 Hz, 0.5H) 3.92 (d, J=4.11 Hz, 3H) 3.93-4.04 (m, 1H) 4.53 (br t, J=6.46 Hz, 0.5H) 7.35 (dd, J=8.51, 6.16 Hz, 2H) 7.49-7.54 (m, 2H) 7.57 (t, J=8.51 Hz, 2H) 7.59-7.66 (m, 2H) 7.79 (d, J=15.85 Hz, 1H) 7.91 (d, J=13.50 Hz, 1H) 8.14 (dd, J=16.43, 1.76 Hz, 1H) 8.50-8.61 (m, 1H); MS (ESI, m/z): 527.3 [M+H]+
Using (2-chloro-5-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.22 (m, 1H) 2.29-2.44 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.73-3.80 (m, 1H) 3.83-3.89 (m, 0.5H) 3.91-3.95 (d, J=4.70 Hz, 3H) 3.95-4.04 (m, 1H) 4.54-4.60 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.12-7.21 (m, 2H) 7.47-7.57 (m, 3H) 7.66 (dd, J=12.33, 8.22 Hz, 2H) 7.90 (d, J=17.02 Hz, 1H) 8.05 (d, J=15.26 Hz, 1H) 8.24 (dd, J=18.19, 1.76 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using 3,5-dihydroxy-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.21 (m, 1H) 2.26-2.43 (m, 1H) 3.43-3.48 (m, 0.5H) 3.51-3.57 (m, 1H) 3.57-3.65 (m, 1H) 3.71 (br dd, J=12.91, 4.70 Hz, 0.5H) 3.76-3.81 (m, 0.5H) 3.93 (d, J=8.22 Hz, 3H) 4.02 (dd, J=12.91, 7.04 Hz, 0.5H) 4.51-4.56 (m, 0.5H) 4.65-4.70 (m, 0.5H) 6.76 (t, J=8.22 Hz, 1H) 7.09 (dt, J=11.30, 7.85 Hz, 1H) 7.19-7.26 (m, 1H) 7.50-7.58 (m, 1H) 7.66 (d, J=19.96 Hz, 1H) 7.85-7.93 (m, 1H) 7.98-8.05 (m, 1H) 8.14-8.24 (m, 1H) 8.58-8.70 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using 5-bromo-1-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.00-2.08 (m, 0.5H) 2.15-2.31 (m, 1H) 2.40-2.49 (m, 0.5H) 3.18 (br dd, J=14.97, 7.34 Hz, 0.5H) 3.23-3.28 (m, 0.5H) 3.32-3.38 (m, 0.5H) 3.48-3.56 (m, 0.5H) 3.78 (dd, J=12.91, 5.28 Hz, 0.5H) 3.81-3.89 (m, 0.5H) 3.93 (d, J=9.39 Hz, 3H) 4.02 (br d, J=5.87 Hz, 0.5H) 4.15 (dd, J=12.91, 7.04 Hz, 0.5H) 4.46 (t, J=6.16 Hz, 0.5H) 4.66-4.72 (m, 0.5H) 7.31-7.45 (m, 1H) 7.59 (dd, J=18.78, 7.04 Hz, 1H) 7.63-7.71 (m, 1H) 7.78-7.92 (m, 3H) 8.02 (d, J=19.95 Hz, 1H) 8.16-8.25 (m, 1H) 8.26-8.36 (m, 1H) 8.55-8.68 (m, 1H); MS (ESI, m/z): 519.2, 521.2 [M+H]+
Using tert-butyl 3-aminoazetidine-1-carboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 3.92 (s, 3H) 4.25 (br dd, J=10.86, 4.99 Hz, 1H) 4.43 (br dd, J=9.39, 5.28 Hz, 1H) 4.53-4.59 (m, 1H) 4.76 (br t, J=8.51 Hz, 1H) 4.85 (tt, J=7.92, 5.28 Hz, 1H) 7.34-7.38 (m, 1H) 7.45 (t, J=7.53 Hz, 2H) 7.52-7.56 (m, 1H) 7.62 (d, J=7.57 Hz, 3H) 7.75-7.79 (m, 1H) 7.87 (t, J=1.76 Hz, 1H) 7.88 (s, 1H) 8.02 (s, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.71 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 453.2 [M+H]+
Using tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate and [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.28-2.50 (m, 2H) 3.67-3.86 (m, 4H) 3.88-4.10 (m, 2H) 3.93 (d, J=4.70 Hz, 3H) 7.33-7.41 (m, 1H) 7.45 (td, J=7.78, 2.05 Hz, 2H) 7.57-7.68 (m, 4H) 7.71 (d, J=8.22 Hz, 2H) 7.90 (d, J=17.61 Hz, 1H) 8.04 (d, J=16.43 Hz, 1H) 8.23 (dd, J=14.97, 2.05 Hz, 1H) 8.60-8.75 (m, 1H); MS (ESI, m/z): 497.3 [M+H]+
Using tert-butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.26-2.49 (m, 2H) 3.64-3.90 (m, 4H) 3.90-3.94 (m, 3.5H) 4.02 (dd, J=11.74, 3.52 Hz, 1H) 4.10 (d, J=12.91 Hz, 0.5H) 7.31-7.39 (m, 1H) 7.43 (t, J=7.63 Hz, 2H) 7.47-7.55 (m, 2H) 7.61 (d, J=8.22 Hz, 2H) 7.70-7.77 (m, 2H) 7.89 (d, J=18.19 Hz, 1H) 8.03 (d, J=15.85 Hz, 1H) 8.20 (dd, J=18.78, 2.35 Hz, 1H) 8.60-8.76 (m, 1H); MS (ESI, m/z): 497.3 [M+H]+
Using (2-chloro-3-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.22 (m, 1H) 2.29-2.44 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.67-3.73 (m, 1H) 3.74-3.80 (m, 1H) 3.83-3.89 (m, 0.5H) 3.94 (d, J=4.70 Hz, 3H) 3.96-4.04 (m, 1H) 4.55-4.60 (m, 0.5H) 4.68-4.73 (m, 0.5H) 7.20-7.24 (m, 1H) 7.28 (t, J=8.73 Hz, 1H) 7.40 (tt, J=7.92, 4.70 Hz, 1H) 7.54 (t, J=7.55 Hz, 1H) 7.66 (dd, J=12.62, 7.92 Hz, 2H) 7.90 (d, J=16.43 Hz, 1H) 8.05 (d, J=15.85 Hz, 1H) 8.24 (dd, J=18.19, 1.76 Hz, 1H) 8.69 (dd, J=44.02, 2.35 Hz, 1H) MS (ESI, m/z):519.2 [M+H]+
Using tert-butyl (3S,4S)-3-amino-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidine-1-carboxylate and [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.10 (t, J=7.63 Hz, 2H) 1.17 (t, J=7.63 Hz, 1H) 2.18 (s, 2H) 2.25 (s, 1H) 2.53 (q, J=7.63 Hz, 1.2H) 2.61 (q, J=7.63 Hz, 0.8H) 3.53 (br d, J=12.33 Hz, 0.5H) 3.58-3.65 (m, 0.5H) 3.73 (dd, J=13.21, 2.64 Hz, 0.5H) 3.78 (br d, J=12.91 Hz, 0.5H) 3.83 (br dd, J=12.03, 4.40 Hz, 0.5H) 3.92 (d, J=9.98 Hz, 3H) 4.06-4.13 (m, 0.5H) 4.15 (br d, J=1.76 Hz, 1H) 4.24-4.28 (m, 0.5H) 4.52 (d, J=11.74 Hz, 0.5H) 4.61-4.65 (m, 1H) 4.65-4.72 (m, 1H) 7.01 (s, 1H) 7.04-7.20 (m, 2H) 7.37 (t, J=7.56 Hz, 1H) 7.43-7.47 (m, 2H) 7.58-7.67 (m, 3H) 7.67-7.72 (m, 2H) 7.83-7.91 (m, 1H) 7.97-8.04 (m, 1H) 8.05-8.10 (m, 1H) 8.19-8.26 (m, 1H) 8.49-8.66 (m, 1H); MS (ESI, m/z): 615.3 [M+H]+
Using tert-butyl (3S,4S)-3-amino-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidine-1-carboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 615.3 [M+H]+
Using (4-(cyanomethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.26-2.42 (m, 1H) 3.55 (dd, J=11.44, 4.99 Hz, 0.5H) 3.64-3.70 (m, 1H) 3.72-3.77 (m, 1H) 3.81-3.89 (m, 0.5H) 3.90-3.95 (m, 5H) 3.95-4.04 (m, 1H) 4.49-4.57 (m, 0.5H) 4.64-4.72 (m, 0.5H) 4.80-4.90 (m, 1H) 6.76 (d, J=8.17 Hz, 1H) 7.13 (d, J=7.93 Hz, 1H) 7.45 (dd, J=7.63, 6.46 Hz, 2H) 7.63 (t, J=7.92 Hz, 1H) 7.65-7.74 (m, 3H) 7.89 (d, J=19.96 Hz, 1H) 8.04 (d, J=18.19 Hz, 1H) 8.22 (dd, J=21.72, 1.76 Hz, 1H) 8.67 (dd, J=46.95, 1.76 Hz, 1H); MS (ESI, m/z): 506.2 [M+H]+
Using (E)-3-(4-boronophenyl)acrylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.21 (m, 1H) 2.25-2.42 (m, 1H) 3.55 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.70 (m, 1H) 3.71-3.79 (m, 1H) 3.80-3.88 (m, 0.5H) 3.92 (d, J=7.04 Hz, 3H) 3.94-4.05 (m, 1H) 4.53 (br t, J=5.87 Hz, 0.5H) 4.64-4.71 (m, 0.5H) 6.50 (dd, J=16.14, 7.34 Hz, 1H) 7.55-7.78 (m, 9H) 7.88 (d, J=21.13 Hz, 1H) 8.02 (d, J=21.13 Hz, 1H) 8.20 (dd, J=24.06, 2.35 Hz, 1H) 8.65 (dd, J=6404.39, 47.54 Hz, 1H); MS (ESI, m/z): 537.3 [M+H]+
Using 3-(4-boronophenyl)propanoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.26-2.44 (m, 1H) 2.63 (td, J=7.63, 3.52 Hz, 2H) 2.95 (td, J=7.63, 3.52 Hz, 2H) 3.56 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.76 (br dd, J=11.44, 7.34 Hz, 1H) 3.81-3.90 (m, 0.5H) 3.94 (d, J=5.87 Hz, 3H) 3.95-4.03 (m, 1H) 4.51-4.58 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.33 (dd, J=7.92, 4.99 Hz, 2H) 7.57 (t, J=7.34 Hz, 2H) 7.62 (dd, J=15.26, 8.22 Hz, 2H) 7.69 (t, J=8.80 Hz, 2H) 7.91 (d, J=18.78 Hz, 1H) 8.04 (d, J=18.19 Hz, 1H) 8.23 (dd, J=21.13, 1.76 Hz, 1H) 8.66 (dd, J=48.71, 2.35 Hz, 1H); MS (ESI, m/z): 539.3 [M+H]+
Using (4-(4-oxopiperidine-1-carbonyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.73 (br s, 2H) 1.84 (br s, 2H) 2.08-2.24 (m, 1H) 2.28-2.43 (m, 1H) 3.47 (br s, 2H) 3.56 (br d, J=11.15 Hz, 0.5H) 3.68 (br d, J=11.74 Hz, 1H) 3.75 (br s, 3H) 3.86 (br s, 0.5H) 3.93 (br s, 3H) 3.96-4.06 (m, 1H) 4.55 (br s, 0.5H) 4.69 (br s, 0.5H) 7.50 (br s, 2H) 7.59-7.70 (m, 2H) 7.74 (br s, 4H) 7.89 (br d, J=19.37 Hz, 1H) 8.04 (br d, J=17.61 Hz, 1H) 8.17-8.26 (m, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 592.2 [M+H]+
Using (4-carbamoyl-3-fluorophenyl)boronic acid, the title compound was obtained as described in general method G.; MS (ESI, m/z): 528.2 [M+H]+
Using (E)-4-(3-oxobut-1-en-1-yl)benzoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.29-2.40 (m, 1H) 2.38 (s, 3H) 3.50 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.60-3.69 (m, 1H) 3.69-3.76 (m, 1H) 3.78-3.87 (m, 0.5H) 3.89-4.01 (m, 1H) 3.93 (d, J=4.70 Hz, 3H) 4.50-4.56 (m, 0.5H) 4.64-4.73 (m, 0.5H) 6.81-6.88 (m, 1H) 7.59 (dd, J=14.38, 8.51 Hz, 2H) 7.65 (dd, J=16.43, 7.63 Hz, 1H) 7.70-7.76 (m, 2H) 7.87-7.92 (m, 1H) 8.04 (d, J=16.43 Hz, 1H) 8.23 (dd, J=18.78, 2.35 Hz, 1H) 8.60-8.74 (m, 1H); MS (ESI, m/z): 649.2 [M+H]+
Using tert-butyl (3S,4R)-3-amino-4-fluoropyrrolidine-1-carboxylate and (2-chloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 3.72-3.87 (m, 2H) 3.93 (d, J=11.15 Hz, 3H) 3.96-4.18 (m, 2H) 4.72-4.83 (m, 0.5H) 4.85-4.93 (br d, J=8.80 Hz, 0.5H) 5.20-5.44 (m, 1H) 7.15-7.22 (m, 1H) 7.30-7.38 (m, 1H) 7.42 (td, J=8.80, 5.87 Hz, 1H) 7.53 (dd, J=8.22, 2.35 Hz, 2H) 7.62-7.73 (m, 2H) 7.89 (d, J=18.19 Hz, 1H) 8.04 (d, J=17.61 Hz, 1H) 8.26 (dd, J=17.61, 2.35 Hz, 1H) 8.64-8.75 (m, 1H); MS (ESI, m/z): 537.1 [M+H]+
Using 1-(tert-butyl) 2-methyl (2R,4R)-4-aminopyrrolidine-1,2-dicarboxylate and [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.16-2.23 (m, 1H) 2.78 (td, J=6.60, 2.05 Hz, 1H) 3.73 (dd, J=10.86, 6.75 Hz, 1H) 3.81 (s, 3H) 3.93 (s, 3H) 4.05 (dd, J=10.56, 6.46 Hz, 1H) 4.54-4.62 (m, 1H) 4.75 (dd, J=8.22, 7.04 Hz, 1H) 7.34-7.39 (m, 1H) 7.42-7.48 (m, 2H) 7.63 (d, J=7.42 Hz, 2H) 7.66-7.75 (m, 4H) 7.91 (s, 1H) 8.04 (s, 1H) 8.22 (d, J=1.76 Hz, 1H) 8.61 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 525.2 [M+H]+
Using 1-(tert-butyl) 2-methyl (2R,4R)-4-aminopyrrolidine-1,2-dicarboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.15-2.25 (m, 1H) 2.71-2.81 (m, 1H) 3.69-3.78 (m, 1H) 3.82 (s, 3H) 3.92 (s, 3H) 3.96-4.04 (m, 1H) 4.54-4.63 (m, 1H) 4.75 (br t, J=7.04 Hz, 1H) 7.35 (br d, J=7.63 Hz, 1H) 7.42 (br t, J=7.04 Hz, 2H) 7.54 (br d, J=9.39 Hz, 2H) 7.59 (br s, 2H) 7.73 (br s, 1H) 7.75-7.83 (m, 1H) 7.87 (br s, 1H) 8.00 (br s, 1H) 8.18 (br s, 1H) 8.59 (br s, 1H); MS (ESI, m/z): 525.2 [M+H]+
Using 1-(tert-butyl) 2-methyl (2R,4S)-4-aminopyrrolidine-1,2-dicarboxylate and [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.16-2.24 (m, 1H) 2.75-2.83 (m, 1H) 3.74 (dd, J=11.15, 6.46 Hz, 1H) 3.81 (s, 3H) 3.94 (s, 3H) 4.06 (dd, J=10.86, 6.16 Hz, 1H) 4.57-4.63 (m, 1H) 4.76 (dd, J=8.80, 7.04 Hz, 1H) 7.34-7.39 (m, 1H) 7.45 (t, J=7.92 Hz, 2H) 7.63-7.67 (m, 2H) 7.67-7.76 (m, 4H) 7.92 (s, 1H) 8.05 (s, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.63 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 525.2 [M+H]+
Using 1-(tert-butyl) 2-methyl (2R,4S)-4-aminopyrrolidine-1,2-dicarboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.15-2.25 (m, 1H) 2.75-2.83 (m, 1H) 3.73 (dd, J=11.15, 6.46 Hz, 1H) 3.82 (s, 3H) 3.93 (s, 3H) 4.02 (dd, J=10.86, 6.16 Hz, 1H) 4.59 (t, J=6.75 Hz, 1H) 4.77 (dd, J=8.80, 6.46 Hz, 1H) 7.33-7.39 (m, 1H) 7.41-7.47 (m, 2H) 7.50-7.59 (m, 2H) 7.61-7.64 (m, 2H) 7.76 (dt, J=7.04, 1.76 Hz, 1H) 7.79-7.85 (m, 1H) 7.91 (s, 1H) 8.02-8.06 (m, 1H) 8.22 (d, J=2.35 Hz, 1H) 8.61 (d, J=1.76 Hz, 1H); MS (ESI, m/z): 525.2 [M+H]+
Using 1-(tert-butyl) 3-ethyl 4-aminopyrrolidine-1,3-dicarboxylate and [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.20 (t, J=7.04 Hz, 1.5H) 1.27 (t, J=7.04 Hz, 1.5H) 3.38 (br d, J=7.63 Hz, 1H) 3.61-3.73 (m, 1H) 3.92-3.96 (m, 3H) 3.92-4.02 (m, 1H) 4.05-4.14 (m, 2H) 4.15-4.18 (m, 1H) 4.19-4.26 (m, 1H) 4.82 (br d, J=7.04 Hz, 0.5H) 4.93-4.98 (m, 0.5H) 7.35-7.41 (m, 1H) 7.43-7.48 (m, 2H) 7.65 (dd, J=11.44, 8.51 Hz, 4H) 7.73 (dd, J=12.03, 8.51 Hz, 2H) 7.86-7.95 (m, 1H) 8.01-8.08 (m, 1H) 8.21-8.30 (m, 1H) 8.59-8.72 (m, 1H); MS (ESI, m/z): 539.2 [M+H]+
Using 1-(tert-butyl) 3-ethyl 4-aminopyrrolidine-1,3-dicarboxylate and [1,1′-biphenyl]-3-carboxylic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 539.2 [M+H]+
Using 1-(tert-butyl) 2-methyl (2R,4R)-4-aminopyrrolidine-1,2-dicarboxylate and (2-chloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.16-2.25 (m, 1H) 2.75-2.85 (m, 1H) 3.74 (dd, J=11.15, 6.46 Hz, 1H) 3.80-3.85 (s, 3H) 3.94 (s, 3H) 4.06 (dd, J=10.56, 6.46 Hz, 1H) 4.61 (t, J=6.75 Hz, 1H) 4.74-4.79 (m, 1H) 7.17 (td, J=8.36, 2.64 Hz, 1H) 7.34 (dd, J=8.80, 2.35 Hz, 1H) 7.41 (dd, J=8.51, 6.16 Hz, 1H) 7.52 (d, J=8.22 Hz, 2H) 7.67-7.72 (m, 2H) 7.92 (s, 1H) 8.05 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.62 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 577.2 [M+H]+
Using 1-(tert-butyl) 3-ethyl 4-aminopyrrolidine-1,3-dicarboxylate and (2-chloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 591.1 [M+H]+
Using 4-bromo-2-methylbenzoic acid and (2-chloro-5-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.21 (m, 1H) 2.30-2.45 (m, 1H) 2.36 (d, J=16.43 Hz, 3H) 3.36-3.44 (m, 0.5H) 3.45-3.52 (m, 0.5H) 3.64-3.70 (m, 1H) 3.72-3.78 (m, 0.5H) 3.87-3.92 (m, 0.5H) 3.94 (d, J=5.87 Hz, 3H) 4.05 (dd, J=12.91, 7.04 Hz, 1H) 4.56 (t, J=6.46 Hz, 0.5H) 4.66-4.72 (m, 0.5H) 7.08-7.20 (m, 2H) 7.27-7.42 (m, 3H) 7.51 (dt, J=8.80, 5.28 Hz, 1H) 7.90 (d, J=14.67 Hz, 1H) 8.05 (d, J=13.50 Hz, 1H) 8.25 (dd, J=13.50, 2.35 Hz, 1H) 8.62-8.74 (m, 1H); MS (ESI, m/z): 533.1 [M+H]+
Using 4-bromo-3-methylbenzoic acid and (2-chloro-5-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.21 (m, 4H) 2.28-2.44 (m, 1H) 3.55 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.81-3.90 (m, 0.5H) 3.91-3.95 (m, 3H) 3.95-4.04 (m, 1H) 4.54-4.60 (m, 0.5H) 4.66-4.74 (m, 0.5H) 7.04 (ddd, J=8.80, 7.04, 2.93 Hz, 1H) 7.17 (tt, J=8.51, 3.23 Hz, 1H) 7.19-7.25 (m, 1H) 7.42-7.55 (m, 3H) 7.91 (d, J=15.26 Hz, 1H) 8.05 (d, J=14.09 Hz, 1H) 8.24 (dd, J=16.43, 1.76 Hz, 1H) 8.63-8.77 (m, 1H); MS (ESI, m/z): 533.1 [M+H]+
Using 4-bromo-2-chlorobenzoic acid and (2-chloro-5-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.22 (m, 1H) 2.32-2.47 (m, 1H) 3.33-3.38 (m, 0.5H) 3.42-3.48 (m, 0.5H) 3.49-3.56 (m, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.80 (m, 0.5H) 3.69-3.92 (m, 0.5H) 3.94 (d, J=5.28 Hz, 3H) 4.04 (dd, J=12.62, 6.75 Hz, 0.5H) 4.55-4.61 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.14-7.24 (m, 2H) 7.47-7.51 (m, 2H) 7.54 (dt, J=8.80, 5.28 Hz, 1H) 7.59 (d, J=17.02 Hz, 1H) 7.89 (d, J=12.33 Hz, 1H) 8.04 (d, J=10.56 Hz, 1H) 8.24 (dd, J=12.03, 2.05 Hz, 1H) 8.63-8.71 (m, 1H); MS (ESI, m/z): 553.1 [M+H]+
Using 4-bromo-2-chlorobenzoic acid and (2-chloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.22 (m, 1H) 2.32-2.47 (m, 1H) 3.35 (br dd, J=10.86, 4.99 Hz, 0.5H) 3.42-3.56 (m, 1H) 3.66-3.73 (m, 1H) 3.73-3.79 (m, 0.5H) 3.89-3.93 (m, 0.5H) 3.94 (d, J=4.70 Hz, 3H) 4.04 (dd, J=12.91, 7.04 Hz, 0.5H) 4.57 (br t, J=6.16 Hz, 0.5H) 4.65-4.72 (m, 0.5H) 7.19 (tdd, 1H) 7.37 (ddd, J=8.51, 5.58, 2.35 Hz, 1H) 7.40-7.45 (m, 1H) 7.45-7.52 (m, 2H) 7.56 (d, J=17.02 Hz, 1H) 7.90 (d, J=12.33 Hz, 1H) 8.04 (d, J=10.56 Hz, 1H) 8.24 (dd, J=12.03, 2.05 Hz, 1H) 8.62-8.71 (m, 1H); MS (ESI, m/z): 553.1 [M+H]+
Using 1-methyl-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.21 (m, 1H) 2.35 (br s, 1H) 3.67 (br d, J=12.91 Hz, 0.5H) 3.71-3.77 (m, 1H) 3.81 (m, 4.5H) 3.90 (br s, 3H) 4.01 (br s, 0.5H) 4.11 (br s, 0.5H) 4.46-4.58 (m, 0.5H) 4.64 (br s, 0.5H) 6.75-6.88 (m, 1H) 7.06 (br d, J=7.04 Hz, 1H) 7.23 (br s, 1H) 7.28-7.41 (m, 1H) 7.55 (br t, J=9.10 Hz, 1H) 7.84 (br d, J=19.96 Hz, 1H) 7.98 (br d, J=19.96 Hz, 1H) 8.06-8.17 (m, 1H) 8.50-8.66 (m, 1H); MS (ESI, m/z): 444.2 [M+H]+
Using 5-fluoro-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.26 (m, 1H) 2.27-2.44 (m, 1H) 3.72 (br d, J=11.74 Hz, 1H) 3.83 (br d, J=5.28 Hz, 3.5H) 3.87-3.98 (m, 1.5H) 4.03 (br d, J=7.04 Hz, 0.5H) 4.20 (br s, 0.5H) 4.54-4.67 (m, 1H) 6.85 (br d, J=14.09 Hz, 1H) 6.94 (dt, J=18.05, 8.88 Hz, 1H) 7.18 (br s, 1H) 7.26-7.38 (m, 1H) 7.79 (br d, J=8.80 Hz, 1H) 7.90 (br d, J=10.56 Hz, 1H) 8.05-8.11 (m, 1H) 8.59 (br s, 1H); MS (ESI, m/z): 448.1 [M+H]+
Using 1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.12-2.30 (m, 1H) 2.31-2.47 (m, 1H) 3.78 (br s, 1H) 3.89 (br s, 3.5H) 3.93-4.08 (m, 1.5H) 4.11 (br s, 0.5H) 4.30 (br s, 0.5H) 4.63-4.74 (m, 1H) 7.01 (br s, 1H) 7.02-7.10 (m, 2H) 7.21 (br d, J=7.04 Hz, 1H) 7.39-7.46 (m, 1H) 7.56-7.64 (m, 1H) 7.85 (br s, 1H) 7.91-8.05 (m, 1H) 8.18 (br s, 1H) 8.64 (br d, J=11.74 Hz, 1H); MS (ESI, m/z): 430.1 [M+H]+
Using 2,3-dimethyl-1H-indole-6-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.17 (m, 1H) 2.17 (br d, J=8.80 Hz, 3H) 2.24-2.40 (m, 1H) 2.33 (br d, J=9.39 Hz, 3H) 3.55-3.64 (m, 0.5H) 3.65-3.83 (m, 2.5H) 3.91 (br s, 3H) 3.96 (br d, J=8.80 Hz, 1H) 4.45-4.69 (m, 1H) 7.05-7.20 (m, 1H) 7.30-7.46 (m, 2H) 7.79-7.90 (m, 1H) 7.92-8.02 (m, 1H) 8.03-8.22 (m, 1H) 8.48-8.68 (m, 1H); MS (ESI, m/z): 458.2 [M+H]+
Using 1,8-naphthyridine-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.17-2.24 (m, 1H) 2.29-2.43 (m, 1H) 3.78-3.89 (m, 1H) 3.92 (d, J=6.46 Hz, 3H) 3.90-3.99 (m, 1H) 4.02-4.13 (m, 1H) 4.19 (br d, J=11.74 Hz, 0.5H) 4.28 (dd, J=12.03, 6.16 Hz, 0.5H) 4.62-4.68 (m, 0.5H) 4.69-4.74 (m, 0.5H) 7.84-7.87 (m, 0.5H) 7.87-7.93 (m, 1H) 7.96 (s, 0.5H) 8.02-8.08 (m, 1H) 8.10 (t, J=8.80 Hz, 1H) 8.23 (dd, J=19.07, 2.05 Hz, 1H) 8.64-8.70 (m, 1.5H) 8.72 (ddd, J=8.07, 6.02, 1.76 Hz, 1H) 8.75 (d, J=2.35 Hz, 0.5H) 9.22 (ddd, J=10.86, 4.40, 1.76 Hz, 1H); MS (ESI, m/z): 443.2 [M+H]+
Using 1,6-naphthyridine-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.16-2.26 (m, 1H) 2.38 (td, J=13.06, 6.16 Hz, 1H) 3.77-3.89 (m, 1H) 3.92 (d, J=5.87 Hz, 3.5H) 3.93-4.00 (m, 1H) 4.05-4.12 (m, 1H) 4.25 (dd, J=12.03, 6.16 Hz, 0.5H) 4.61-4.67 (m, 0.5H) 4.68-4.73 (m, 0.5H) 7.85-7.92 (m, 1H) 8.04 (d, J=18.78 Hz, 1H) 8.18 (dd, J=8.51, 6.75 Hz, 1H) 8.22 (dd, J=18.19, 2.35 Hz, 1H) 8.32 (dd, J=9.39, 6.46 Hz, 1H) 8.64-8.74 (m, 1H) 8.82-8.85 (m, 1H) 8.87 (d, J=8.95 Hz, 1H) 9.70 (d, J=8.22 Hz, 1H); MS (ESI, m/z): 443.2 [M+H]+
Using 1-ethyl-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.31 (dt, J=18.49, 7.19 Hz, 3H) 2.08-2.25 (m, 1H) 2.28-2.47 (m, 1H) 3.68 (br dd, J=12.91, 4.11 Hz, 0.5H) 3.72-3.79 (m, 1H) 3.80-3.95 (m, 1.5H) 3.93 (s, 3H) 4.01-4.15 (m, 1H) 4.30-4.44 (m, 2H) 4.47-4.61 (m, 0.5H) 4.64-4.73 (m,0.5H) 6.77-6.89 (m, 1H) 7.02-7.14 (m, 1H) 7.25 (q, J=6.85 Hz, 1H) 7.43 (br t, J=9.10 Hz, 1H) 7.59 (br t, J=6.75 Hz, 1H) 7.88 (br d, J=16.43 Hz, 1 H) 8.02 (br d, J=15.26 Hz, 1H) 8.20 (br d, J=17.02 Hz, 1H) 8.58-8.72 (m, 1H); MS (ESI, m/z): 458.2 [M+H]+
Using 1-benzyl-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 520.2 [M+H]+
Using 7-chloro-1-methyl-4-(trifluoromethyl)-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.11-2.25 (m, 1H) 2.29-2.46 (m, 1H) 3.63 (dd, J=11.44, 5.58 Hz, 0.5H) 3.68-3.84 (m, 2H) 3.85-3.90 (m, 0.5H) 3.92 (d, J=6.46 Hz, 3H) 3.97-4.12 (m, 1H) 4.17 (d, J=8.22 Hz, 3H) 4.53-4.61 (m, 0.5H) 4.66-4.73 (m, 0.5H) 6.85-6.94 (m, 1H) 7.33 (d, J=8.75 Hz, 2H) 7.87 (d, J=18.19 Hz, 1H) 8.02 (d, J=17.02 Hz, 1H) 8.14-8.23 (m, 1H) 8.59-8.68 (m, 1H); MS (ESI, m/z): 546.1 [M+H]+
Using 7-chloro-4-(trifluoromethyl)-1H-indole-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.19 (br s, 1H) 2.35-2.47 (m, 1H) 3.75-3.84 (m, 1H) 3.86-3.95 (m, 1H) 3.90 (s, 3H) 4.04 (br dd, J=12.62, 6.75 Hz, 1H) 4.08 (br s, 0.5H) 4.28 (br dd, J=11.15, 6.46 Hz, 0.5H) 4.65-4.73 (m, 1H) 7.04-7.13 (m, 1H) 7.39 (d, J=7.04 Hz, 2H) 7.86 (d, J=11.15 Hz, 1H) 8.00 (d, J=10.56 Hz, 1H) 8.20 (dd, J=12.91, 1.76 Hz, 1H) 8.65 (dd, J=18.78, 1.76 Hz, 1H); MS (ESI, m/z): 532.1 [M+H]+
Using (1S,2S)-2-phenylcyclopropane-1-carboxylic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 431.2 [M+H]+
Using 6-hydroxy-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.24-2.46 (m, 1H) 3.59 (dd, J=11.15, 4.70 Hz, 0.5H) 3.70 (br dd, J=12.62, 4.99 Hz, 1H) 3.72-3.83 (m, 1H) 3.87-3.90 (m, 0.5H) 3.92 (d, J=8.80 Hz, 3H) 3.95-4.06 (m, 1H) 4.49-4.55 (m, 0.5H) 4.64-4.71 (m, 0.5H) 7.05-7.16 (m, 2H) 7.46-7.55 (m, 1H) 7.67 (dd, J=18.19, 8.80 Hz, 1H) 7.71-7.80 (m, 1H) 7.82-7.90 (m, 1H) 7.90-7.97 (m, 1H) 7.97-8.05 (m, 1H) 8.12-8.26 (m, 1H) 8.55-8.73 (n, 1H); MS (ESI, m/z): 457.2 [M+H]+
Using 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.11 (br dd, J=13.21, 4.99 Hz, 1H) 2.23-2.38 (m, 1H) 3.58-3.66 (m, 1.5H) 3.69-3.76 (m, 1H) 3.79 (dt, J=12.47, 7.85 Hz, 1H) 3.83-3.88 (m, 0.5H) 3.89 (d, J=1.76 Hz, 3H) 4.53-4.65 (m, 1H) 7.08 (br t, J=8.22 Hz, 1H) 7.21 (br t, J=8.22 Hz, 1H) 7.24 (br s, 1H) 7.30 (dd, J=8.80, 4.70 Hz, 1H) 7.74 (s, 0.5H) 7.82 (d, J=6.46 Hz, 1H) 7.85 (d, J=9.98 Hz, 1H) 7.98 (s, 0.5H) 8.20 (dd, J=17.90, 2.05 Hz, 1H) 8.55-8.63 (m, 1H); MS (ESI, m/z): 519.2 [M+H]+
Using 5-bromobenzo[b]thiophene-2-carboxylic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.17-2.29 (m, 1H) 2.36-2.49 (m, 1H) 3.75 (br dd, J=12.91, 4.11 Hz, 0.5H) 3.77-3.83 (m, 0.5H) 3.86-3.93 (m, 1H) 3.94 (s, 3H) 4.01-4.08 (m, 0.5H) 4.08-4.15 (m, 0.5H) 4.31 (br dd, J=10.86, 6.16 Hz, 1H) 4.67-4.74 (m, 1H) 7.52-7.57 (m, 1H) 7.78-7.84 (m, 2H) 7.87 (d, J=9.39 Hz, 1H) 8.00 (d, J=8.22 Hz, 1H) 8.06 (s, 1H) 8.22 (br d, J=7.04 Hz, 1H) 8.70 (d, J=22.30 Hz, 1H); MS (ESI, m/z): 525.0/527.0 [M+H]+
Using 1-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)-1H-indole-5-carboxylic acid and trifluoroacetic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 527.3 [M+H]+
Using 1H-indole-3-carboxylic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 430.2 [M+H]+
Using (4-(morpholinomethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.04-2.20 (m, 1H) 2.23-2.39 (m, 1H) 2.47 (br s, 4H) 2.80-2.83 (m, 2H) 3.50-3.54 (m, 0.5H) 3.55 (d, J=5.28 Hz, 1H) 3.62-3.66 (m, 2H) 3.66-3.70 (m, 2H) 3.70-3.76 (m, 1H) 3.81-3.87 (m, 0.5H) 3.90 (d, J=5.28 Hz, 3H) 3.94 (br s, 0.5H) 3.99 (dd, J=12.91, 7.04 Hz, 0.5H) 4.47-4.53 (m, 0.5H) 4.62-4.69 (m, 0.5H) 7.43 (t, J=7.92 Hz, 2H) 7.55-7.66 (m, 4H) 7.67-7.73 (m, 2H) 7.79 (d, J=18.19 Hz, 1H) 7.90 (d, J=17.02 Hz, 1H) 8.09 (dd, J=45.78, 2.35 Hz, 1H) 8.25 (dd, J=18.78, 2.35 Hz, 1H); MS (ESI, m/z): 566.3 [M+H]+
Using (3-(1-methyl-1H-tetrazol-5-yl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.27-2.43 (m, 1H) 3.53-3.59 (m, 0.5H) 3.65-3.80 (m, 2H) 3.84-3.91 (m, 0.5H) 3.93 (d, J=7.04 Hz, 3H) 3.95-4.05 (m, 1H) 4.43 (d, J=3.52 Hz, 3H) 4.51-4.57 (m, 0.5H) 4.66-4.74 (m, 0.5H) 7.62 (td, J=7.63, 5.28 Hz, 1H) 7.69 (dd, J=15.85, 8.22 Hz, 2H) 7.75-7.82 (m, 3H) 7.86 (d, J=19.96 Hz, 1H) 7.99 (d, J=19.96 Hz, 1H) 8.08-8.13 (m, 1H) 8.21-8.28 (m, 1H) 8.38 (dt, J=6217.70, 6.80 Hz, 1H) 8.44 (dd, J=54.00, 2.35 Hz, 1H); MS (ESI, m/z): 549.2 [M+H]+
Using (3-(1H-tetrazol-5-yl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.20 (m, 1H) 2.28 (br d, J=7.04 Hz, 1H) 3.53-3.59 (m, 0.5H) 3.63-3.71 (m, 1H) 3.71-3.80 (m, 1H) 3.84 (br s, 0.5H) 3.90 (d, J=7.04 Hz, 3H) 3.92-4.05 (m, 1H) 4.49-4.56 (m, 0.5H) 4.68 (br d, J=5.87 Hz, 0.5H) 7.56 (td, J=7.78, 4.99 Hz, 1H) 7.61-7.74 (m, 3H) 7.74-7.85 (m, 3H) 7.90 (d, J=19.37 Hz, 1H) 8.03-8.06 (m, 1H) 8.12 (dd, J=46.95, 2.35 Hz, 1H) 8.26 (br dd, J=19.66, 2.05 Hz, 1H) 8.36 (br d, J=5.87 Hz, 1H); MS (ESI, m/z): 535.2 [M+H]+
Using (3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.20 (m, 1H) 2.26-2.41 (m, 1H) 2.66 (d, J=3.52 Hz, 3H) 3.55 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.71 (m, 1H) 3.72-3.80 (m, 1H) 3.81-3.89 (m, 0.5H) 3.91 (d, J=5.87 Hz, 3H) 3.92-4.04 (m, 1H) 4.51 (br t, J=5.87 Hz, 0.5H) 4.65-4.71 (m, 0.5H) 7.59-7.64 (m, 1H) 7.68 (dd, J=17.61, 8.22 Hz, 2H) 7.74-7.82 (m, 3H) 7.82-7.86 (m, 1H) 7.91 (d, J=16.43 Hz, 1H) 8.04 (dd, J=7.04, 5.87 Hz, 1H) 8.10 (dd, J=45.78, 2.35 Hz, 1H) 8.26 (br d, J=18.78 Hz, 1H) 8.31 (br d, J=5.87 Hz, 1H); MS (ESI, m/z): 549.2 [M+H]+
Using 4-bromo-3-methylbenzoic acid and (2-chloro-4-fluorophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.21 (m, 1H) 2.14 (d, J=7.63 Hz, 3H) 2.31-2.45 (m, 1H) 3.57 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.67-3.73 (m, 1H) 3.75-3.82 (m, 1H) 3.84-3.90 (m, 0.5H) 3.96 (d, J=2.35 Hz, 3H) 3.97-4.07 (m, 1H) 4.55-4.62 (m, 0.5H) 4.68-4.75 (m, 0.5H) 7.14-7.20 (m, 1H) 7.21 (t, J=7.92 Hz, 1H) 7.25-7.31 (m, 1H) 7.34-7.38 (m, 1H) 7.45 (br dd, J=13.79, 7.92 Hz, 1H) 7.50 (br d, J=11.74 Hz, 1H) 7.92 (d, J=15.26 Hz, 1H) 8.07 (d, J=13.50 Hz, 1H) 8.26 (d, J=15.85 Hz, 1H) 8.73 (dd, J=39.32, 2.35 Hz, 1H); MS (ESI, m/z): 533.2 [M+H]+
Using 2-chloro-4-fluorobenzoic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 443.1 [M+H]+
Using 3-bromobenzoic acid and (1-(phenylsulfonyl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 597.2 [M+H]+
Using 4-(2-chlorophenoxy)benzoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.26-2.41 (m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.70 (m, 1H) 3.70-3.77 (m, 1H) 3.77-3.85 (m, 0.5H) 3.93 (s, 3H) 3.94-4.02 (m, 1H) 4.51-4.56 (m, 0.5H) 4.65-4.70 (m, 0.5H) 6.93 (t, J=8.51 Hz, 2H) 7.14 (t, J=6.46 Hz, 1H) 7.23 (t, J=7.81 Hz, 1H) 7.30-7.41 (m, 1H) 7.49-7.54 (m, 1H) 7.57 (dd, J=13.79, 8.51 Hz, 2H) 7.89 (d, J=14.09 Hz, 1H) 8.04 (d, J=12.91 Hz, 1H) 8.23 (dd, J=14.97, 2.05 Hz, 1H) 8.61-8.75 (m, 1H); MS (ESI, m/z): 517.2 [M+H]+
Using 4-(2-chloro-4-fluorophenoxy)benzoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.19 (m, 1H) 2.26-2.40 (m, 1H) 3.53 (br dd, J=11.44, 4.99 Hz, 0.5H) 3.62-3.69 (m, 1H) 3.69-3.77 (m, 1H) 3.78-3.88 (m, 0.5H) 3.94 (s, 3H) 3.95-4.01 (m, 1H) 4.51-4.56 (m, 0.5H) 4.65-4.70 (m, 0.5H) 6.94 (t, J=7.85 Hz, 2H) 7.12-7.18 (m, 1H) 7.18-7.24 (m, 1H) 7.35-7.43 (m, 1H) 7.57 (dd, J=12.91, 8.80 Hz, 2H) 7.90 (d, J=14.09 Hz, 1H) 8.04 (d, J=12.91 Hz, 1H) 8.24 (dd, J=14.38, 2.05 Hz, 1H) 8.60-8.72 (m, 1H); MS (ESI, m/z): 535.2 [M+H]+
Using 6-(benzyl(1-methylpiperidin-4-yl)amino)-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.20 (br t, J=6.16 Hz, 3H) 1.51 (s, 6H) 1.58 (s, 6H) 2.04-2.15 (m, 2.5H) 2.19 (br d, J=12.91 Hz, 2.5H) 2.28-2.44 (m, 1H) 2.86 (s, 3H) 3.53-3.63 (m, 2.5H) 3.71 (br dd, J=12.62, 4.99 Hz, 1H) 3.74-3.83 (m, 1H) 3.88 (br d, J=6.46 Hz, 0.5H) 3.93 (br d, J=5.28 Hz, 3H) 3.96-4.08 (m, 1H) 4.39 (br t, J=11.44 Hz, 1H) 4.51-4.59 (m, 0.5H) 4.67-4.74 (m, 0.5H) 7.40 (br s, 1H) 7.45 (br s, 1H) 7.55-7.62 (m, 1H) 7.82 (br t, J=8.22 Hz, 1H) 7.89 (d, J=22.89 Hz, 1H) 7.93 (br t, J=7.92 Hz, 1H) 8.00 (br d, J=15.85 Hz, 1H) 8.04 (d, J=20.54 Hz, 1H) 8.22 (d, J=24.65 Hz, 1H) 8.66 (d, J=56.34 Hz, 1H); MS (ESI, m/z): 643.3 [M+H]+
Using 6-(ethyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.96 (br d, J=13.50 Hz, 0.5H) 2.11 (br s, 0.5H) 2.20 (br s, 2H) 2.30 (br s, 0.5H) 2.33-2.49 (m, 2.5H) 3.04 (br s, 2H) 3.08 (br s, 1H) 3.43-3.58 (m, 2H) 3.59-3.92 (m, 6H) 3.94 (br s, 3H) 4.03 (br s, 1H) 4.54 (br s, 0.5H) 4.60-4.68 (m, 2H) 4.68-4.74 (m, 0.5H) 6.91 (br s, 1H) 6.98-7.11 (m, 1H) 7.50 (br s, 1H) 7.52-7.61 (m, 4H) 7.62-7.68 (m, 1H) 7.71 (br s, 1H) 7.85-7.97 (m, 2H) 8.04 (br d, J=18.78 Hz, 1H) 8.18-8.29 (m, 1H) 8.59-8.74 (m, 1H) MS (ESI, m/z): 637.4 [M+H]+
Using 6-((1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.50 (s, 6H) 1.61 (s, 6H) 1.74 (br t, J=12.91 Hz, 2H) 2.07-2.23 (m, 1H) 2.29 (br d, J=6.46 Hz, 0.5H) 2.35 (br d, J=13.50 Hz, 2H) 2.37-2.46 (m, 0.5H) 2.87 (s, 3H) 3.58-3.63 (m, 0.5H) 3.67-3.83 (m, 2H) 3.84-3.90 (m, 0.5H) 3.93 (br s, 3H) 3.97-4.09 (m, 2H) 4.50-4.57 (m, 0.5H) 4.65-4.73 (m, 0.5H) 6.87-6.96 (m, 1H) 7.04 (br d, J=6.46 Hz, 1H) 7.49 (br dd, J=12.62, 9.10 Hz, 1H) 7.60-7.74 (m, 2H) 7.86 (br s, 1H) 7.90 (br d, J=5.28 Hz, 1H) 8.03 (br d, J=19.96 Hz, 1H) 8.23 (d, J=27.00 Hz, 1H) 8.70 (d, J=55.17 Hz, 1H) MS (ESI, m/z): 609.4 [M+H]+
Using 6-(ethyl(1-methylpiperidin-4-yl)amino)-2-naphthoic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.34-1.49 (m, 3H) 1.97 (br d, J=5.48 Hz, 2H) 2.09 (br s, 1H) 2.32 (br d, J=12.91 Hz, 2.5H) 2.36-2.47 (m, 0.5H) 3.12 (s, 3H) 3.42-3.68 (m, 6H) 3.70-3.90 (m, 3H) 3.95 (s, 3H) 4.04 (br dd, J=11.93, 6.46 Hz, 1H) 4.56 (br d, J=5.48 Hz, 0.5H) 4.71 (br s, 0.5H) 6.90 (br s, 1H) 7.05 (br d, J=9.39 Hz, 1H) 7.51 (br t, J=7.43 Hz, 1H) 7.64 (br s, 1H) 7.70 (br d, J=5.87 Hz, 1H) 7.89 (s, 1H) 7.92 (br d, J=5.09 Hz, 1H) 8.05 (br d, J=13.30 Hz, 1H) 8.24 (br d, J=16.04 Hz, 1H) 8.60-8.76 (n, 1H); MS (ESI, m/z): 581.3 [M+H]+
Using 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.20 (m, 1H) 2.27 (s, 3H) 2.28 (s, 3H) 2.28-2.41 (m, 1H) 3.56 (br dd, J=11.44, 5.58 Hz, 0.5H) 3.67 (td, J=12.33, 5.87 Hz, 1H) 3.71-3.80 (m, 1H) 3.83-3.89 (m, 0.5H) 3.92 (d, J=5.28 Hz, 3H) 3.94-4.03 (m, 1H) 4.49-4.54 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.24 (d, J=5.28 Hz, 2H) 7.55-7.61 (m, 2H) 7.61-7.66 (m, 2H) 7.81 (d, J=17.02 Hz, 1H) 7.92 (d, J=15.85 Hz, 1H) 8.13 (dd, J=45.78, 2.35 Hz, 1H) 8.27 (br d, J=17.61 Hz, 1H); MS (ESI, m/z): 511.2 [M+H]+
Using 2-(4-methoxy-3,5-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.30-2.42 (m, 1H) 2.33 (s, 3H) 2.34 (s, 3H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.67-3.74 (m, 1H) 3.75 (d, J=3.52 Hz, 3H) 3.76-3.80 (m, 1H) 3.83-3.91 (m, 0.5H) 3.95 (d, J=5.28 Hz, 3H) 3.96-4.04 (m, 1H) 4.52-4.58 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.31 (d, J=5.87 Hz, 2H) 7.58-7.64 (m, 2H) 7.64-7.69 (m, 2H) 7.90 (d, J=18.78 Hz, 1H) 8.03 (d, J=18.19 Hz, 1H) 8.25 (dd, J=19.66, 2.05 Hz, 1H) 8.53-8.66 (m, 1H); MS (ESI, m/z): 525.2 [M+H]+
Using (4-cyanophenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.43 (m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.70 (m, 1H) 3.72-3.79 (m, 1H) 3.86 (dt, J=12.03, 7.48 Hz, 0.5H) 3.93 (d, J=5.28 Hz, 3H) 4.04 (br s, 1H) 4.50-4.62 (m, 0.5H) 4.63-4.72 (m, 0.5H) 6.87 (d, J=8.80 Hz, 0.5H) 7.52 (d, J=8.80 Hz, 0.5H) 7.63-7.73 (m, 2H) 7.75-7.86 (m, 5H) 7.89 (d, J=18.78 Hz, 1H) 8.04 (d, J=17.02 Hz, 1H) 8.23 (dd, J=20.54, 2.35 Hz, 1H) 8.67 (dd, J=46.37, 2.35 Hz, 1H); MS (ESI, m/z): 492.2 [M+H]+
Using (3-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.29-2.43 (m, 1H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.68 (td, J=13.50, 5.87 Hz, 1H) 3.73-3.81 (m, 1H) 3.83-3.90 (m, 0.5H) 3.94 (d, J=5.28 Hz, 3H) 3.95-4.05 (m, 1H) 4.19 (d, J=3.52 Hz, 2H) 4.53-4.57 (m, 0.5H) 4.67-4.74 (m, 0.5H) 7.48 (br d, J=7.63 Hz, 1H) 7.56 (td, J=7.63, 5.28 Hz, 1H) 7.67 (dd, J=13.50, 8.22 Hz, 2H) 7.70-7.81 (m, 4H) 7.89 (d, J=19.37 Hz, 1H) 8.04 (d, J=17.02 Hz, 1H) 8.24 (dd, J=17.31, 2.05 Hz, 1H) 8.63 (dd, J=54.00, 2.35 Hz, 1H); MS (ESI, m/z): 496.2 [M+H]+
Using 2-amino-4-bromobenzoic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.18 (br d, J=11.35 Hz, 1H) 2.28-2.46 (m, 1H) 3.59 (br s, 0.5H) 3.63-3.74 (m, 1H) 3.78 (br s, 1H) 3.81-3.91 (m, 0.5H) 3.94 (s, 3H) 3.97-4.13 (m, 1H) 4.56 (br s, 0.5H) 4.70 (br s, 0.5H) 7.30-7.42 (m, 3H) 7.42-7.57 (m, 3H) 7.62 (br d, J=7.04 Hz, 2H) 7.90 (br d, J=7.04 Hz, 1H) 8.05 (br d, J=8.22 Hz, 1H) 8.24 (br d, J=7.83 Hz, 1H) 8.69 (d, J=26.22 Hz, 1H); MS (ESI, m/z): 482.2 [M+H]+
Using 3-bromobenzoic acid and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described in general method G. MS (ESI, m/z): 579.3 [M+H]+
Using (E)-3-(4-bromophenyl)acrylic acid and phenylboronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.24 (br s, 1H) 2.43 (br s, 1H) 3.46 (br d, J=9.39 Hz, 0.5H) 3.65 (br s, 1H) 3.79 (br s, 1H) 3.93 (s, 3.5H) 4.16 (br s, 0.5H) 4.65 (br s, 0.5H) 4.71 (br s, 0.5H) 7.04 (br s, 1H) 7.35 (br s, 1H) 7.44 (br d, J=5.87 Hz, 2H) 7.51-7.59 (m, 1H) 7.60-7.81 (m, 6H) 7.90 (s, 1H) 8.04 (s, 1H) 8.24 (s, 1H) 8.69 (br s, 1H); MS (ESI, m/z): 493.2 [M+H]+
Using 4-phenoxybenzoic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.14 (ddd, J=19.07, 12.81, 6.46 Hz, 1H) 2.23-2.43 (m, 1H) 3.56 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.62-3.71 (m, 1H) 3.71-3.87 (m, 1.5H) 3.94 (s, 3H) 3.95-4.03 (m, 1H) 4.50-4.58 (m, 0.5H) 4.64-4.73 (m, 0.5H) 6.97-7.07 (m, 4H) 7.18 (brt, J=7.63 Hz, 1H) 7.34-7.47 (m, 2H) 7.57 (t, J=9.19 Hz, 2H) 7.90 (d, J=9.00 Hz, 1H) 8.05 (d, J=7.83 Hz, 1H) 8.24 (dd, J=9.39, 1.96 Hz, 1H) 8.66 (dd, J=28.17, 1.96 Hz, 1H); MS (ESI, m/z): 483.22 [M+H]+
Using tert-butyl (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate and 4-bromobenzoic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 485.1/487.1 [M+H]+
Using 3-bromobenzoic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.26-2.45 (m, 1H) 3.48 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.58-3.66 (m, 1H) 3.66-3.77 (m, 1H) 3.79-3.92 (m, 1H) 3.95 (d, J=2.35 Hz, 3H) 3.96-4.03 (m, 0.5H) 4.51-4.59 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.40 (td, J=7.83, 5.48 Hz, 1H) 7.53 (br t, J=8.22 Hz, 1H) 7.66 (br t, J=6.46 Hz, 1H) 7.72 (br d, J=8.61 Hz, 1H) 7.91 (d, J=10.17 Hz, 1H) 8.06 (d, J=9.78 Hz, 1H) 8.25 (dd, J=10.96, 2.35 Hz, 1H) 8.67 (dd, J=28.17, 1.96 Hz, 1H); MS (ESI, m/z): 469.1/471.1 [M+H]+
Using [1,1′-biphenyl]-4-carboxylic acid and (R)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-ylmethyl)nicotinamide, title compound was obtained as described for Example 342 in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.88 (m, 2H) 2.01-2.10 (m, 1H) 2.15 (m, 1H) 3.22-3.36 (m, 1H) 3.44-3.60 (m, 1H) 3.60-3.78 (m, 2H) 3.82 (m, 3H) 3.93 (m, 1H) 7.30 (m, 1H) 7.32-7.49 (m, 2H) 7.46-7.55 (m, 2H) 7.69-7.77 (m, 2H) 7.77-7.86 (m, 2H) 7.87 (s, 1H) 8.17 (s, 1H) 8.29 (s, 1H) 8.58 (s, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using [1,1′-biphenyl]-3-carboxylic acid and (R)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-ylmethyl)nicotinamide, title compound was obtained as described for Example 342 in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.75-1.92 (m, 1H) 2.07-2.26 (m, 1H) 2.57-2.69 (m, 1H) 3.37-3.54 (m, 3H) 3.54-3.68 (m, 2H) 3.76-3.90 (m, 1H) 3.92 (d, J=17.02 Hz, 3H) 7.31-7.41 (m, 1H) 7.41-7.55 (m, 4H) 7.57-7.72 (m, 4H) 7.78 (m, 0.5H) 7.86 (m, 0.5H) 7.90 (s, 0.5H) 7.95 (s, 0.5H) 8.10 (m, 0.5H) 8.19 (m, 0.5H) 8.48 (d, J=1.76 Hz, 0.5H) 8.64 (d, J=2.35 Hz, 0.5H); MS (ESI, m/z): 481.2 [M+H]+
Using [1,1′-biphenyl]-4-carboxylic acid and (S)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-ylmethyl)nicotinamide, title compound was obtained as described for Example 342 in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.87 (m, 2H) 2.00-2.19 (m, 1H) 2.14 (m, 1H) 3.21-3.35 (m, 1H) 3.44-3.60 (m, 1H) 3.60-3.78 (m, 2H) 3.81 (m, 3H) 3.92 (m, 1H) 7.30 (m, 1H) 7.31-7.48 (m, 2H) 7.46-7.55 (m, 2H) 7.69-7.77 (m, 2H) 7.78-7.86 (m, 2H) 7.86 (s, 1H) 8.15 (s, 1H) 8.28 (s, 1H) 8.57 (s, 1H); MS (ESI, m/z): 481.2 [M+H]+
Using [1,1′-biphenyl]-3-carboxylic acid and (S)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-ylmethyl)nicotinamide, title compound was obtained as described for Example 342 in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.76-1.93 (m, 1H) 2.08-2.27 (m, 1H) 2.57-2.70 (m, 1H) 3.38-3.56 (m, 3H) 3.57-3.69 (m, 2H) 3.76-3.91 (m, 1H) 3.92 (d, J=17.02 Hz, 3H) 7.32-7.42 (m, 1H) 7.42-7.55 (m, 4H) 7.56-7.74 (m, 4H) 7.79 (m, 0.5H) 7.86 (m, 0.5H) 7.91 (s, 0.5H) 7.95 (s, 0.5H) 8.11 (m, 0.5H) 8.19 (m, 0.5H) 8.49 (d, J=1.76 Hz, 0.5H) 8.65 (d, J=2.35 Hz, 0.5H); MS (ESI, m/z): 481.2 [M+H]+
Using tert-butyl (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate, the title compound was obtained as described in general method G. MS (ESI, m/z): 483.2 [M+H]+
Using tert-butyl (3R,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate, the title compound was obtained as described in general method G.; MS (ESI, m/z): 483.2 [M+H]+
Using 3-amino-6-bromopyrazine-2-carboxylic acid, the title compound was obtained as described in general method G.; MS (ESI, m/z): 468.2 [M+H]+
Using 3-amino-6-bromopyrazine-2-carboxylic acid and 2-chloro-4-fluorobenzeneboronic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 520.2 [M+H]+
Using tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method G and following deprotection with trifluoroacetic acid. MS (ESI, m/z): 552.3 [M+H]+
Using (4-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.05-2.26 (m, 1H) 2.27-2.48 (m, 1H) 3.58 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.65-3.81 (m, 2H) 3.83-3.90 (m, 0.5H) 3.95 (d, J=3.52 Hz, 3H) 3.98-4.07 (m, 1H) 4.53-4.60 (m, 0.5H) 4.66 (s, 2H) 4.70 (br d, J=5.48 Hz, 0.5H) 7.46 (br d, J=5.87 Hz, 2H) 7.61-7.70 (m, 3H) 7.70-7.80 (m, 3H) 7.91 (d, J=12.52 Hz, 1H) 8.05 (d, J=11.74 Hz, 1H) 8.25 (dd, J=13.30, 1.96 Hz, 1H) 8.66 (dd, J=32.08, 1.57 Hz, 1H); MS (ESI, m/z): 497.2 [M+H]+
Using (3-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.26 (m, 1H) 2.27-2.48 (m, 1H) 3.58 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.66-3.84 (m, 2H) 3.84-3.92 (m, 0.5H) 3.96 (d, J=3.52 Hz, 3H) 3.98-4.09 (m, 1H) 4.53-4.63 (m, 0.5H) 4.69 (d, J=2.35 Hz, 3H) 4.71-4.76 (m, 0.5H) 7.36-7.42 (m, 1H) 7.42-7.50 (m, 1H) 7.51-7.61 (m, 1H) 7.62-7.72 (m, 3H) 7.72-7.81 (m, 2H) 7.91 (d, J=12.52 Hz, 1H) 8.06 (d, J=11.35 Hz, 1H) 8.25 (dd, J=13.50, 2.15 Hz, 1H) 8.66 (dd, J=32.48, 1.96 Hz, 1H); MS (ESI, m/z): 497.2 [M+H]+
Using (6-hydroxypyridin-3-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.25 (m, 1H) 2.26-2.46 (m, 1H) 3.55 (br dd, J=11.54, 5.28 Hz, 0.5H) 3.64-3.81 (m, 2H) 3.82-3.92 (m, 0.5H) 3.95 (d, J=2.74 Hz, 3H) 4.01 (td, J=12.33, 7.04 Hz, 1H) 4.51-4.60 (m, 0.5H) 4.70 (br d, J=6.65 Hz, 0.5H) 6.67 (dd, J=9.59, 2.93 Hz, 1H) 7.65 (d, J=7.83 Hz, 4H) 7.76-7.81 (m, 1H) 7.91 (d, J=11.74 Hz, 1H) 7.96-8.02 (m, 1H) 8.06 (d, J=10.56 Hz, 1H) 8.25 (dd, J=11.54, 2.15 Hz, 1H) 8.66 (dd, J=31.69, 1.57 Hz, 1H); MS (ESI, m/z): 484.2 [M+H]+
Using naphthalen-2-ylboronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.25-2.46 (m, 1H) 3.55-3.61 (m, 0.5H) 3.63-3.83 (m, 2H) 3.84-3.92 (m, 0.5H) 3.92-3.95 (m, 3H) 3.95-4.09 (m, 1H) 4.51-4.58 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.52 (br dd, J=6.85, 3.33 Hz, 2 H) 7.70 (dd, J=11.74, 8.22 Hz, 2H) 7.82 (br d, J=11.74 Hz, 2H) 7.85-7.93 (m, 3H) 7.93-8.00 (m, 2H) 8.09 (d, J=2.35 Hz, 1H) 8.17 (br d, J=2.35 Hz, 2H) 8.28 (dd, J=12.52, 1.96 Hz, 1H); MS (ESI, m/z): 517.2 [M+H]+
Using (1H-indol-6-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.23 (m, 1H) 2.24-2.45 (m, 1H) 3.59 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.64-3.82 (m, 2H) 3.83-3.90 (m, 0.5H) 3.94 (d, J=7.04 Hz, 3H) 3.97-4.06 (m, 1H) 4.49-4.59 (m, 0.5H) 4.65-4.74 (m, 0.5H) 6.46 (br s, 1H) 7.28 (br s, 1H) 7.32 (br t, J=7.04 Hz, 1H) 7.57-7.69 (m, 4H) 7.75 (br t, J=7.92 Hz, 2H) 7.89 (br d, J=19.96 Hz, 1H) 8.00-8.07 (m, 1H) 8.23 (br d, J=19.37 Hz, 1H) 8.64 (dd, J=50.47, 1.17 Hz, 1H); MS (ESI, m/z): 506.2 [M+H]+
Using (4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.25 (m, 1H) 2.27-2.47 (m, 1H) 2.94 (s, 3H) 3.61 (br s, 0.5H) 3.75 (br d, J=18.78 Hz, 2H) 3.89 (br s, 0.5H) 3.96 (d, J=3.13 Hz, 3H) 3.99 (br s, 1H) 4.31 (br s, 2H) 4.56 (br s, 0.5H) 4.72 (br s, 0.5H) 6.73-6.84 (m, 1H) 7.04 (s, 1H) 7.16 (br d, J=6.65 Hz, 1H) 7.55-7.71 (m, 4H) 7.90 (br d, J=12.52 Hz, 1H) 8.03 (br d, J=11.74 Hz, 1H) 8.27 (br d, J=13.30 Hz, 1H) 8.46-8.61 (m, 1H); MS (ESI, m/z): 538.3 [M+H]+
Using (1,2,3,6-tetrahydropyridin-4-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.02-2.18 (m, 1H) 2.22-2.40 (m, 1H) 2.77-2.83 (m, 2H) 3.43-3.47 (m, 2H) 3.62 (br dd, J=12.91, 4.70 Hz, 0.5H) 3.65-3.76 (m, 2H) 3.77-3.86 (m, 2H) 3.86-3.90 (m, 0.5H) 3.91 (d, J=3.52 Hz, 3H) 3.98 (br dd, J=12.62, 6.75 Hz, 1H) 4.47-4.52 (m, 0.5H) 4.62-4.69 (m, 0.5H) 6.23 (br dd, J=4.70, 2.93 Hz, 1H) 7.53-7.58 (m, 4H) 7.84 (d, J=19.96 Hz, 1H) 7.98 (d, J=18.19 Hz, 1H) 8.23 (br dd, J=13.50, 1.76 Hz, 1H) 8.38-8.42 (m, 1H) 8.51 (dd, J=66.32, 1.17 Hz, 1H); MS (ESI, m/z): 472.2 [M+H]+
Using (1-methyl-1,2,3,6-tetrahydropyridin-4-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.02-2.19 (m, 1H) 2.22-2.39 (m, 1H) 2.87 (br s, 2H) 2.98 (d, J=4.11 Hz, 3H) 3.41-3.50 (m, 0.5H) 3.56-3.65 (m, 2H) 3.65-3.75 (m, 2H) 3.76-3.86 (m, 2H) 3.87 (br d, J=6.46 Hz, 0.5H) 3.91 (d, J=3.52 Hz, 3H) 3.98 (br dd, J=12.91, 7.04 Hz, 1H) 4.43-4.54 (m, 0.5H) 4.61-4.70 (m, 0.5H) 6.21 (dt, J=3.67, 1.98 Hz, 1H) 7.50-7.61 (m, 4H) 7.85 (d, J=18.78 Hz, 1H) 7.99 (d, J=17.02 Hz, 1H) 8.23 (dd, J=13.79, 2.05 Hz, 1H) 8.52 (dd, J=60.45, 2.35 Hz, 1H); MS (ESI, m/z): 486.3 [M+H]+
Using (4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.01-2.22 (m, 1H) 2.25-2.48 (m, 1H) 2.83 (br s, 0.5H) 3.43-3.50 (m, 0.5H) 3.51-3.58 (m, 0.5H) 3.60-3.79 (m, 4H) 3.81-3.87 (m, 1H) 3.89-3.94 (m, 3H) 3.94-4.05 (m, 1H) 4.49-4.59 (m, 0.5H) 4.68 (br d, J=7.04 Hz, 0.5H) 6.23 (br s, 1H) 7.36 (br s, 1H) 7.53-7.66 (m, 6H) 7.77-7.87 (m, 1H) 7.87-7.96 (m, 1H) 8.00-8.07 (m, 1H) 8.17-8.29 (m, 1H) 8.46-8.63 (m, 1H) 8.77 (br s, 1H); MS (ESI, m/z): 548.3 [M+H]+
Using (1-methyl-1H-indol-5-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.02-2.20 (m, 1H) 2.24-2.45 (m, 1H) 3.57 (br dd, J=10.86, 4.99 Hz, 0.5H) 3.61-3.79 (m, 4H) 3.81 (d, J=2.93 Hz, 3H) 3.82-3.89 (m, 0.5H) 3.92 (d, J=6.46 Hz, 3H) 3.95-4.04 (m, 1H) 4.49-4.57 (m, 0.5H) 4.64-4.73 (m, 0.5H) 6.47 (t, J=3.52 Hz, 1H) 7.17 (t, J=2.93 Hz, 1H) 7.40-7.50 (m, 2H) 7.61 (dd, J=14.67, 8.80 Hz, 2H) 7.73 (t, J=7.92 Hz, 2H) 7.81 (br d, J=4.70 Hz, 1H) 7.88 (d, J=19.37 Hz, 1H) 8.02 (d, J=18.78 Hz, 1H) 8.22 (dd, J=21.13, 2.35 Hz, 1H) 8.60 (dd, J=51.06, 1.76 Hz, 1H); MS (ESI, m/z): 520.2 [M+H]+
Using (1-methyl-1H-indazol-5-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.04-2.21 (m, 1H) 2.26-2.44 (m, 1H) 3.56 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.63-3.79 (m, 2H) 3.81-3.87 (m, 0.5H) 3.92 (d, J=6.46 Hz, 3H) 3.95-4.04 (m, 1H) 4.07 (d, J=2.93 Hz, 3H) 4.53 (br d, J=6.46 Hz, 0.5H) 4.68 (br d, J=6.46 Hz, 0.5H) 7.60-7.68 (m, 3H) 7.72-7.79 (m, 3H) 7.88 (d, J=19.37 Hz, 1H) 7.99-8.08 (m, 3H) 8.22 (dd, J=19.96, 2.35 Hz, 1H) 8.60 (dd, J=50.47, 1.76 Hz, 1H); MS (ESI, m/z): 521.2 [M+H]+
Using (1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.99-2.22 (m, 5H) 2.24-2.43 (m, 1H) 3.54 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.60-3.80 (m, 8H) 3.82-3.89 (m, 0.5H) 3.93 (d, J=4.11 Hz, 3H) 4.00 (dd, J=12.91, 7.04 Hz, 1H) 4.48-4.55 (m, 0.5H) 4.60 (q, J=5.28 Hz, 2H) 4.68 (t, J=5.87 Hz, 0.5H) 7.58 (br dd, J=16.73, 7.92 Hz, 2H) 7.63-7.70 (m, 2H) 7.86 (d, J=19.37 Hz, 1H) 7.96-8.03 (m, 2H) 8.17 (d, J=7.04 Hz, 1H) 8.25 (br d, J=14.09 Hz, 1H) 8.44 (dd, J=61.04, 1.17 Hz, 1H); MS (ESI, m/z): 554.3 [M+H]+
Using (1H-indazol-5-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.25-2.44 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.82-3.89 (m, 0.5H) 3.92 (d, J=7.63 Hz, 3H) 3.94-4.05 (m, 1H) 4.53 (dt, J=11.59, 5.65 Hz, 0.5H) 4.68 (dt, J=11.74, 5.87 Hz, 0.5H) 7.58-7.67 (m, 3H) 7.67-7.72 (m, 1H) 7.72-7.78 (m, 2H) 7.83-7.90 (m, 1H) 7.96-8.05 (m, 2H) 8.09 (d, J=5.87 Hz, 1H) 8.21 (br ddd, J=21.13, 19.96, 1.17 Hz, 1H) 8.58 (dd, J=49.89, 1.76 Hz, 1H); MS (ESI, m/z): 507.2 [M+H]+
Using (1H-indazol-6-yl)boronic acid, the title compound was obtained as described in general method G. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.26-2.44 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.83-3.90 (m, 0.5H) 3.92 (d, J=7.04 Hz, 3H) 3.95-4.05 (m, 1H) 4.54 (dt, J=11.59, 5.65 Hz, 0.5H) 4.69 (dt, J=12.18, 5.94 Hz, 0.5H) 7.44 (t, J=7.92 Hz, 1H) 7.66 (dd, J=14.67, 8.22 Hz, 2H) 7.74-7.81 (m, 3H) 7.82-7.91 (m, 2H) 8.01 (d, J=19.96 Hz, 1H) 8.06 (d, J=3.52 Hz, 1H) 8.23 (dd, J=20.54, 1.17 Hz, 1H) 8.56 (dd, J=51.06, 1.17 Hz, 1H); MS (ESI, m/z): 507.2 [M+H]+
Using 4-hydroxybenzoic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 407.2 [M+H]+
Using 4-formylbenzoic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 419.2 [M+H]+
Using 6-(methoxycarbonyl)-2-naphthoic acid, the title compound was obtained as described in general method G. MS (ESI, m/z): 499.22 [M+H]+
The title compound was obtained as described in general method G.
A mixture of Example 380 (20 mg, 0.04 mmol), tert-butyl 4-(chloromethyl)piperidine-1-carboxylate (19 mg, 0.08 mmol) and K2CO3 (14 mg, 0.1 mmol) in 1 mL of acetone was heated at 60° C. for 12 h, cooled to room temperature, and extracted with ethyl acetate, dried over anhydrous MgSO4 and concentrated under vacuum. The crude residue was dissolved in 0.5 mL of dichloromethane/trifluoroacetic acid (4/1) and stirred at room temperature for 3 h. After concentration in vacuo, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.56-1.71 (m, 2H) 2.11 (br d, J=12.91 Hz, 2H) 2.10-2.20 (m, 1H) 2.28-2.46 (m, 1H) 3.01-3.11 (m, 2H) 3.46 (br d, J=12.91 Hz, 2H) 3.58 (br dd, J=11.35, 4.70 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.82 (m, 1H) 3.82-3.91 (m, 0.5H) 3.95 (d, J=3.52 Hz, 3H) 3.96 (d, J=1.96 Hz, 2H) 3.98-4.05 (m, 1H) 4.52-4.60 (m, 0.5H) 4.64-4.75 (m, 0.5H) 7.03 (dd, J=9.00, 2.74 Hz, 2H) 7.55-7.65 (m, 4H) 7.65-7.72 (m, 2H) 7.91 (d, J=11.74 Hz, 1H) 8.06 (d, J=10.96 Hz, 1H) 8.25 (dd, J=12.72, 2.15 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 580.2 [M+H]+
Using 3-diethylaminopropyl chloride-hydrochloride, the title compound was obtained as described in general method H. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.21 (m, 1H) 2.21-2.29 (m, 2H) 2.40 (br s, 1H) 2.96 (s, 6H) 3.35-3.42 (m, 2H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.62-3.82 (m, 2H) 3.82-3.90 (m, 0.5H) 3.95 (d, J=3.13 Hz, 3H) 3.97-4.06 (m, 1H) 4.13-4.20 (m, 2H) 4.53-4.60 (m, 0.5H) 4.72 (br d, J=6.26 Hz, 0.5H) 7.06 (dd, J=8.80, 2.93 Hz, 2H) 7.63 (dt, J=8.41, 4.01 Hz, 4H) 7.66-7.75 (m, 2H) 7.91 (d, J=12.13 Hz, 1H) 8.06 (d, J=10.96 Hz, 1H) 8.25 (dd, J=12.72, 2.15 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 568.2 [M+H]+
Using 4-(chloromethyl)-1-methylpiperidine hydrochloride, the title compound was obtained as described in general method H. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.61-1.76 (m, 2H) 2.08-2.24 (m, 3H) 2.26-2.44 (m, 1H) 2.89 (s, 3H) 3.06 (brt, J=12.13 Hz, 2H) 3.58 (br d, J=11.35 Hz, 2.5H) 3.63-3.81 (m, 2H) 3.86 (br d, J=11.35 Hz, 0.5H) 3.95 (d, J=3.13 Hz, 3H) 3.97 (br d, J=1.96 Hz, 2H) 3.99-4.07 (m, 1H) 4.52-4.60 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.03 (dd, J=9.00, 2.74 Hz, 2H) 7.53-7.65 (m, 4H) 7.65-7.73 (m, 2H) 7.91 (d, J=12.13 Hz, 1H) 8.06 (d, J=10.96 Hz, 1H) 8.25 (dd, J=12.72, 2.15 Hz, 1H) 8.63-8.78 (m, 1H); MS (ESI, m/z): 594.2 [M+H]+
Using Example 706, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.61-1.72 (m, 2H) 2.07-2.15 (m, 2.5H) 2.20 (dt, J=13.50, 6.75 Hz, 1.5H) 2.25-2.44 (m, 1H) 3.06 (br t, J=12.91 Hz, 2H) 3.42-3.51 (m, 2H) 3.60 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.71 (br dd, J=12.91, 4.11 Hz, 1H) 3.74-3.83 (m, 1H) 3.87-3.91 (m, 0.5H) 3.93 (d, J=7.04 Hz, 3H) 3.99-4.04 (m, 1H) 4.01-4.09 (m, 2H) 4.49-4.57 (m, 0.5H) 4.66-4.73 (m, 0.5H) 7.16-7.22 (m, 1H) 7.28 (dd, J=9.39, 2.35 Hz, 1H) 7.52-7.63 (m, 1H) 7.82 (ddd, J=12.91, 9.39, 2.93 Hz, 1H) 7.86-7.92 (m, 1H) 7.95-8.01 (m, 1H) 8.01-8.09 (m, 1H) 8.16-8.27 (m, 1H) 8.59-8.74 (m, 1H); MS (ESI, m/z): 554.3 [M+H]+
Using Example 706 and 2-chloro-N,N-dimethylethan-1-amine, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.26-2.45 (m, 1H) 3.01 (d, J=2.93 Hz, 6H) 3.59 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.69 (m, 2H) 3.69-3.73 (m, 1H) 3.75-3.83 (m, 1H) 3.87-3.91 (m, 0.5H) 3.93 (d, J=6.46 Hz, 3H) 3.96-4.11 (m, 1H) 4.49 (q, J=4.70 Hz, 2H) 4.52-4.56 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.30 (ddd, J=8.80, 6.46, 2.35 Hz, 1H) 7.40 (dd, J=7.63, 2.35 Hz, 1H) 7.62 (ddd, J=15.41, 8.36, 1.47 Hz, 1H) 7.83-7.94 (m, 3H) 8.02 (s, 1H) 8.04-8.07 (m, 1H) 8.18-8.28 (m, 1H) 8.59-8.78 (m, 1H); MS (ESI, m/z): 528.3 [M+H]+
Using Example 706 and 3-(chloromethyl)-1-methylpyrrolidine, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.98-2.15 (m, 1H) 2.19 (br dd, J=13.79, 6.75 Hz, 1H) 2.31 (br dd, J=12.91, 6.46 Hz, 1H) 2.37-2.50 (m, 1H) 2.99 (br d, J=12.91 Hz, 3H) 3.04-3.15 (m, 1H) 3.15-3.28 (m, 1H) 3.34-3.42 (m, 1H) 3.59 (br dd, J=11.44, 4.99 Hz, 0.5H) 3.68-3.75 (m, 1H) 3.75-3.83 (m, 1H) 3.87-3.93 (m, 0.5H) 3.94 (d, J=6.46 Hz, 3H) 3.99-4.08 (m, 1H) 4.09-4.19 (m, 1H) 4.19-4.29 (m, 1H) 4.52-4.58 (m, 0.5H) 4.69-4.74 (m, 0.5H) 7.22-7.29 (m, 1H) 7.34 (dd, J=5.87, 2.35 Hz, 1H) 7.58-7.64 (m, 1H) 7.83-7.87 (m, 1H) 7.88 (s, 1H) 7.98-8.09 (m, 2H) 8.19-8.31 (m, 1H) 8.60-8.76 (m, 1H); MS (ESI, m/z): 554.3 [M+H]+
Using Example 706 and 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.93 (br d, J=9.98 Hz, 1H) 2.06-2.22 (m, 4H) 2.24-2.33 (m, 1H) 2.41 (dt, J=13.50, 6.75 Hz, 1H) 2.47 (br dd, J=8.22, 4.70 Hz, 1H) 2.93-2.97 (m, 3H) 2.99 (d, J=2.35 Hz, 2H) 3.16-3.23 (m, 1H) 3.41-3.46 (m, 0.5H) 3.53-3.62 (m, 2H) 3.68-3.75 (m, 2H) 3.76-3.83 (m, 1H) 3.85-3.91 (m, 0.5H) 3.94 (d, J=6.46 Hz, 3H) 3.99-4.08 (m, 1H) 4.23-4.35 (m, 1H) 4.52-4.58 (m, 0.5H) 4.69-4.74 (m, 0.5H) 7.21-7.27 (m, 1H) 7.34 (br d, J=2.93 Hz, 1H) 7.55-7.64 (m, 1H) 7.81-7.88 (m, 2H) 7.88 (s, 1H) 7.99-8.09 (m, 2H) 8.19-8.28 (m, 1H) 8.72 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 568.3 [M+H]+
Using Example 706 and 1-(2-chloroethyl)pyrrolidine hydrochloride, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.03-2.15 (m, 3H) 2.17-2.25 (m, 2H) 2.27-2.44 (m, 1H) 3.22-3.28 (m, 2H) 3.59 (br dd, J=11.44, 4.99 Hz, 0.5H) 3.68-3.84 (m, 6H) 3.87-3.93 (m, 0.5H) 3.94 (d, J=6.46 Hz, 3H) 3.98-4.06 (m, 1H) 4.45-4.51 (m, 2H) 4.51-4.57 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.31 (ddd, J=8.66, 5.72, 2.64 Hz, 1H) 7.40 (dd, J=7.04, 2.35 Hz, 1H) 7.63 (ddd, J=12.91, 8.51, 1.47 Hz, 1H) 7.82-7.96 (m, 3H) 7.98-8.12 (m, 2H) 8.19-8.28 (m, 1H) 8.61-8.77 (m, 1H); MS (ESI, m/z): 554.3 [M+H]+
Using Example 706 and 3-chloro-N,N-dimethylpropan-1-amine hydrochloride, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.25-2.34 (m, 2H) 2.25-2.45 (m, 1H) 2.95 (d, J=2.35 Hz, 6H) 3.37-3.43 (m, 2H) 3.59 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.75 (m, 1H) 3.79 (td, J=7.34, 2.93 Hz, 1H) 3.84-3.91 (m, 0.5H) 3.94 (d, J=7.04 Hz, 3H) 3.98-4.06 (m, 1H) 4.24 (q, J=5.87 Hz, 2H) 4.51-4.57 (m, 0.5H) 4.67-4.74 (m, 0.5H) 7.23 (ddd, J=8.80, 6.16, 2.64 Hz, 1H) 7.32 (dd, J=7.63, 2.35 Hz, 1H) 7.60 (ddd, J=14.67, 8.51, 1.47 Hz, 1H) 7.80-7.87 (m, 2H) 7.87-7.93 (m, 1H) 7.99-8.09 (m, 2H) 8.18-8.27 (m, 1H) 8.60-8.78 (m, 1H); MS (ESI, m/z): 542.3 [M+H]+
Using Example 706 and 4-(bromomethyl)-1-methylpiperidine hydrochloride, the title compound was obtained as described in general method H. MS (ESI, m/z): 568.3 [M+H]+
Using Example 706 and tert-butyl 4-bromopiperidine-1-carboxylate, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.28 (m, 5H) 2.28-2.46 (m, 1H) 3.23-3.29 (m, 2H) 3.40-3.48 (m, 2H) 3.59 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.71 (br dd, J=12.62, 4.99 Hz, 1H) 3.75-3.83 (m, 1H) 3.86-3.90 (m, 0.5H) 3.94 (d, J=6.46 Hz, 3H) 3.96-4.08 (m, 1H) 4.51-4.57 (m, 0.5H) 4.68-4.73 (m, 0.5H) 7.26 (ddd, J=8.66, 6.02, 2.35 Hz, 1H) 7.40 (dd, J=6.75, 2.05 Hz, 1H) 7.55-7.65 (m, 1H) 7.81-7.95 (m, 3H) 7.99-8.10 (m, 2H) 8.18-8.28 (m, 1H) 8.60-8.76 (m, 1H); MS (ESI, m/z): 540.3 [M+H]+
Using Example 840 and 4-nitrobenzyl bromide, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.19 (m, 1H) 2.24-2.40 (m, 1H) 3.54 (br dd, J=11.44, 4.99 Hz, 0.5H) 3.60-3.69 (m, 1H) 3.69-3.77 (m, 1H) 3.78-3.87 (m, 0.5H) 3.93 (d, J=1.76 Hz, 3H) 3.94-4.02 (m, 1H) 4.48-4.54 (m, 0.5H) 4.62-4.71 (m, 0.5H) 5.28 (d, J=5.28 Hz, 2H) 7.08 (dd, J=9.98, 8.80 Hz, 2H) 7.55 (dd, J=16.43, 8.80 Hz, 2H) 7.68 (t, J=7.63 Hz, 2H) 7.89 (d, J=17.02 Hz, 1H) 8.04 (d, J=15.26 Hz, 1H) 8.20-8.28 (m, 3H) 8.60-8.73 (m, 1H); MS (ESI, m/z): 542.2 [M+H]+
Using Example 840 and 3-nitrobenzyl bromide, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.21 (m, 1H) 2.24-2.40 (m, 1H) 3.54 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.69 (m, 1H) 3.69-3.77 (m, 1H) 3.77-3.86 (m, 0.5H) 3.89-3.99 (m, 1H) 3.92-3.94 (m, 3H) 4.47-4.55 (m, 0.5H) 4.62-4.71 (m, 0.5H) 5.27 (d, J=5.28 Hz, 2H) 7.09 (t, J=9.39 Hz, 2H) 7.56 (dd, J=16.14, 8.51 Hz, 2H) 7.63 (td, J=7.92, 4.11 Hz, 1H) 7.85 (t, J=6.35 Hz, 1H) 7.87-7.91 (m, 1H) 8.04 (d, J=15.85 Hz, 1H) 8.13-8.20 (m, 1H) 8.23 (dd, J=17.02, 1.76 Hz, 1H) 8.32 (br d, J=8.80 Hz, 1H) 8.59-8.74 (m, 1H); MS (ESI, m/z): 542.2 [M+H]+
Using Example 778 and tert-butyl 4-(bromomethyl)piperidine-1-carboxylate, the title compound was obtained as described in general method H. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.50-1.61 (m, 2H) 1.93-2.00 (m, 2H) 2.05-2.21 (m, 2H) 2.27-2.42 (m, 1H) 2.94-3.05 (m, 2H) 3.37-3.45 (m, 2H) 3.55 (dd, J=11.15, 4.70 Hz, 0.5H) 3.62-3.70 (m, 1H) 3.70-3.77 (m, 1H) 3.78-3.86 (m, 0.5H) 3.93-4.02 (m, 3H) 4.53-4.59 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.08-7.20 (m, 3H) 7.34 (dt, J=8.66, 2.71 Hz, 1H) 7.38-7.44 (m, 2H) 7.45-7.54 (m, 3H) 7.62 (t, J=7.90 Hz, 2H) 8.29 (d, J=1.76 Hz, 1H) 8.57-8.69 (m, 1H); MS (ESI, m/z): 656.2 [M+H]+
Using Example 778 and 3-(chloromethyl)-1-methylpyrrolidine hydrochloride, the title compound was obtained as described in general method H. MS (ESI, m/z): 628.2 [M+H]+
Using Example 778 and 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride, the title compound was obtained as described in general method H. MS (ESI, m/z): 642.3 [M+H]+
The title compound was obtained as described in general method H.
A mixture of Example 400 (30 mg, 0.06 mmol), Pd(PPh3)2Cl2 (2 mg, 5 mol %) and CuI (1 mg, 10 mol %) in 0.6 mL of N,N-dimethylformamide/triethylamine (5/1) was degassed with nitrogen, and but-3-yn-1-ol (9 μl, 0.12 mmol) was added. The mixture was heated at 100° C. for 12 h. After cooling, the mixture was partitioned between ethyl acetate and water. The organic layer was separated and washed with water, brine dried over MgSO4 and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 15 mg of the title compound. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.03-2.23 (m, 1H) 2.23-2.43 (m, 1H) 2.63 (td, J=6.65, 2.74 Hz, 2H) 3.47-3.54 (m, 0.5H) 3.59-3.70 (m, 1H) 3.73 (td, J=6.65, 2.35 Hz, 2H) 3.78-3.86 (m, 1H) 3.86-3.92 (m, 0.5H) 3.94 (d, J=1.96 Hz, 3H) 3.98 (dd, J=13.11, 6.85 Hz, 1H) 4.49-4.59 (m, 0.5H) 4.63-4.71 (m, 0.5H) 7.42-7.60 (m, 4H) 7.90 (d, J=10.56 Hz, 1H) 8.05 (d, J=9.39 Hz, 1H) 8.24 (dd, J=10.96, 1.96 Hz, 1H) 8.60-8.72 (m, 1H); MS (ESI, m/z): 459.2 [M+H]+
Using pent-4-yn-1-ol, the title compound was obtained as described in general method I. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.77-1.85 (m, 2H) 2.01-2.22 (m, 1H) 2.26-2.47 (m, 1H) 2.52 (td, J=7.24, 2.74 Hz, 2H) 3.46-3.53 (m, 0.5H) 3.63-3.76 (m, 1H) 3.69 (td, J=6.26, 2.35 Hz, 2H) 3.79-3.86 (m, 1H) 3.86-3.93 (m, 0.5H) 3.95 (d, J=1.96 Hz, 3H) 3.96-4.05 (m, 1H) 4.50-4.58 (m, 0.5H) 4.63-4.73 (m, 0.5H) 7.37-7.58 (m, 4H) 7.90 (d, J=10.56 Hz, 1H) 8.05 (d, J=9.78 Hz, 1H) 8.24 (dd, J=11.35, 1.96 Hz, 1H) 8.61-8.71 (m, 1H); MS (ESI, m/z): 473.2 [M+H]+
To a mixture of 2-amino-5-bromonicotinic acid (1.0 g, 4.58 mmol) and triethylamine (0.958 mL, 6.87 mmol) in 12 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.7 g, 4.58 mmol) followed by (R)-[1,1′-biphenyl]-4-yl(3-aminopyrrolidin-1-yl)methanone (0.853 g, 4.58 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silica gel column chromatography (0 to 60% ethyl acetate/hexanes for 30 min) to give an off-white solid. To a mixture of product in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL) and stirred at room temperature for overnight. After removing volatiles, the crude product was diluted with diethyl ether and the precipitate was collected by filtration and dried to afford 1.3 g of the title compound. MS (ESI, m/z): 465.1/467.1 [M+H]+
To a mixture of Intermediate 4 (4.48 g, 20.6 mmol) and 4-methoxybenzeneboronic acid (5.5 g, 26.8 mmol) in 100 mL of 1,4-dioxane/water (3/1) was added K2CO3 (8.5 g, 61.9 mmol) followed by Pd(PPh3)4(1.19 g, 1.03 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and extracted with ethyl acetate, dried over anhydrous MgSO4 and concentrated under vacuum. The crude residue was purified by preparative HPLC to afford 10 mg of the title compound. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.24-2.43 (m, 1H) 3.48-3.80 (m, 3H) 3.84 (s, 3H) 3.89-4.07 (m, 1H) 4.49 (br d, J=5.48 Hz, 0.5H) 4.52-4.61 (m, 0.5H) 7.06 (dd, J=8.41, 5.67 Hz, 2H) 7.34-7.41 (m, 1H) 7.46 (br t, J=6.46 Hz, 2H) 7.57-7.68 (m, 6H) 7.68-7.78 (m, 2H) 8.20-8.27 (m, 1H) 8.68-8.80 (m, 1H); MS (ESI, m/z): 493.2 [M+H]+
Using (4-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.25 (m, 1H) 2.26-2.48 (m, 1H) 2.98 (s, 3H) 3.00-3.18 (m, 2H) 3.30-3.81 (m, 2H) 3.55-3.80 (m, 4H) 3.80-3.91 (m, 1H) 3.91-4.06 (m, 3H) 4.52-4.63 (m, 0.5H) 4.67-4.75 (m, 0.5H) 7.15 (dd, J=8.61, 5.48 Hz, 2H) 7.33-7.41 (m, 1H) 7.41-7.50 (m, 2H) 7.56-7.68 (m, 6H) 7.68-7.76 (m, 2H) 8.24 (dd, J=13.69, 1.96 Hz, 1H) 8.67-8.80 (m, 1H); MS (ESI, m/z): 561.2 [M+H]+
Using (4-morpholinophenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.09-2.25 (m, 1H) 2.28-2.45 (m, 1H) 3.19-3.25 (m, 4H) 3.58 (br dd, J=11.54, 4.89 Hz, 0.5H) 3.64-3.80 (m, 2.5H) 3.83-3.89 (m, 4H) 3.91-4.06 (m, 1H) 4.57 (br d, J=5.87 Hz, 0.5H) 4.72 (br d, J=5.48 Hz, 0.5H) 7.10 (br dd, J=8.61, 5.48 Hz, 2H) 7.34-7.41 (m, 1H) 7.46 (br t, J=6.85 Hz, 2H) 7.57-7.69 (m, 6H) 7.69-7.75 (m, 2H) 8.23 (dd, J=13.69, 1.96 Hz, 1H) 8.68-8.81 (m, 1H); MS (ESI, m/z): 548.2 [M+H]+
Using pyridine-3-boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.28-2.47 (m, 1H) 3.58 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.69 (br d, J=8.61 Hz, 1H) 3.74-3.82 (m, 1H) 3.86 (br dd, J=11.93, 6.46 Hz, 0.5H) 3.92-4.08 (m, 1H) 4.51-4.64 (m, 0.5H) 4.67-4.76 (m, 0.5H) 7.34-7.41 (m, 1H) 7.45 (td, J=7.43, 3.13 Hz, 2H) 7.60-7.67 (m, 4H) 7.67-7.75 (m, 2H) 7.97-8.05 (m, 1H) 8.36 (br dd, J=14.67, 6.85 Hz, 1H) 8.53 (dd, J=14.87, 1.96 Hz, 1H) 8.66-8.75 (m, 1H) 8.81 (br s, 1H) 9.14 (br d, J=12.91 Hz, 1H); MS (ESI, m/z): 464.2 [M+H]+
Using (6-morpholinopyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.07-2.25 (m, 1H) 2.29-2.47 (m, 1H) 3.52-3.60 (m, 0.5H) 3.64 (br d, J=4.30 Hz, 4H) 3.67-3.81 (m, 2.5H) 3.81-3.89 (m, 4H) 3.95-4.06 (m, 1H) 4.54-4.59 (m, 0.5H) 4.72 (br d, J=4.70 Hz, 0.5H) 7.19 (br dd, J=8.61, 5.87 Hz, 1H) 7.29-7.42 (m, 1H) 7.42-7.50 (m, 2H) 7.55-7.69 (m, 4H) 7.69-7.76 (m, 2H) 8.06-8.15 (m, 1H) 8.32 (br d, J=14.09 Hz, 1H) 8.38 (br d, J=15.26 Hz, 1H) 8.58-8.71 (m, 1H); MS (ESI, m/z): 549.2 [M+H]+
Using (6-fluoropyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.23 (m, 1H) 2.27-2.45 (m, 1H) 3.56 (dd, J=11.15, 4.70 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.80-3.90 (m, 0.5H) 3.92-4.06 (m, 1H) 4.52-4.62 (m, 0.5H) 4.65-4.74 (m, 0.5H) 7.21 (td, J=8.95, 2.64 Hz, 1H) 7.30-7.40 (m, 1H) 7.44 (td, J=7.63, 4.11 Hz, 2H) 7.59-7.67 (m, 4H) 7.70 (t, J=8.51 Hz, 2H) 8.19-8.32 (m, 1H) 8.33-8.42 (m, 1H) 8.48-8.57 (m, 1H) 8.68-8.81 (m, 1H); MS (ESI, m/z): 482.2 [M+H]+
Using (1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 636.2 [M+H]+
Following deprotection of example 561 with trifluoroacetic acid, the title compound was obtained. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.25-2.51 (m, 5H) 3.19-3.27 (m, 2H) 3.52-3.63 (m, 2.5H) 3.69 (br dd, J=12.91, 5.09 Hz, 1H) 3.74-3.82 (m, 1H) 3.82-3.91 (m, 0.5H) 3.92-4.06 (m, 1H) 4.52-4.65 (m, 1.5H) 4.66-4.75 (m, 0.5H) 7.33-7.41 (m, 1H) 7.45 (td, J=7.53, 3.33 Hz, 2H) 7.61-7.68 (m, 4H) 7.68-7.75 (m, 2H) 7.98 (d, J=12.13 Hz, 1H) 8.20 (d, J=11.35 Hz, 1H) 8.26 (dd, J=13.69, 1.96 Hz, 1H) 8.64-8.77 (m, 1H); MS (ESI, m/z): 536.2 [M+H]+
Using (1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 550.2 [M+H]+
Using 1-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazine, the title compound was obtained as described in general method J. MS (ESI, m/z): 589.2 [M+H]+
Using 2-(4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazin-1-yl)ethan-1-ol, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.32 (br s, 1H) 2.96 (br s, 2H) 3.24 (br d, J=5.87 Hz, 4H) 3.33-3.43 (m, 4H) 3.59 (br d, J=11.74 Hz, 0.5H) 3.65-3.81 (m, 2H) 3.85 (br s, 2.5H) 3.91-4.07 (m, 1H) 4.58 (br s, 0.5H) 4.72 (br s, 0.5H) 7.31-7.41 (m, 1H) 7.41-7.51 (m, 2H) 7.59-7.80 (m, 10H) 8.32 (br d, J=14.09 Hz, 1H) 8.82 (s, 1H); MS (ESI, m/z): 633.2 [M+H]+
Using 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.26-2.44 (m, 1H) 2.92 (s, 3H) 3.04-3.17 (m, 4H) 3.39-3.51 (m, 4H) 3.58 (br dd, J=11.54, 5.28 Hz, 0.5H) 3.70 (br dd, J=12.72, 5.28 Hz, 1H) 3.73-3.80 (m, 1H) 3.83 (br d, J=7.43 Hz, 0.5H) 3.95-4.07 (m, 1H) 4.02 (s, 2H) 4.53-4.61 (m, 0.5H) 4.66-4.76 (m, 0.5H) 7.34-7.40 (m, 1H) 7.42-7.49 (m, 2H) 7.50-7.85 (m, 10H) 8.30-8.38 (m, 1H) 8.73-8.85 (m, 1H); MS (ESI, m/z): 575.2 [M+H]+
Using (4-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 493.2 [M+H]+
Using (4-(morpholinomethyl)phenyl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 562.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (4-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 596.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (4-morpholinophenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.24 (m, 1H) 2.28-2.43 (m, 1H) 3.28-3.30 (m, 4H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.79 (m, 1H) 3.81-3.85 (m, 4H) 3.85-3.89 (m, 0.5H) 3.92-4.03 (m, 1H) 4.52-4.64 (m, 0.5H) 4.64-4.74 (m, 0.5H) 7.08 (dd, J=8.80, 7.04 Hz, 2H) 7.32-7.40 (m, 3H) 7.48-7.53 (m, 3H) 7.57 (d, J=8.80 Hz, 1H) 7.60 (d, J=8.80 Hz, 1H) 7.63 (dd, J=9.98, 8.22 Hz, 2H) 8.22 (dd, J=18.78, 1.76 Hz, 1H) 8.68-8.79 (m, 1H); MS (ESI, m/z): 583.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described in general method J. MS (ESI, m/z): 610.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (1-(2-methoxyethyl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.17 (ddd, J=19.56, 12.91, 6.65 Hz, 1H) 2.29-2.47 (m, 1H) 3.33 (s, 3H) 3.58 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.68-3.82 (m, 4H) 3.82-3.91 (m, 0.5H) 4.01 (td, J=12.72, 6.65 Hz, 1H) 4.33-4.41 (m, 2H) 4.55-4.62 (m, 0.5H) 4.71 (t, J=6.46 Hz, 0.5H) 7.31-7.44 (m, 3H) 7.50-7.59 (m, 3H) 7.65 (br t, J=8.41 Hz, 2H) 7.94 (d, J=10.96 Hz, 1H) 8.11 (d, J=10.96 Hz, 1H) 8.26 (dd, J=12.52, 1.96 Hz, 1H) 8.65-8.76 (m, 1H); MS (ESI, m/z): 546.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (4-(azetidin-1-ylsulfonyl)phenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.04-2.11 (m, 2H) 2.11-2.24 (m, 1H) 2.28-2.46 (m, 1H) 3.60 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.67-3.74 (m, 1H) 3.78 (t, J=7.63 Hz, 4H) 3.81-3.92 (m, 1.5H) 4.01 (td, J=13.11, 6.65 Hz, 1H) 4.55-4.66 (m, 0.5H) 4.68-4.75 (m, 0.5H) 7.34-7.43 (m, 3H) 7.44-7.58 (m, 3H) 7.64 (t, J=8.22 Hz, 2H) 7.92-8.05 (m, 4H) 8.47 (dd, J=12.72, 2.15 Hz, 1H) 8.73-8.85 (m, 1H); MS (ESI, m/z): 617.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (4-sulfamoylphenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.26 (m, 1H) 2.27-2.49 (m, 1H) 3.59 (dd, J=10.96, 5.09 Hz, 0.5H) 3.66-3.74 (m, 1H) 3.74-3.81 (m, 1H) 3.81-3.92 (m, 0.5H) 3.96-4.13 (m, 1H) 4.54-4.62 (m, 0.5H) 4.69-4.75 (m, 0.5H) 7.26-7.42 (m, 3H) 7.44-7.57 (m, 3H) 7.58-7.72 (m, 2H) 7.86 (br d, J=8.61 Hz, 1H) 7.88-7.95 (m, 1H) 8.02 (dd, J=8.41, 4.89 Hz, 2H) 8.42 (dd, J=12.72, 2.15 Hz, 1H) 8.72-8.85 (m, 1H); MS (ESI, m/z): 577.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (4-(methylsulfonamido)phenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.29-2.48 (m, 1H) 3.00 (s, 3H) 3.59 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.80 (m, 2H) 3.80-3.92 (m, 0.5H) 3.93-4.07 (m, 1H) 4.55-4.62 (m, 0.5H) 4.71 (d, J=5.87 Hz, 0.5H) 7.35-7.45 (m, 4H) 7.50-7.61 (m, 4H) 7.61-7.74 (m, 4H) 8.30 (dd, J=12.52, 2.35 Hz, 1H) 8.69-8.81 (m, 1H); MS (ESI, m/z): 591.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[1,1′-biphenyl]-4-yl)methanone and (1-(tert-butyl)-1H-pyrazol-4-yl)boronic acid pinacole ester, the title compound was obtained as described in general method J. MS (ESI, m/z): 544.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-[l1,1′-biphenyl]-4-yl)methanone and 4-carboxybenzeneboronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 542.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[111′-biphenyl]-4-yl)methanone and 2-aminonicotinic acid, the title compound was obtained as described for Intermediate 4 in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.22 (m, 1H) 2.26-2.42 (m, 1H) 3.53 (dd, J=11.15, 4.70 Hz, 0.5H) 3.61-3.71 (m, 1H) 3.71-3.78 (m, 1H) 3.79-3.88 (m, 0.5H) 3.89-4.03 (m, 1H) 4.48-4.61 (m, 0.5H) 4.61-4.77 (m, 0.5H) 6.95-7.03 (m, 1H) 7.14-7.22 (m, 1H) 7.32-7.38 (m, 1H) 7.41 (dt, J=8.66, 5.94 Hz, 1H) 7.51 (t, J=7.95 Hz, 2H) 7.63 (dd, J=12.33, 8.22 Hz, 2H) 8.03 (ddd, J=17.61, 6.16, 1.47 Hz, 1H) 8.36-8.50 (m, 1H); MS (ESI, m/z): 439.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[111′-biphenyl]-4-yl)methanone, the title compound was obtained as described for Intermediate 4 in general method J. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.18 (m, 1H) 2.26-2.42 (m, 1H) 3.54 (br dd, J=11.15, 4.89 Hz, 0.5H) 3.66 (br dd, J=12.72, 4.89 Hz, 1H) 3.71-3.79 (m, 1H) 3.83 (br s, 0.5H) 3.87-4.03 (m, 1H) 4.47-4.59 (m, 0.5H) 4.60-4.73 (m, 0.5H) 7.18 (tt, J=8.41, 2.93 Hz, 1H) 7.33 (dt, J=8.80, 2.84 Hz, 1H) 7.41 (dt, J=8.41, 5.77 Hz, 1H) 7.50 (dd, J=7.83, 5.87 Hz, 2H) 7.63 (br t, J=8.41 Hz, 2H) 8.18-8.24 (m, 1H) 8.46-8.57 (m, 1H); MS (ESI, m/z): 517.2/519.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (2-(piperazin-1-yl)pyridin-4-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.25 (m, 1H) 2.28-2.44 (m, 1H) 3.39-3.44 (m, 4H) 3.58 (dd, J=11.15, 5.87 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.83-3.89 (m, 0.5H) 3.94-4.05 (m, 5H) 4.55-4.61 (m, 0.5H) 4.68-4.75 (m, 0.5H) 7.14-7.20 (m, 1H) 7.29-7.36 (m, 2H) 7.40 (dt, J=8.51, 6.31 Hz, 1H) 7.47-7.52 (m, 3H) 7.62 (br d, J=8.22 Hz, 1H) 7.64 (br d, J=8.22 Hz, 1H) 8.19 (t, J=6.46 Hz, 1H) 8.60 (dd, J=17.61, 2.35 Hz, 1H) 8.73-8.86 (m, 1H); MS (ESI, m/z): 601.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (6-acetamidopyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.20 (m, 1H) 2.21 (s, 3H) 2.27-2.43 (m, 1H) 3.57 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.80-3.88 (m, 0.5H) 3.95-4.04 (m, 1H) 4.55-4.61 (m, 0.5H) 4.65-4.74 (m, 0.5H) 7.13-7.20 (m, 1H) 7.34 (dt, J=8.80, 3.23 Hz, 1H) 7.40 (dt, J=8.66, 6.24 Hz, 2H) 7.45-7.52 (m, 2H) 7.62 (br d, J=8.22 Hz, 1H) 7.64 (br d, J=8.22 Hz, 1H) 8.10 (br t, J=8.22 Hz, 1H) 8.20 (br ddd, J=19.96, 8.80, 2.35 Hz, 1H) 8.37 (dd, J=19.07, 2.05 Hz, 1H) 8.62 (dd, J=19.37, 2.35 Hz, 1H) 8.71-8.82 (m, 1H); MS (ESI, m/z): 574.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (5-aminopyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.29-2.44 (m, 1H) 3.56 (dd, J=11.15, 4.70 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.81-3.89 (m, 0.5H) 3.95-4.05 (m, 1H) 4.51-4.63 (m, 0.5H) 4.64-4.78 (m, 0.5H) 7.11-7.22 (m, 1H) 7.34 (dt, J=6.75, 4.26 Hz, 1H) 7.41 (ddd, J=8.95, 5.72, 3.52 Hz, 1H) 7.50 (dd, J=8.22, 5.87 Hz, 2H) 7.60-7.67 (m, 2H) 7.84-7.91 (m, 1H) 7.99 (dd, J=5.28, 2.35 Hz, 1H) 8.26 (dd, J=18.78, 1.17 Hz, 1H) 8.44 (dd, J=17.90, 2.05 Hz, 1H) 8.47-8.57 (m, 1H); MS (ESI, m/z): 531.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (6-morpholinopyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.25 (m, 1H) 2.28-2.46 (m, 1H) 3.57 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.73 (m, 5H) 3.73-3.79 (m, 1H) 3.81-3.89 (m, 4.5H) 3.91-4.04 (m, 1H) 4.50-4.64 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.10-7.20 (m, 1H) 7.30-7.36 (m, 1H) 7.36-7.45 (m, 2H) 7.46-7.53 (m, 2H) 7.57-7.68 (m, 2H) 8.22-8.28 (m, 1H) 8.33-8.35 (m, 1H) 8.37 (d, J=2.35 Hz, 1H) 8.64-8.79 (m, 1H); MS (ESI, m/z): 602.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (4-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.44 (m, 1H) 2.97 (s, 3H) 3.09 (br t, J=12.62 Hz, 2H) 3.19-3.28 (m, 2H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.60-3.66 (m, 2H) 3.66-3.72 (m, 1H) 3.72-3.78 (m, 1H) 3.81-3.90 (m, 0.5H) 3.90-4.05 (m, 3H) 4.45-4.64 (m, 0.5H) 4.64-4.79 (m, 0.5H) 7.12-7.22 (m, 3H) 7.27-7.37 (m, 1H) 7.41 (dt, J=8.51, 5.72 Hz, 1H) 7.50 (dd, J=7.92, 6.75 Hz, 2H) 7.56-7.67 (m, 4H) 8.24 (dd, J=17.90, 2.05 Hz, 1H) 8.66-8.78 (m, 1H); MS (ESI, m/z): 614.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and 3-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)pyridine, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.23 (m, 1H) 2.28-2.43 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.82-3.88 (m, 0.5H) 3.94-4.05 (m, 1H) 4.54-4.60 (m, 0.5H) 4.67-4.73 (m, 0.5H) 5.64 (d, J=4.70 Hz, 2H) 7.14-7.20 (m, 1H) 7.34 (ddd, J=8.80, 4.70, 2.35 Hz, 1H) 7.40 (dt, J=8.66, 5.94 Hz, 1H) 7.50 (t, J=7.92 Hz, 2H) 7.60-7.66 (m, 2H) 7.98 (dd, J=7.92, 6.16 Hz, 1H) 8.02 (d, J=16.43 Hz, 1H) 8.27 (dd, J=17.61, 2.35 Hz, 1H) 8.30 (d, J=13.50 Hz, 1H) 8.36-8.42 (m, 1H) 8.65-8.76 (m, 1H) 8.79 (d, J=4.70 Hz, 2H); MS (ESI, m/z): 597.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and 5-(carboxypyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.23 (m, 1H) 2.27-2.46 (m, 1H) 3.57 (dd, J=11.15, 5.28 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.83-3.89 (m, 0.5H) 3.95-4.04 (m, 1H) 4.54-4.61 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.16 (tdd, J=8.29, 8.29, 5.43, 2.64 Hz, 1H) 7.33 (ddd, J=8.66, 6.02, 2.35 Hz, 1H) 7.36-7.44 (m, 1H) 7.46-7.53 (m, 2H) 7.59-7.69 (m, 3H) 8.45 (dd, J=18, 1.76 Hz, 1H) 8.72 (td, J=24, 2.05 Hz, 1H), 8.74 (dd, J=48, 1.76 Hz, 1H) 9.6 (dd, J=18, 2.35 Hz, 1H) 9.14 (dd, J=4.70, 1.76 Hz, 1H); MS (ESI, m/z): 560.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (6-fluoropyridin-3-yl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 534.1 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and phenylboronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.27-2.43 (m, 1H) 3.57 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.71 (m, 1H) 3.71-3.80 (m, 1H) 3.80-3.88 (m, 0.5H) 3.94-4.04 (m, 1H) 4.53-4.60 (m, 0.5H) 4.67-4.73 (m, 0.5H) 7.14-7.20 (m, 1H) 7.32-7.36 (m, 1H) 7.37-7.46 (m, 2H) 7.47-7.53 (m, 4H) 7.60-7.71 (m, 4H) 8.30 (dd, J=18.78, 2.35 Hz, 1H) 8.66-8.78 (m, 1H); MS (ESI, m/z): 515.1 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (2-carbamoylphenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.04-2.18 (m, 1H) 2.24-2.39 (m, 1H) 3.53 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65 (br dd, J=12.62, 4.40 Hz, 1H) 3.68-3.76 (m, 1H) 3.76-3.86 (m, 0.5H) 3.91-4.01 (m, 1H) 4.51-4.57 (m, 0.5H) 4.64-4.71 (m, 0.5H) 7.16 (tt, J=8.44, 2.42 Hz, 1H) 7.33 (dt, J=8.51, 2.79 Hz, 1H) 7.40 (ddd, J=8.66, 6.02, 2.93 Hz, 1H) 7.46-7.56 (m, 4H) 7.58-7.64 (m, 3H) 7.65-7.70 (m, 1H) 8.01 (dd, J=16.73, 2.05 Hz, 1H) 7.98-8.01 (m, 1H) 8.44-8.56 (m, 1H); MS (ESI, m/z): 558.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and 2-boronobenzoic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.01-2.16 (m, 1H) 2.24-2.39 (m, 1H) 3.51 (dd, J=11.15, 4.70 Hz, 0.5H) 3.58-3.67 (m, 1H) 3.67-3.75 (m, 1H) 3.75-3.83 (m, 0.5H) 3.90-4.00 (m, 1H) 4.51-4.57 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.14-7.20 (m, 1H) 7.34 (dd, J=8.80, 1.76 Hz, 1H) 7.39-7.47 (m, 2H) 7.49 (dd, J=8.22, 2.93 Hz, 2H) 7.55-7.64 (m, 3H) 7.64-7.72 (m, 1H) 8.00 (dd, J=19.96, 2.35 Hz, 1H) 8.10-8.14 (m, 1H) 8.42-8.54 (m, 1H); MS (ESI, m/z): 559.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (2-hydroxyphenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.22 (m, 1H) 2.26-2.41 (m, 1H) 3.54 (dd, J=11.44, 4.99 Hz, 0.5H) 3.61-3.69 (m, 1H) 3.69-3.76 (m, 1H) 3.79-3.88 (m, 0.5H) 3.91-4.01 (m, 1H) 4.52-4.58 (m, 0.5H) 4.66-4.72 (m, 0.5H) 6.92-6.99 (m, 2H) 7.14-7.19 (m, 1H) 7.22-7.27 (m, 1H) 7.31-7.36 (m, 1H) 7.38-7.46 (m, 2H) 7.47-7.51 (m, 2H) 7.62 (t, J=8.72 Hz, 2H) 8.27-8.36 (m, 1H) 8.65-8.77 (m, 1H); MS (ESI, m/z): 531.1 [M+H]+
Using 3-amino-6-bromopyrazine-2-carboxylic acid and (2-aminophenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.02-2.20 (m, 1H) 2.22-2.39 (m, 1H) 3.42 (br d, J=9.98 Hz, 0.5H) 3.53-3.61 (m, 1.5H) 3.68 (br d, J=5.28 Hz, 0.5H) 3.79 (br d, J=6.46 Hz, 1H) 3.97 (br dd, J=12.62, 7.34 Hz, 0.5H) 4.46-4.52 (m, 0.5H) 4.66-4.71 (m, 0.5H) 6.94-7.03 (m, 2H) 7.05-7.20 (m, 1H) 7.23 (br dd, J=15.55, 7.92 Hz, 2H) 7.27-7.34 (m, 1H) 7.37 (dd, J=18.49, 7.92 Hz, 2H) 7.42-7.59 (m, 3H) 7.71-7.79 (m, 1H); MS (ESI, m/z): 531.1 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (2-(4-methylpiperazin-1-yl)pyridin-4-yl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.21 (m, 1H) 2.30-2.43 (m, 1H) 2.97 (s, 3H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.73 (m, 1H) 3.75 (br dd, J=11.15, 7.04 Hz, 1H) 3.85 (br s, 0.5H) 3.96-4.05 (m, 1H) 4.55-4.59 (m, 0.5H) 4.72 (br s, 0.5H) 7.15-7.22 (m, 2H) 7.29 (br d, J=17.02 Hz, 1H) 7.33-7.37 (m, 1H) 7.41 (ddd, J=8.80, 5.87, 3.52 Hz, 1H) 7.50 (t, J=7.63 Hz, 2H) 7.63 (dd, J=12.33, 8.22 Hz, 2H) 8.24 (t, J=5.90 Hz, 1H) 8.50 (dd, J=17.31, 2.05 Hz, 1H) 8.67 (dd, J=48.71, 2.35 Hz, 1H); MS (ESI, m/z): 614.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (3-chloro-4-(morpholine-4-carbonyl)phenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.22 (m, 1H) 2.28-2.44 (m, 1H) 3.24-3.34 (m, 2H) 3.54-3.64 (m, 2H) 3.64-3.72 (m, 3H) 3.72-3.90 (m, 7H) 3.96-4.04 (m, 1H) 4.55-4.61 (m, 0.5H) 4.68-4.73 (m, 0.5H) 7.14-7.20 (m, 1H) 7.34 (ddd, J=8.66, 4.55, 2.64 Hz, 1H) 7.38-7.43 (m, 1H) 7.47-7.51 (m, 2H) 7.63 (dd, J=13.50, 8.22 Hz, 2H) 7.67-7.77 (m, 1.5H) 7.81 (d, J=1.17 Hz, 0.5H) 7.90 (d, J=22.89 Hz, 1H) 8.40 (dd, J=20.54, 2.35 Hz, 1H) 8.79 (dd, J=44.60, 2.35 Hz, 1H); MS (ESI, m/z): 662.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (4-morpholinophenyl)boronic acid, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.24 (m, 1H) 2.28-2.42 (m, 1H) 3.19-3.23 (m, 4H) 3.57 (dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.78 (m, 1H) 3.82-3.84 (m, 4H) 3.84-3.87 (m, 0.5H) 3.94-4.02 (m, 1H) 4.54-4.59 (m, 0.5H) 4.67-4.72 (m, 0.5H) 7.06-7.11 (m, 2H) 7.17 (tdd, 1H) 7.32-7.36 (m, 1H) 7.40 (dt, J=8.36, 6.09 Hz, 1H) 7.49 (dd, J=8.22, 6.46 Hz, 2H) 7.55-7.65 (m, 4H) 8.22 (dd, J=18.49, 2.05 Hz, 1H) 8.72 (dd, J=41.67, 1.76 Hz, 1H); MS (ESI, m/z): 600.1 [M+H]+
Using 1-((2-nitrophenyl)sulfonyl)-4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazine, the title compound was obtained as described in general method J. MS (ESI, m/z): 774.3 [M+H]+
Using Example 777 and (1r,4r)-4-aminocyclohexan-1-ol, the title compound was obtained as described in general method J. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.22-1.35 (m, 2H) 1.35-1.49 (m, 1H) 1.54-1.68 (m, 1H) 1.85 (br s, 1H) 1.87-2.02 (m, 2H) 2.03-2.19 (m, 2H) 2.24-2.42 (m, 1H) 3.52 (br dd, J=11.15, 5.28 Hz, 1H) 3.63-3.84 (m, 3H) 3.91-4.02 (m, 1H) 4.53-4.58 (m, 0.5H) 4.65-4.70 (m, 0.5H) 4.82-4.92 (m, 1H) 7.13-7.20 (m, 1H) 7.31-7.37 (m, 1H) 7.37-7.43 (m, 1H) 7.46-7.73 (m, 8H) 7.95-8.03 (m, 1H) 8.40-8.50 (m, 1H); MS (ESI, m/z): 656.2 [M+H]+
Using (R)-(3-aminopyrrolidin-1-yl)(2′-chloro-4′-fluoro-[1,1′-biphenyl]-4-yl)methanone and (2-formylphenyl)boronic acid, the title compound was obtained as described in general method J. MS (ESI, m/z): 543.2 [M+H]+
To a mixture of Example 578 (10 mg, 0.02 mmol) and triethylamine (8 μl, 0.06 mmol) in 0.5 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (7 g, 0.02 mmol) followed by 1-methylpiperazine (2 μl, 0.02 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. After removing volatiles, the crude product was diluted with diethyl ether and the precipitate was collected by filtration and dried to afford 5 mg of the title compound. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.10-2.26 (m, 1H) 2.28-2.46 (m, 1H) 2.95 (s, 3H) 3.60 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.71 (br dd, J=12.72, 4.89 Hz, 1H) 3.79 (br d, J=10.17 Hz, 1H) 3.85 (br s, 0.5H) 3.92-4.08 (m, 1H) 4.59 (t, J=5.87 Hz, 0.5H) 4.72 (t, J=5.48 Hz, 0.5H) 7.33-7.41 (m, 3H) 7.48-7.56 (m, 3H) 7.60-7.73 (m, 4H) 7.82 (br d, J=8.61 Hz, 1H) 7.84-7.88 (m, 1H) 8.35-8.44 (m, 1H) 8.76-8.88 (m, 1H); MS (ESI, m/z): 624.1 [M+H]+
Using 1-(2-hydroxyethyl)piperazine, the title compound was obtained as described in general method K. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.26 (m, 1H) 2.27-2.50 (m, 1H) 3.34 (br d, J=5.09 Hz, 4H) 3.60 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.71 (br dd, J=12.13, 4.70 Hz, 1H) 3.79 (br d, J=9.78 Hz, 1H) 3.85 (br s, 0.5H) 3.88-3.94 (m, 2H) 3.95-4.06 (m, 1H) 4.57-4.62 (m, 0.5H) 4.72 (t, J=5.87 Hz, 0.5H) 7.38 (s, 3H) 7.52 (br dd, J=8.22, 3.13 Hz, 3H) 7.60-7.71 (m, 4H) 7.82 (br d, J=7.83 Hz, 1H) 7.85 (br d, J=8.22 Hz, 1H) 8.39 (dd, J=12.33, 2.15 Hz, 1H) 8.75-8.86 (m, 1H); MS (ESI, m/z): 654.2 [M+H]+
Using morpholine, the title compound was obtained as described in general method K. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.09-2.26 (m, 1H) 2.26-2.51 (m, 1H) 3.43-3.56 (m, 2H) 3.56-3.62 (m, 0.5H) 3.66 (br d, J=11.74 Hz, 2H) 3.68-3.83 (m, 6H) 3.84 (br d, J=7.83 Hz, 0.5H) 4.01 (br d, J=6.65 Hz, 1H) 4.56-4.64 (m, 0.5H) 4.69-4.75 (m, 0.5H) 7.35-7.43 (m, 3H) 7.49-7.55 (m, 3H) 7.58 (dd, J=8.22, 5.09 Hz, 2H) 7.64 (t, J=7.63 Hz, 2H) 7.79 (s, 1H) 7.80 (s, 1H) 7.83 (br d, J=8.61 Hz, 1H) 8.38 (dd, J=13.11, 2.15 Hz, 1H); MS (ESI, m/z): 611.2 [M+H]+
Using 4-amino-1-methylpiperidine, the title compound was obtained as described in general method K. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.87-1.98 (m, 2H) 2.11-2.20 (m, 1H) 2.25 (br d, J=15.26 Hz, 2H) 2.29-2.45 (m, 1H) 2.89 (s, 3H) 3.13-3.22 (m, 2H) 3.60 (br d, J=11.35 Hz, 2H) 3.71 (br dd, J=13.11, 4.11 Hz, 1H) 3.74-3.81 (m, 1H) 3.90 (brs, 1H) 3.96-4.06 (m, 1H) 4.13-4.23 (m, 1H) 4.57-4.63 (m, 0.5H) 4.68-4.76 (n, 0.5H) 7.31-7.41 (m, 3H) 7.44-7.54 (m, 3H) 7.64 (t, J=7.63 Hz, 2H) 7.80 (br d, J=8.22 Hz, 1H) 7.84 (br d, J=8.22 Hz, 1H) 7.94-8.02 (m, 2H) 8.40 (dd, J=12.52, 2.35 Hz, 1H) 8.76-8.87 (m, 1H); MS (ESI, m/z): 638.2 [M+H]+
Using 4-methylcyclohexan-1-amine, the title compound was obtained as described in general method K. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.01 (d, J=6.65 Hz, 3H) 1.10 (br d, J=14.87 Hz, 1H) 1.35-1.52 (m, 2H) 1.60-1.74 (m, 3H) 1.74-1.86 (m, 2H) 1.96 (br d, J=9.78 Hz, 1H) 2.10-2.24 (m, 1H) 2.28-2.46 (m, 1H) 3.59 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.71 (br dd, J=12.52, 4.70 Hz, 1H) 3.74-3.82 (m, 1H) 3.82-3.92 (m, 1H) 3.97-4.07 (m, 1.5H) 4.56-4.66 (m, 0.5H) 4.66-4.78 (m, 0.5H) 7.34-7.43 (m, 3H) 7.46-7.57 (m, 3H) 7.59-7.68 (m, 2H) 7.76-7.85 (m, 2H) 7.92-7.98 (m, 2H) 8.40 (dd, J=12.72, 1.76 Hz, 1H) 8.77-8.89 (m, 1H); MS (ESI, m/z): 637.2 [M+H]+
Using tetrahydro-2H-pyran-4-amine, the title compound was obtained as described in general method K. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.68 (qd, J=12.13, 4.11 Hz, 2H) 1.90 (dt, J=12.47, 1.98 Hz, 2H) 2.06-2.25 (m, 1H) 2.29-2.44 (m, 1H) 3.52 (td, J=11.74, 1.76 Hz, 2H) 3.58 (dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.82-3.89 (m, 0.5H) 3.98 (br dd, J=11.44, 5.58 Hz, 2H) 4.00-4.04 (m, 1H) 4.12 (tt, J=11.22, 4.33 Hz, 1H) 4.55-4.62 (m, 0.5H) 4.68-4.74 (m, 0.5H) 7.32-7.40 (m, 3H) 7.45-7.54 (m, 3H) 7.63 (dd, J=10.56, 8.22 Hz, 2H) 7.76-7.83 (m, 2H) 7.96 (t, J=8.22 Hz, 2H) 8.39 (dd, J=19.07, 2.05 Hz, 1H) 8.72-8.84 (m, 1H); MS (ESI, m/z): 625.2 [M+H]+
Using (1-methylpyrrolidin-3-yl)methanamine, the title compound was obtained as described in general method K. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.80-1.87 (m, 0.5H) 1.98-2.06 (m, 0.5H) 2.09-2.25 (m, 1.5H) 2.29-2.43 (m, 1.5H) 2.71-2.78 (m, 0.5H) 2.88-2.92 (m, 0.5H) 2.94 (br d, J=11.15 Hz, 3H) 3.09-3.20 (m, 1H) 3.48-3.55 (m, 2H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.73 (m, 2H) 3.73-3.80 (m, 2H) 3.82-3.89 (m, 1H) 3.96-4.05 (m, 1H) 4.35-4.38 (m, 0.5H) 4.55-4.61 (m, 0.5H) 4.68-4.75 (m, 0.5H) 7.32-7.41 (m, 3H) 7.48-7.55 (m, 3H) 7.62 (br d, J=8.22 Hz, 1H) 7.63-7.67 (m, 1H) 7.80 (d, J=8.22 Hz, 1H) 7.83 (br d, J=8.80 Hz, 1H) 7.96 (t, J=7.63 Hz, 2H) 8.40 (dd, J=18.19, 2.35 Hz, 1H) 8.64-8.75 (m, 1H); MS (ESI, m/z): 638.2 [M+H]+
Using 1-(3-aminopropyl)pyrrolidin-2-one, the title compound was obtained as described in general method K. MS (ESI, m/z): 666.2 [M+H]+
Using Example 843, the title compound was obtained as described in general method K. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.26 (m, 1H) 2.29-2.45 (m, 1H) 2.95 (d, J=2.93 Hz, 3H) 3.16-3.27 (m, 2H) 3.56 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.67-3.83 (m, 2H) 3.88-3.93 (m, 0.5H) 3.94 (d, J=7.04 Hz, 3H) 3.95-4.01 (m, 0.5H) 4.06 (br dd, J=12.91, 6.46 Hz, 0.5H) 4.53-4.58 (m, 0.5H) 4.70-4.75 (m, 0.5H) 7.61-7.66 (m, 1H) 7.73 (ddd, J=11.74, 8.80, 1.76 Hz, 1H) 7.87-7.94 (m, 1H) 8.02-8.12 (m, 4H) 8.16 (d, J=13.50 Hz, 1H) 8.21-8.29 (m, 1H) 8.61-8.75 (m, 1H); MS (ESI, m/z): 567.3 [M+H]+
Using Example 843 and 1-(2-hydroxyethyl)piperazine, the title compound was obtained as described in general method K. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10-2.26 (m, 1H) 2.30-2.47 (m, 1H) 3.20-3.30 (m, 2H) 3.33-3.37 (m, 2H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.85 (m, 3H) 3.92 (br d, J=3.52 Hz, 2.5H) 3.95 (d, J=7.04 Hz, 3H) 3.96-4.00 (m, 0.5H) 4.07 (br dd, J=12.91, 7.04 Hz, 0.5H) 4.54-4.59 (m, 0.5H) 4.71-4.76 (m, 0.5H) 7.65 (ddd, J=8.51, 7.04, 1.47 Hz, 1H) 7.73 (ddd, J=14.09, 8.51, 1.47 Hz, 1H) 7.87-7.98 (m, 1H) 8.02-8.11 (m, 4H) 8.13-8.19 (m, 1H) 8.20-8.29 (m, 1H) 8.63-8.79 (m, 1H); MS (ESI, m/z): 597.3 [M+H]+
Using Example 812 and dimethylamine, the title compound was obtained as described in general method K. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.23 (m, 1H) 2.28-2.44 (m, 1H) 3.05 (br s, 3H) 3.10 (br s, 3H) 3.58 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.73 (m, 1H) 3.73-3.82 (m, 1H) 3.87 (br d, J=6.46 Hz, 0.5H) 3.94 (d, J=5.87 Hz, 3H) 3.96-4.05 (m, 1H) 4.53-4.59 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.08 (dd, J=8.51, 4.99 Hz, 2H) 7.13 (t, J=7.92 Hz, 2H) 7.46 (dd, J=8.51, 3.23 Hz, 2H) 7.58-7.75 (m, 6H) 7.90 (d, J=19.37 Hz, 1H) 8.05 (d, J=18.19 Hz, 1H) 8.19-8.27 (m, 1H) 8.62-8.74 (m, 1H) MS (ESI, m/z): 630.3 [M+H]+
Using Example 812 and ammonium acetate, the title compound was obtained as described in general method K. MS (ESI, m/z): 602.2 [M+H]+
Using Example 677 and dimethylamine, the title compound was obtained as described in general method K. MS (ESI, m/z): 564.3 [M+H]+
To a solution of Intermediate 2 (116 mg, 0.3 mmol) and triethylamine (0.05 mL, 0.36 mmol) in 2 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (137 mg, 0.36 mmol) followed by 1-phenylpyrrolidin-3-amine (53 mg, 0.33 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. A solution of Intermediate 5 (133 mg, 0.25 mmol) and 0.5 mL of N,N-dimethylformamide dimethyl acetal (DMFDMA) in 1 mL of N,N-dimethylformamide was heated at 120° C. for 3 h. The mixture was extracted with ethyl acetate and saturated aqueous NaHCO3 solution, dried over MgSO4, and concentrated in vacuo. A solution of the crude product and NaBH4 (20 mg, 0.5 mmol) in 2 mL of methanol was refluxed for 3 h. The mixture was extracted with ethyl acetate and saturated aqueous NaHCO3 solution, dried over MgSO4, and concentrated in vacuo. The residue in solution of 0.3 mL of trifluoroacetic acid and 1 mL of dichloromethane was stirred for 1 h. The mixture was evaporated to remove volatiles and purified by preparative HPLC to afford 40 mg of the title compound. MS (ESI, m/z): 444.24 [M+H]+
Using (R)-1-phenylpyrrolidin-3-amine, the title compound was obtained as described in general method L. MS (ESI, m/z): 444.24 [M+H]+
To a mixture of 5-bromo-2-chloronicotinic acid (5.57 g, 23.7 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (6.4 g, 30.8 mmol) in 100 mL of 1,4-dioxane/water (3/1) was added K2CO3 (6.5 g, 47.4 mmol) followed by Pd(PPh3)4(1.9 g, 1.66 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature, and partitioned between water and ethyl acetate. Water layer was separated and adjusted to pH value around 4. The precipitate was collected by filtration, washed with water, and dried to afford 5.2 g of the title compound. The crude product was used for the next step without further purification. MS (ESI, m/z): 238.0 [M+H]+
To a mixture of 2-chloro-5-(1-methyl-1H-pyrazol-4-yl)nicotinic acid (1.0 mmol) and triethylamine (1.2 mmol) in 3 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.2 mmol) followed by amine (1.0 mmol). The mixture was stirred at room temperature for 1 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was used for the next step without further purification.
To a solution of amide coupled product from Step 2 (0.8 mmol) in 5 mL of tetrahydrofuran was added Lawessons's reagent (0.9 mmol). The mixture was stirred at between 40° C.—reflux, (50° C. for the exemplified reaction) for 1 h, and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was used for the next step without further purification.
To a solution of thioamide product from step 3 (0.8 mmol) in dimethyl sulfoxide (3 mL) was added hydrazine-monohydrate (6.4 mmol). The mixture was stirred at between 80-120° C. (80° C. for the exemplified reaction) for 6 h and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was used for the next step without further purification.
To a solution of pyrazolopyridine product from step 4 (0.5 mmol) in dichloromethane (2 mL) was added 0.5 mL of trifluoroacetic acid. The mixture was stirred at room temperature for 1 h. The mixture was extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of carboxylic acid (0.1 mmol) and triethylamine (0.12 mmol) in 1 mL of N,N-dimethylformamide was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.12 mmol) followed by Boc-deprotected amine (from step 5, 0.1 mmol). The mixture was stirred at room temperature for 1 h and extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was purified by preparative HPLC to afford a corresponding compound.
Using benzylamine and 1-(1-boc-piperidin-4-yl)-pyrazol-4-yl)boronic acid pinacol ester in place of 1-methylpyrazole-4-boronic acid pinacol ester, the title compound was obtained as described in general method M. MS (ESI, m/z): 374.20 [M+H]+
Using (R)-1-benzylpyrrolidin-3-amine and 1-(1-boc-piperidin-4-yl)-pyrazol-4-yl)boronic acid pinacol ester, in place of 1-methylpyrazole-4-boronic acid pinacol ester, the title compound was obtained as described in general method M. MS (ESI, m/z): 443.26 [M+H]+
Using 2-phenylethan-1- and 1-(1-boc-piperidin-4-yl)-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method M. MS (ESI, m/z): 388.22 [M+H]+
Using (1S,2S)-2-(benzyloxy)cyclopentan-1-amine and 1-(1-boc-piperidin-4-yl)-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described in general method M. MS (ESI, m/z): 458.26 [M+H]+
Using (1R,2R)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 389.20 [M+H]+
Using (1R,2S)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 389.20 [M+H]+
Using (1R,2R)-2-(benzyloxy)cyclohexan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 403.22 [M+H]+
Using (3R,4S)-4-(benzyloxy)tetrahydrofuran-3-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 391.18 [M+H]+
Using 3-(benzyloxy)cyclohexan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 403.22 [M+H]+
Using 3-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 389.20 [M+H]+
Using (1S,2S)-2-((benzyloxy)methyl)cyclopentan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 403.22 [M+H]+
Using tert-butyl (3R,4S)-3-amino-4-((benzyloxy)methyl)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method M. MS (ESI m/z): 404.21 [M+H]+
Using tert-butyl (3S,4S)-3-amino-4-(benzyloxy)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method M. MS (ESI, m/z): 390.20 [M+H]+
Using 1-methylpyrazole-4-boronic acid pinacol ester and tert-butyl (3R,4R)-3-amino-4-(benzyloxy)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method M. MS (ESI, m/z): 390.20 [M+H]+
Using (1S,2S)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described in general method M. MS (ESI, m/z): 389.20 [M+H]+
Using tert-butyl (3R,4R)-3-amino-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidine-1-carboxylate, the title compound was obtained as described in general method M. MS (ESI, m/z): 432.24 [M+H]+
Using 4-(5-methylthiophen-2-yl)benzoic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 484.18 [M+H]+
Using [1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 464.21 [M+H]+
Using 2′-chloro-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 498.17 [M+H]+
Using 4-bromobenzoic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 466.09 [M+H]+
Using 4′-phenoxy-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 556.24 [M+H]+
Using 4′-(4-aminophenoxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 571.25 [M+H]+
Using 4-(1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 519.3 [M+H]+
Using 4-phenoxybenzoic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 480.2 [M+H]+
Using 4′-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 563.3 [M+H]+
Using 4′-(morpholinomethyl)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 563.3 [M+H]+
Using 4′-((4-methylpiperazin-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylic acid, the title compound was obtained as described in general method M. MS (ESI, m/z): 576.3 [M+H]+
To the aniline (0.5 mmol) and triethylamine (0.105 mL, 0.75 mmol) in 1.5 mL of 1,4-dioxane was added phenyl chloroformate (0.078 g, 0.5 mmol). The mixture was stirred at room temperature for 1 h and then concentrated in vacuo. To a mixture of the crude carbamate and triethylamine (0.105 mL, 0.75 mmol) in 1.5 mL of N,N-dimethylformamide was added tert-butyl (R)-pyrrolidin-3-ylcarbamate (0.093 g, 0.5 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. To a mixture of crude urea in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL) and stirred at room temperature for overnight. The mixture was extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of isocyanate (0.5 mmol) and triethylamine (0.105 mL, 0.75 mmol) in 1.5 mL of N,N-dimethylformamide was added tert-butyl (R)-pyrrolidin-3-ylcarbamate (0.093 g, 0.5 mmol). The reaction mixture was stirred at room temperature for 3 h, cooled to room temperature. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. To a mixture of crude urea in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL). The mixture was allowed to stir overnight and extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification
To a suspension of N,N′-carbonyldiimidazole (CDI, 60.0 mmol) in tetrahydrofuran (100 mL) was added tert-butyl (R)-pyrrolidin-3-ylcarbamate (55.0 mmol). The mixture was refluxed for 16 h. Removal of solvent under vacuum gave a viscous oil, which was dissolved in CH2Cl2 (100 mL) and washed with water (2×100 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield the carbamoylimidazole.
To a solution of carbamoylimidazole (8.00 mmol) in acetonitrile (15 mL) was added methyl iodide (32.0 mmol). The mixture was stirred at rt for 24 h. The solvent was removed under vacuum to yield the carbamoylimidazolium salt.
To a solution of carbamoylimidazolium salt (1.00 mmol) in acetonitrile (6 mL) was added the phenol (1.00 mmol) and triethylamine (1.00 mmol). The reaction was refluxed overnight. The solvent was removed under vacuum and the residue was dissolved in CH2Cl2 (15 mL) and 0.1 M HCl (15 mL) was added. The aqueous layer was extracted with CH2Cl2 (3×15 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to yield carbamate.
Alternatively, to a solution of carbamoylimidazolium salt (2.00 mmol) and alcohol (2.00 mmol) in tetrahydrofuran/N,N-dimethylformamide (2:1, 12 mL) was added portionwise NaH (2.20 mmol, 80% in mineral oil). The solution was stirred at rt for 1 day. H2O (10 mL) and Et2O (20 mL) were added, and the organic layer was washed with H2O (2×10 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The oil was purified by flash column chromatography (CH2Cl2) to yield carbamate.
To a mixture of crude carbamate in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL) and stirred at room temperature for overnight. The mixture was extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of 3-bromoaniline (0.172 g, 1 mmol) and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester (0.474 g, 1.5 mmol) in 3 mL of 1,4-dioxane/water (3/1) was added K2CO3 (0.276 g, 2 mmol) followed by Pd(PPh3)4(0.05 mmol). The reaction mixture was heated at 100° C. for 3 h, cooled to room temperature. The mixture was extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of the crude aniline in dichloromethane (5 mL) was added triethylamine (0.210 mL, 1.5 mmol) followed by di-2-pyridyl thionocarbonate (0.255 mg, 1.1 mmol). The reaction mixture was stirred room temperature for 3 h and to the reaction mixture was added tert-butyl (R)-pyrrolidin-3-ylcarbamate (0.186 mg, 1.0 mmol). The mixture was allowed to stir overnight and extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of crude product in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL) and stirred at room temperature for overnight. The mixture was extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a suspension of tert-butyl (R)-pyrrolidin-3-ylcarbamate (0.186 mg, 1.0 mmol), 4-bromotoluene (0.171 mg, 1 mmol), 2,2′-BIS(DIPHENYLPHOSPHINO)-1,1′-BINAPHTHYL (60 mg, 10 mol %) and sodium tert-butoxide (190 mg, 2.0 mmol) in 1,4-dioxane was added palladium(II) acetate (20 mg, 10 mol %) under nitrogen atmosphere. The mixture was heated at reflux and allowed to stir overnight. After being cooled to ambient temperature, the mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. To a mixture of crude compound in dichloromethane (3 mL) was added trifluoroacetic acid (0.5 mL). The mixture was allowed to stir overnight and extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of tert-butyl (R)-pyrrolidin-3-ylcarbamate (50 mg, 0.27 mmol) in 1,2-dichloroethane (1.5 mL) was added benzaldehyde (0.055 mL, 0.54 mmol) followed by NaBH(OAc)3 (171 mg, 0.81 mmol). The mixture was stirred at room temperature for 4 h and then water was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. To a mixture of crude compound in dichloromethane (3 mL) was added trifluoroacetic acid (0.5 mL). The mixture was allowed to stir overnight and extracted with UCT SPE CUBCX cartridge. The extract was concentrated in vacuo and the crude product was used for the next step without further purification.
To a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.65 g, 2.61 mmol) and triethylamine (1.09 mL, 7.83 mmol) in N,N-dimethylformamide (13 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.0 g, 2.61 mmol) followed by Intermediate 3 (1.0 g, 2.61 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silica gel column chromatography (5% methanol/CH2Cl2) to give 1.0 g off-white solid. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.35 (s, 6H) 1.36 (s, 6H) 2.04-2.21 (m, 1H) 2.24-2.41 (m, 1H) 3.48 (td, J=10.56, 5.28 Hz, 0.5H) 3.56-3.75 (m, 2H) 3.79-3.90 (m, 1H) 3.93 (d, J=5.28 Hz, 3H) 3.99 (dd, J=12.91, 7.04 Hz, 0.5H) 4.47-4.54 (m, 0.5H) 4.65-4.71 (m, 0.5H) 7.47-7.56 (m, 2H) 7.79-7.86 (m, 2H) 7.96 (d, J=15.85 Hz, 1H) 8.24 (br d, J=4.11 Hz, 1H) 8.25-8.34 (m, 1H) 8.41 (dd, J=8.22, 1.17 Hz, 0.5H) 8.71 (d, J=3.52 Hz, 0.5H). MS (ESI, m/z): 517.3 [M+H]+
To a mixture of Intermediate 6 (30 mg, 0.058 mmol) and 4-(4-bromophenoxy)-2-chloropyridine (17 mg, 0.058 mmol) in 0.4 mL of 1,4-dioxane/water (3/1) was added K2CO3 (24 mg, 0.17 mmol) followed by Pd(PPh3)4(3.4 mg, 0.003 mmol). The reaction mixture was heated at 100° C. for 3 hrs, cooled to room temperature, and extracted with ethyl acetate, dried over anhydrous MgSO4 and concentrated under vacuum. The crude residue was purified by preparative HPLC to afford 20 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.25 (m, 1H) 2.29-2.45 (m, 1H) 3.57 (br d, J=11.15 Hz, 0.5H) 3.69 (br d, J=10.56 Hz, 1H) 3.77 (br s, 1H) 3.86 (br s, 0.5H) 3.94 (br s, 3H) 3.96-4.07 (m, 1H) 4.56 (br s, 0.5H) 4.66-4.75 (m, 0.5H) 6.96 (br s, 1H) 6.98 (s, 1H) 7.26 (br s, 2H) 7.59-7.70 (m, 2H) 7.71-7.81 (m, 4H) 7.89 (br d, J=18.19 Hz, 1H) 8.04 (br d, J=17.02 Hz, 1H) 8.18-8.26 (m, 2H) 8.60-8.73 (m, 1H); MS (ESI, m/z): 594.2 [M+H]+
Using 4-(4-bromo-3-chlorophenoxy)aniline, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.11-2.26 (m, 1H) 2.29-2.46 (m, 1H) 3.59 (dd, J=11.15, 5.28 Hz, 0.5H) 3.66-3.74 (m, 1H) 3.74-3.83 (m, 1H) 3.84-3.91 (m, 0.5H) 3.94 (d, J=4.70 Hz, 3H) 3.96-4.06 (m, 1H) 4.58 (br t, J=5.87 Hz, 0.5H) 4.68-4.74 (m, 0.5H) 7.07 (ddd, J=8.36, 6.31, 2.35 Hz, 1H) 7.18 (dd, J=5.87, 2.35 Hz, 1H) 7.20-7.27 (m, 2H) 7.42 (t, J=8.22 Hz, 1H) 7.45 (dd, J=9.10, 2.64 Hz, 2H) 7.53 (t, J=8.51 Hz, 2H) 7.65 (dd, J=14.67, 8.22 Hz, 2H) 7.91 (d, J=16.43 Hz, 1H) 8.06 (d, J=15.26 Hz, 1H) 8.24 (dd, J=18.78, 1.76 Hz, 1H) 8.64-8.75 (m, 1H); MS (ESI, m/z): 608.2 [M+H]+
Using 3-(4-bromo-3-chlorophenoxy)aniline, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.11-2.25 (m, 1H) 2.31-2.46 (m, 1H) 3.60 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.71 (br dd, J=13.21, 4.99 Hz, 1H) 3.76-3.84 (m, 1H) 3.86-3.92 (m, 0.5H) 3.96 (d, J=4.11 Hz, 3H) 3.98-4.07 (m, 1H) 4.57-4.62 (m, 0.5H) 4.70-4.76 (m, 0.5H) 7.03-7.07 (m, 1H) 7.09-7.17 (m, 3H) 7.23 (dd, J=4.11, 2.35 Hz, 1H) 7.43-7.47 (m, 1H) 7.49-7.58 (m, 3H) 7.67 (dd, J=12.03, 7.92 Hz, 2H) 7.92 (d, J=17.02 Hz, 1H) 8.07 (d, J=14.67 Hz, 1H) 8.26 (dd, J=17.61, 1.76 Hz, 1H) 8.65-8.76 (m, 1H); MS (ESI, m/z): 608.2 [M+H]+
Using 4-(4-bromophenoxy)pyridine, the title compound was obtained as described in general method U. MS (ESI, m/z): 560.2 [M+H]+
Using N-(4-bromophenyl)-1H-indol-5-amine, the title compound was obtained as described in general method U. MS (ESI, m/z): 597.3 [M+H]+
Using 4-(4-bromophenoxy)phenol, the title compound was obtained as described in general method U. MS (ESI, m/z): 642.3 [M+H]+
Using 2-(4-bromophenyl)propan-2-amine, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.76 (d, J=3.52 Hz, 6H) 2.05-2.24 (m, 1H) 2.25-2.44 (m, 1H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.82 (m, 1H) 3.82-3.88 (m, 0.5H) 3.93 (d, J=4.70 Hz, 3H) 3.94-4.06 (m, 1H) 4.52-4.58 (m, 0.5H) 4.66-4.72 (m, 0.5H) 6.81 (br t, J=8.80 Hz, 2H) 7.40-7.54 (m, 2H) 7.59-7.68 (m, 2H) 7.71-7.80 (m, 2H) 7.89 (d, J=18.78 Hz, 1H) 8.05 (d, J=17.02 Hz, 1H) 8.22 (dd, J=19.96, 1.76 Hz, 1H) 8.67 (dd, J=46.37, 1.76 Hz, 1H); MS (ESI, m/z): 524.4 [M+H]+
Using 3-(4-bromophenoxy)pyridine, the title compound was obtained as described in general method U. MS (ESI, m/z): 560.2 [M+H]+
Using 4-bromo-N-methyl-N-(4-nitrophenyl)aniline, the title compound was obtained as described in general method U. MS (ESI, m/z): 617.3 [M+H]+
Using N-(4-bromophenyl)-2-fluoro-N-methyl-4-nitroaniline, the title compound was obtained as described in general method U. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.26-2.48 (m, 1H) 3.46 (d, J=2.35 Hz, 3H) 3.58 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.63-3.73 (m, 1H) 3.76 (br dd, J=11.15, 7.24 Hz, 1H) 3.86 (br d, J=7.43 Hz, 0.5H) 3.94 (d, J=3.91 Hz, 3H) 3.96-4.08 (m, 1H) 4.51-4.61 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.12 (br dd, J=8.41, 4.50 Hz, 2H) 7.37 (td, J=8.61, 2.35 Hz, 1H) 7.54-7.66 (m, 4H) 7.66-7.75 (m, 2H) 7.90 (d, J=13.30 Hz, 1H) 7.98 (br d, J=12.13 Hz, 1H) 8.01-8.12 (m, 2H) 8.23 (dd, J=14.87, 1.96 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 635.3 [M+H]+
Using N-(4-bromophenyl)-N,2-dimethyl-4-nitroaniline, the title compound was obtained as described in general method U. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.10-2.20 (br s, 1H) 2.16 (d, J=3.13 Hz, 3H) 2.35-2.40 (m, 1H) 3.36 (d, J=3.52 Hz, 3H) 3.52-3.61 (m, 0.5H) 3.62-3.70 (m, 1H) 3.75 (br t, J=7.04 Hz, 1H) 3.80-3.88 (m, 0.5H) 3.88-3.95 (m, 3H) 3.95-4.02 (m, 1H) 4.52 (br s, 0.5H) 4.67 (br s, 0.5H) 6.77 (dd, J=8.41, 5.67 Hz, 2H) 7.38 (dd, J=8.61, 3.91 Hz, 1H) 7.51-7.71 (m, 6H) 7.86 (d, J=13.69 Hz, 1H) 8.00 (d, J=12.91 Hz, 1 H) 8.07-8.17 (m, 2H) 8.23 (dd, J=14.48, 1.56 Hz, 1H) 8.44 (s, 1H); MS (ESI, m/z): 631.3 [M+H]+
Using N-(4-bromophenyl)-2-chloro-N-methyl-4-nitroaniline, the title compound was obtained as described in general method U. 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.23 (m, 1H) 2.25-2.44 (m, 1H) 3.39 (d, J=3.52 Hz, 3H) 3.57 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.67 (br dd, J=13.50, 4.89 Hz, 1H) 3.76 (br t, J=6.85 Hz, 1H) 3.81-3.89 (m, 0.5H) 3.92-3.96 (m, 3H) 3.96-4.03 (m, 1H) 4.50-4.58 (m, 0.5H) 4.65-4.71 (m, 0.5H) 6.88 (dd, J=8.41, 6.06 Hz, 2H) 7.50-7.73 (m, 7H) 7.89 (d, J=14.09 Hz, 1H) 8.04 (d, J=13.30 Hz, 1H) 8.14-8.29 (m, 2H) 8.33 (t, J=2.35 Hz, 1H) 8.59-8.75 (m, 1H); MS (ESI, m/z): 651.2 [M+H]+
Using 4-(4-bromobenzyl)piperidine, the title compound was obtained as described in general method U. MS (ESI, m/z): 564.3 [M+H]+
Using 4-(4-bromo-2-chlorophenoxy)phenol, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.21 (m, 1H) 2.28-2.43 (m, 1H) 3.55 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.64-3.71 (m, 1H) 3.71-3.79 (m, 1H) 3.82-3.90 (m, 0.5H) 3.93 (d, J=5.28 Hz, 3H) 3.95-4.04 (m, 1H) 4.52-4.57 (m, 0.5H) 4.66-4.72 (m, 0.5H) 6.80 (br d, J=7.63 Hz, 2H) 6.84-6.94 (m, 3H) 7.47-7.52 (m, 1H) 7.62 (dd, J=14.09, 8.22 Hz, 2H) 7.65-7.71 (m, 2H) 7.75 (dd, J=7.63, 2.35 Hz, 1H) 7.89 (d, J=18.19 Hz, 1H) 8.03 (d, J=17.02 Hz, 1H) 8.22 (dd, J=19.37, 1.76 Hz, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 609.2 [M+H]+
Using 4-(4-bromophenoxy)-1-methylpiperidine, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.89 (br d, J=10.56 Hz, 1H) 2.06-2.21 (m, 2H) 2.22-2.36 (m, 2H) 2.36-2.42 (m, 1H) 2.90 (s, 3H) 3.18 (br t, J=12.91 Hz, 1H) 3.31-3.45 (m, 2.5H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.61 (br d, J=12.33 Hz, 0.5H) 3.67 (br dd, J=13.21, 4.40 Hz, 1H) 3.72-3.81 (m, 1H) 3.81-3.89 (m, 0.5H) 3.93 (d, J=4.70 Hz, 3H) 3.94-4.02 (m, 1H) 4.51-4.58 (m, 0.5H) 4.59-4.66 (m, 0.5H) 4.66-4.72 (m, 0.5H) 4.79-4.85 (m, 0.5H) 7.03-7.14 (m, 2H) 7.56-7.70 (m, 6H) 7.89 (d, J=18.19 Hz, 1H) 8.04 (d, J=16.43 Hz, 1H) 8.22 (dd, J=19.37, 1.76 Hz, 1H) 8.62-8.72 (m, 1H); MS (ESI, m/z): 580.3 [M+H]+
Using tert-butyl (4-(4-bromophenoxy)cyclohexyl)carbamate and trifluoroacetic acid, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.74 (br d, J=14.09 Hz, 2H) 1.80-1.89 (m, 4H) 2.07-2.22 (m, 3H) 2.28-2.43 (m, 1H) 3.17-3.25 (m, 1H) 3.57 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.62-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.80-3.89 (m, 0.5H) 3.94 (d, J=4.70 Hz, 3H) 3.95-4.03 (m, 1H) 4.52-4.58 (m, 0.5H) 4.65-4.75 (m, 1.5H) 7.05 (dd, J=8.51, 4.40 Hz, 2H) 7.56-7.69 (m, 6H) 7.90 (d, J=18.19 Hz, 1H) 8.05 (d, J=16.43 Hz, 1H) 8.24 (dd, J=18.78, 1.76 Hz, 1H) 8.61-8.73 (m, 1H); MS (ESI, m/z): 580.3 [M+H]+
Using 4-(4-bromophenoxy)benzaldehyde, the title compound was obtained as described in general method U. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.24 (m, 1H) 2.28-2.43 (m, 1H) 3.56 (br dd, J=11.15, 4.70 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.76 (br dd, J=10.86, 7.34 Hz, 1H) 3.82-3.90 (m, 10.5H) 3.93 (d, J=5.28 Hz, 3H) 3.95-4.03 (m, 1H) 4.52-4.57 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.02 (dd, J=8.80, 3.52 Hz, 2H) 7.07 (dd, J=8.80, 5.28 Hz, 2H) 7.43 (dd, J=8.22, 1.76 Hz, 2H) 7.59-7.76 (m, 6H) 7.89 (d, J=18.78 Hz, 1H) 8.04 (d, J=18.19 Hz, 1H) 8.14-8.26 (m, 1H) 8.60-8.74 (m, 1H); MS (ESI, m/z): 587.2 [M+H]+
Using 4-(4-bromophenoxy)benzoic acid, the title compound was obtained as described in general method U. MS (ESI, m/z): 603.2 [M+H]+
Using 5-(4-bromophenoxy)pyridin-2-amine, the title compound was obtained as described in general method U. MS (ESI, m/z): 575.2 [M+H]+
Using 5-(4-bromophenoxy)-2H-tetrazole, the title compound was obtained as described in general method U. MS (ESI, m/z): 551.2 [M+H]+
Using N-(4-bromophenyl)benzene-1,4-diamine, the title compound was obtained as described in general method U. MS (ESI, m/z): 573.3 [M+H]+
Using 4-(4-bromo-3-chlorophenoxy)benzaldehyde, the title compound was obtained as described in general method U. MS (ESI, m/z): 621.2 [M+H]+
To a mixture of 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-2-naphthoic acid (80 mg, 0.208 mmol) and triethylamine (0.087 mL, 0.624 mmol) in N,N-dimethylformamide (1 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (79 mg, 0.028 mmol) followed by Intermediate 3 (67 mg, 0.028 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified through silica gel column chromatography (trieithylamine/methanol/CH2Cl2 0.5/4.5/95) to give 0.1 g off-white solid. The isolated compound was dissolved in of 4:1 dichloromethane/trifluoroacetic acid (1 mL) and stirred at rt for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 80 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.68-1.82 (m, 2H) 2.07-2.24 (m, 1H) 2.30 (br d, J=13.50 Hz, 2H) 2.29-2.40 (m, 1H) 3.19 (br t, J=12.03 Hz, 2H) 3.47 (br d, J=12.91 Hz, 2H) 3.62 (br dd, J=10.86, 4.99 Hz, 0.5H) 3.69 (br dd, J=12.91, 4.70 Hz, 0.5H) 3.73-3.90 (m, 3H) 3.94 (d, J=5.87 Hz, 3H) 4.02 (dd, J=12.03, 6.75 Hz, 1H) 4.50-4.57 (m, 0.5H) 4.67-4.74 (m, 0.5H) 6.91 (br d, J=6.46 Hz, 1H) 6.97-7.09 (m, 1H) 7.49 (br dd, J=14.67, 8.80 Hz, 1H) 7.59-7.71 (m, 2H) 7.84-7.94 (m, 2H) 8.00-8.08 (m, 1H) 8.24 (s, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 539.3 [M+H]+
To a mixture of Example 816 (30 mg, 0.056 mmol) and potassium carbonate (15 mg, 0.111 mmol) in methanol (0.5 mL) was added 2-bromoethanol (5.90 μl, 0.084 mmol). The mixture was stirred at 50° C. for 4 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 20 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.69-1.88 (m, 2H) 2.09 (br dd, J=12.03, 6.16 Hz, 1H) 2.19 (dt, J=13.35, 6.53 Hz, 1H) 2.27 (dt, J=13.06, 6.68 Hz, 1H) 2.32-2.42 (m, 1H) 3.13-3.23 (m, 2H) 3.23-3.28 (m, 2H) 3.34-3.54 (m, 2H) 3.62 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.67-3.88 (m, 3.5H) 3.89 (brd, J=4.70 Hz, 2H) 3.92 (d, J=6.46 Hz, 3H) 3.95-4.05 (m, 1H) 4.46-4.55 (m, 0.5H) 4.63-4.71 (m, 0.5H) 6.90 (br d, J=12.33 Hz, 1H) 7.03 (q, J=9.39 Hz, 1H) 7.41-7.52 (m, 1H) 7.58-7.70 (m, 2H) 7.84 (d, J=8.22 Hz, 1H) 7.89 (br d, J=9.98 Hz, 1H) 7.98-8.07 (m, 1H) 8.13-8.25 (m, 1H) 8.57-8.73 (m, 1H); MS (ESI, m/z): 583.3 [M+H]+
Using 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-2-naphthoic acid, the title compound was obtained as described in general method V. MS (ESI, m/z): 553.3 [M+H]+
Using Example 807, the title compound was obtained as described in general method V. MS (ESI, m/z): 608.3 [M+H]+
Using Example 818, the title compound was obtained as described in general method V. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.03 (br d, J=11.15 Hz, 2H) 2.06-2.23 (m, 3H) 2.26-2.43 (m, 1H) 2.98 (br d, J=7.63 Hz, 3H) 3.21 (br t, J=12.62 Hz, 2H) 3.25 (br s, 2H) 3.61 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.68-3.84 (m, 4H) 3.86-3.91 (m, 2.5H) 3.93 (d, J=7.04 Hz, 3H) 4.01 (td, J=13.21, 6.46 Hz, 1H) 4.16-4.30 (m, 1H) 4.49-4.57 (m, 0.5H) 4.65-4.73 (m, 0.5H) 7.23 (br d, J=14.67 Hz, 1H) 7.42 (br t, J=9.10 Hz, 1H) 7.49-7.57 (m, 1H) 7.74 (br dd, J=14.97, 8.51 Hz, 1H) 7.79-7.85 (m, 1H) 7.86-7.91 (m, 1H) 7.91-7.98 (m, 1H) 8.00-8.08 (m, 1H) 8.16-8.27 (m, 1H) 8.59-8.75 (m, 1H); MS (ESI, m/z): 597.3 [M+H]+
Using Example 768, the title compound was obtained as described in general method V. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.97-2.14 (m, 1H) 2.17-2.26 (m, 2H) 2.26-2.35 (m, 2H) 2.37-2.50 (m, 1H) 3.27 (br d, J=5.28 Hz, 1H) 3.32 (d, J=3.52 Hz, 2H) 3.37-3.44 (m, 1H) 3.55 (br d, J=10.56 Hz, 1H) 3.59 (br dd, J=10.56, 4.70 Hz, 0.5H) 3.68-3.84 (m, 3H) 3.86-3.92 (m, 2.5H) 3.94 (d, J=6.46 Hz, 3H) 3.98-4.08 (m, 1H) 4.51-4.57 (m, 0.5H) 4.67-4.74 (m, 0.5H) 4.80 (br d, J=4.70 Hz, 0.5H) 4.97-5.02 (m, 0.5H) 7.21-7.34 (m, 1H) 7.41 (br d, J=4.70 Hz, 1H) 7.58-7.64 (m, 1H) 7.85 (br t, J=9.10 Hz, 1H) 7.87-7.95 (m, 2H) 8.00-8.08 (m, 2H) 8.03-8.03 (m, 1H) 8.24 (dd, J=27.58, 2.35 Hz, 1H) 8.67 (dd, J=59.28, 2.35 Hz, 1H); MS (ESI, m/z): 584.3 [M+H]+
To an oven dried round bottom flask equipped with magnetic stir bar was added Example 681 (1.0 equiv.) and a 1:3 mixture of tetrahydrofuran and methanol, (0.65 M) and then the mixture was cooled to 0° C. Sodium borohydride (NaBH4), (2.0 equiv.) was added portion-wise and the reaction mixture was allowed to warm to room temperature and stirred for 2 hours. The reaction was monitored by TLC. After the complete consumption of the starting material the reaction mixture was quenched with saturated NH4Cl and the solvent volume was reduced under vacuum. The residue left behind was extracted with ethyl acetate (3×30 mL). The organic layer was separated and dried over MgSO4. The solvent was evaporated to yield the allylic alcohol which was used without further purification. To an oven dried round bottom flask equipped with magnetic stir bar was added allylic alcohol (1.0 equiv.), tetrahydrofuran (1.35 M), acetic anhydride (1.2 equiv.), 4-dimethylamino pyridine (DMAP), (0.005 equiv.), and triethylamine (1.8 equiv.). The reaction mixture was stirred at 0° C. for 1 hour and then warmed to room temperature and stirred for 14 hours. The reaction was monitored by TLC. After the complete consumption of the starting material the solvent was removed under vacuum. The residual oil was diluted with ethyl acetate. The organic layer was then washed with water and brine and then dried over MgSO4 to obtain the desired Intermediate 6 which was used without further pwhich was used without further purification. MS (ESI, m z): 503.2 [M+H]b purification. MS (ESI, m/z): 503.2 [M+H]+
To an oven dried round bottom flask equipped with magnetic stir bar was added Intermediate 7 (20 mg, 0.04 mmol), dichloromethane (CH2Cl2), (0.3 mL), tetrakis(triphenylphosphine)palladium(0), (Pd(PPh3)4), (1 mg, 0.03 equiv.) and 1-methylpiperazine (0.05 mL, 005 mmol) under an Argon atmosphere. The reaction mixture was then heated to 40° C. for 16 hours. The reaction was monitored by TLC. After the complete consumption of the starting material the reaction mixture was quenched with NH4OH. The organic layer was then separated, dried over MgSO4 and concentrated to obtain the crude product. The crude residue was purified by preparative HPLC to afford 20 mg of the title compound. 1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.54-1.62 (m, 3H) 2.00-2.06 (m, 0.5H) 2.15-2.22 (m, 0.5H) 2.28-2.44 (m, 1H) 2.92 (d, J=4.11 Hz, 3H) 3.39-3.47 (m, 1H) 3.54-3.66 (m, 1H) 3.69 (s, 8H) 3.71-3.81 (m, 2H) 3.91 (br dd, J=13.21, 7.34 Hz, 0.5H) 3.95 (d, J=1.17 Hz, 3H) 4.01-4.12 (m, 0.5H) 4.62 (br s, 0.5H) 4.65-4.75 (m, 0.5H) 6.20-6.30 (m, 1H) 6.68-6.80 (m, 1H) 7.19-7.27 (m, 1H) 7.32-7.38 (m, 1H) 7.44-7.52 (m, 2H) 7.66-7.73 (m, 1H) 7.76 (s, 1H) 7.85-7.89 (m, 0.5H) 8.04 (d, J=1.76 Hz, 0.5H) 8.37-8.41 (m, 0.5H) 8.58 (s, 0.5H); MS (ESI, m/z): 543.3 [M+H]+
Using 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described in general method W. 1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.48-1.61 (m, 3H) 1.94-2.18 (m, 1H) 2.19-2.37 (m, 1H) 3.20-3.30 (m, 4H) 3.34-3.41 (m, 1H) 3.48-3.55 (m, 1H) 3.56-3.64 (m, 4H) 3.64-3.79 (m, 5H) 3.84-3.89 (m, 2H) 3.90 (d, J=2.35 Hz, 3H) 3.93-4.06 (m, 1H) 4.55 (br dd, J=9.39, 4.70 Hz, 0.5H) 4.60-4.70 (m, 0.5H) 6.15-6.24 (m, 1H) 6.66-6.76 (m, 1H) 7.20-7.30 (m, 1H) 7.33 (dd, J=8.22, 5.87 Hz, 1H) 7.38-7.50 (m, 2H) 7.66 (dd, J=11.44, 3.23 Hz, 1H) 7.72 (d, J=2.35 Hz, 1H) 7.87 (dd, J=7.04, 1.76 Hz, 0.5H) 8.00 (d, J=2.35 Hz, 0.5H) 8.37 (s, 0.5H) 8.54 (s, 0.5H); MS (ESI, m/z): 573.3 [M+H]+
A mixture of Example 400 (30 mg, 0.06 mmol), Pd(PPh3)2Cl2 (2 mg, 5 mol %) and triethylamine (24 μL, 0.17 mmol) in N,N-dimethylformamide (0.5 mL) was degassed with nitrogen and 4-vinylpyridine (9 mg, 0.09 mmol) were added. The mixture was heated at 100° C. for 12 hrs. After cooling, the mixture was partitioned between ethyl acetate and water. The organic layer was separated and washed with water, brine dried over MgSO4 and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 15 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.24 (m, 1H) 2.28-2.47 (m, 1H) 3.53 (dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.71 (m, 1H) 3.71-3.78 (m, 1H) 3.81-3.89 (m, 0.5H) 3.94 (d, J=5.28 Hz, 3H) 3.91-3.95 (m, 0.5H) 4.02 (dd, J=12.91, 7.04 Hz, 0.5H) 4.52-4.58 (m, 0.5H) 4.67-4.72 (m, 0.5H) 7.53 (dd, J=16.43, 7.04 Hz, 1H) 7.65 (dd, J=14.09, 8.22 Hz, 2H) 7.84 (t, J=8.51 Hz, 2H) 7.90 (d, J=17.61 Hz, 1H) 7.95 (dd, J=16.43, 7.04 Hz, 1H) 8.05 (d, J=15.26 Hz, 1H) 8.19-8.30 (m, 3H) 8.64 (d, J=1.76 Hz, 0.5H) 8.72 (d, J=2.35 Hz, 0.5H) 8.72-8.77 (m, 2H); MS (ESI, m/z): 494.2 [M+H]+
Using 2-vinylpyridine, the title compound was obtained as described in general method X. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.09-2.24 (m, 1H) 2.27-2.44 (m, 1H) 3.53 (dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.70 (m, 1H) 3.70-3.79 (m, 1H) 3.81-3.89 (m, 0.5H) 3.91-3.96 (m, 0.5H) 3.94 (d, J=4.70 Hz, 3H) 4.01 (dd, J=12.91, 6.46 Hz, 0.5H) 4.52-4.58 (m, 0.5H) 4.66-4.72 (m, 0.5H) 7.47 (dd, J=16.43, 5.87 Hz, 1H) 7.66 (dd, J=15.26, 8.22 Hz, 2H) 7.82 (t, J=8.80 Hz, 2H) 7.84-7.93 (m, 2H) 7.96 (dd, J=16.43, 7.63 Hz, 1H) 8.05 (d, J=15.85 Hz, 1H) 8.24 (dd, J=17.90, 2.05 Hz, 1H) 8.35-8.40 (m, 1H) 8.49-8.56 (m, 1H) 8.64 (d, J=1.76 Hz, 0.5H) 8.70-8.79 (n, 1.5H); MS (ESI, m/z): 494.2 [M+H]+
Using prop-1-en-2-ylbenzene, the title compound was obtained as described in general method X. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.21 (m, 1H) 2.27 (dd, J=5.87, 1.17 Hz, 3H) 2.29-2.43 (m, 1H) 3.56 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.65-3.72 (m, 1H) 3.72-3.79 (m, 1H) 3.82-3.88 (m, 0.5H) 3.90-4.04 (m, 1H) 3.94 (d, J=4.7 Hz, 3H) 4.52-4.57 (m, 0.5H) 4.66-4.73 (m, 0.5H) 6.85 (br d, J=6.46 Hz, 1H) 7.25-7.31 (m, 1H) 7.35 (td, J=7.63, 2.93 Hz, 2H) 7.43-7.50 (m, 2H) 7.53 (dd, J=7.04, 5.28 Hz, 2H) 7.58 (dd, J=14.67, 8.22 Hz, 2H) 7.85-7.96 (m, 1H) 8.00-8.09 (m, 1H) 8.19-8.27 (m, 1H) 8.62-8.77 (m, 1H); MS (ESI, m/z): 507.2 [M+H]+
Using tert-butyl 4-vinylpiperidine-1-carboxylate and trifluoroacetic acid, the title compound was obtained as described in general method X. 1H NMR (600 MHz, METHANOL-d4) δ ppm 1.31-1.40 (m, 1H) 1.67 (br d, J=13.50 Hz, 1H) 1.77 (br d, J=12.91 Hz, 1H) 2.04-2.22 (m, 2H) 2.28 (br dd, J=12.03, 6.75 Hz, 0.5H) 2.36 (dt, J=13.06, 6.68 Hz, 1H) 2.50-2.58 (m, 0.5H) 2.84 (br d, J=9.98 Hz, 1H) 3.01-3.11 (m, 1H) 3.39-3.47 (m, 1H) 3.52 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.68 (m, 1H) 3.68-3.77 (m, 1H) 3.78-3.86 (m, 0.5H) 3.89-4.01 (m, 1H) 3.93 (d, J=3.52 Hz, 3H) 4.09 (br d, J=11.15 Hz, 1H) 4.50-4.55 (m, 0.5H) 4.64-4.71 (m, 0.5H) 6.28-6.36 (m, 1H) 6.43-6.57 (m, 1H) 7.42-7.58 (m, 4H) 7.89 (d, J=17.02 Hz, 1H) 8.05 (d, J=14.09 Hz, 1H) 8.18-8.28 (m, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 500.3 [M+H]+
Using methyl acrylate, the title compound was obtained as described in general method X. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.07-2.20 (m, 1H) 2.26-2.41 (m, 1H) 3.50 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.60-3.75 (m, 2H) 3.78 (d, J=4.11 Hz, 3H) 3.81-3.88 (m, 0.5H) 3.90 (dd, J=11.15, 6.46 Hz, 0.5H) 3.94 (d, J=4.11 Hz, 3H) 3.99 (br dd, J=12.91, 6.46 Hz, 0.5H) 4.49-4.57 (m, 0.5H) 4.64-4.72 (m, 0.5H) 6.60 (dd, J=16.14, 7.34 Hz, 1H) 7.58 (dd, J=15.26, 8.22 Hz, 1H) 7.63-7.76 (m, 4H) 7.85-7.93 (m, 1H) 8.00-8.08 (m, 1H) 8.17-8.28 (m, 1H) 8.59-8.75 (m, 1H); MS (ESI, m/z): 475.2 [M+H]+
To a stirred slurry of 1-fluoro-3-nitrobenzene (52 mg, 0.37 mmol) and Example 840 (0.1 g, 0.25 mmol) in N,N-dimethylformamide (1.5 mL) was added K2CO3 (68 mg, 0.49 mmol). The mixture was heated to 90° C. overnight. After cooling, the mixture was partitioned between ethyl acetate and water. The organic layer was separated and washed with water, brine dried over MgSO4 and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 80 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.28-2.43 (m, 1H) 3.53-3.58 (m, 0.5H) 3.64-3.71 (m, 1H) 3.71-3.80 (m, 1H) 3.81-3.87 (m, 0.5H) 3.93 (d, J=1.76 Hz, 3H) 3.95-4.02 (m, 1H) 4.52-4.58 (m, 0.5H) 4.66-4.71 (m, 0.5H) 7.15 (t, J=8.80 Hz, 2H) 7.46 (br d, J=8.22 Hz, 1H) 7.60-7.71 (m, 3H) 7.78-7.85 (m, 1H) 7.89 (d, J=14.67 Hz, 1H) 8.00-8.03 (m, 1H) 8.04 (d, J=12.91 Hz, 1H) 8.24 (dd, J=14.67, 2.35 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 528.2 [M+H]+
To a stirred solution of Example 829 (22 mg, 0.042 mmol) in AcOH (0.3 mL) at 0° C. was added zinc powder (27 mg, 0.42 mmol). The mixture was stirred at rt for 2 h. The reaction mixture was filtered and filtrate was concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 15 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.22 (m, 1H) 2.25-2.41 (m, 1H) 3.56 (dd, J=11.15, 5.28 Hz, 0.5H) 3.62-3.69 (m, 1H) 3.70-3.78 (m, 1H) 3.79-3.87 (m, 0.5H) 3.92 (d, J=1.76 Hz, 3H) 3.93-4.03 (m, 1H) 4.50-4.57 (m, 0.5H) 4.63-4.71 (m, 0.5H) 7.05 (dt, J=4.70, 2.35 Hz, 1H) 7.06-7.13 (m, 3H) 7.13-7.17 (m, 1H) 7.51 (td, J=8.22, 5.28 Hz, 1H) 7.59-7.62 (m, 1H) 7.63 (d, J=7.88 Hz, 1H) 7.88 (d, J=12.91 Hz, 1H) 8.04 (d, J=11.15 Hz, 1H) 8.23 (dd, J=12.33, 1.76 Hz, 1H) 8.62-8.75 (m, 1H); MS (ESI, m/z): 498.2 [M+H]+
Using 1-fluoro-4-nitrobenzene, the title compound was obtained as described in general method Y. MS (ESI, m/z): 528.2 [M+H]+
Using Example 831, the title compound was obtained as described in general method Y 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.06-2.23 (m, 1H) 2.26-2.41 (m, 1H) 3.55 (dd, J=11.15, 5.28 Hz, 0.5H) 3.61-3.70 (m, 1H) 3.70-3.78 (m, 1H) 3.78-3.88 (m, 0.5H) 3.93 (s, 3H) 3.94-4.02 (m, 1H) 4.50-4.57 (m, 0.5H) 4.64-4.72 (m, 0.5H) 7.08 (t, J=8.51 Hz, 2H) 7.14-7.24 (m, 2H) 7.42 (d, J=7.60 Hz, 2H) 7.60 (d, J=7.71 Hz, 1H) 7.62 (d, J=8.43 Hz, 1H) 7.89 (d, J=12.91 Hz, 1H) 8.05 (d, J=11.15 Hz, 1H) 8.23 (dd, J=12.33, 2.35 Hz, 1H) 8.62-8.74 (m, 1H); MS (ESI, m/z): 498.2 [M+H]+
Using Example 706 and I-fluoro-4-nitrobenzene, the title compound was obtained as described in general method Y. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.08-2.26 (m, 1H) 2.28-2.47 (m, 1H) 3.59 (br d, J=10.56 Hz, 0.5H) 3.72 (br d, J=11.15 Hz, 1H) 3.80 (br s, 1H) 3.89 (br s, 0.5H) 3.94 (br s, 3H) 3.98-4.11 (m, 1H) 4.56 (br s, 0.5H) 4.69-4.76 (m, 0.5H) 7.17-7.28 (m, 2H) 7.34 (br s, 1H) 7.43 (br s, 2H) 7.64 (br t, J=9.68 Hz, 1H) 7.85 (br s, 1H) 7.87-7.97 (m, 1H) 7.99-8.08 (m, 2H) 8.11 (br d, J=12.91 Hz, 1H) 8.20-8.30 (m, 1H) 8.61-8.78 (m, 1H); MS (ESI, m/z): 548.2 [M+H]+
Using Example 803, the title compound was obtained as described in general method Y 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.08-2.25 (m, 1H) 2.25-2.46 (m, 1H) 3.36 (d, J=2.74 Hz, 3H) 3.59 (br dd, J=10.96, 5.09 Hz, 0.5H) 3.69 (br dd, J=12.72, 4.89 Hz, 1H) 3.72-3.82 (m, 1H) 3.86 (br dd, J=13.11, 7.24 Hz, 0.5H) 3.94 (d, J=3.13 Hz, 3H) 3.96-4.10 (m, 1H) 4.50-4.61 (m, 0.5H) 4.62-4.73 (m, 0.5H) 7.04-7.14 (m, 2H) 7.19 (dd, J=8.41, 4.50 Hz, 2H) 7.26 (br d, J=8.22 Hz, 2H) 7.59-7.75 (m, 5H) 7.90 (d, J=12.13 Hz, 1H) 8.05 (d, J=10.96 Hz, 1H) 8.23 (dd, J=13.30, 1.96 Hz, 1H) 8.61-8.74 (m, 1H); MS (ESI, m/z): 651.2 [M+H]+
Using Example 804, the title compound was obtained as described in general method Y 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.24 (m, 1H) 2.25-2.45 (m, 1H) 3.57 (br dd, J=11.15, 4.89 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.81 (m, 1H) 3.84 (br s, 0.5H) 3.88-3.96 (m, 3H) 3.96-4.05 (m, 1H) 4.48-4.58 (m, 0.5H) 4.63-4.72 (m, 0.5H) 6.82 (br s, 2H) 7.08-7.19 (m, 2H) 7.37 (br d, J=5.09 Hz, 1H) 7.47-7.75 (m, 6H) 7.89 (d, J=12.91 Hz, 1H) 8.04 (d, J=12.13 Hz, 1H) 8.22 (dd, J=14.09, 1.96 Hz, 1H) 8.59-8.73 (m, 1H); MS (ESI, m/z): 605.3 [M+H]+
Using Example 805, the title compound was obtained as described in general method Y 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.97-2.15 (m, 1H) 2.19 (s, 3H) 2.23-2.46 (m, 1H) 3.28 (br s, 3H) 3.58 (br dd, J=11.35, 5.09 Hz, 0.5H) 3.63-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.84 (br dd, J=13.50, 6.85 Hz, 0.5H) 3.92-3.96 (br s, 3H) 3.96-4.10 (m, 1H) 4.51-4.58 (m, 0.5H) 4.64-4.73 (m, 0.5H) 6.62 (br dd, J=8.61, 3.52 Hz, 2H) 7.27-7.43 (m, 3H) 7.45-7.75 (m, 6H) 7.89 (d, J=12.13 Hz, 1H) 8.05 (d, J=11.74 Hz, 1H) 8.23 (br d, J=13.69 Hz, 1H) 8.60-8.74 (n, 1H); MS (ESI, m/z): 601.3 [M+H]+
Using Example 806, the title compound was obtained as described in general method Y 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.06-2.23 (m, 1H) 2.23-2.45 (m, 1H) 3.26 (br s, 3H) 3.57 (br dd, J=11.35, 5.48 Hz, 0.5H) 3.64-3.72 (m, 1H) 3.72-3.80 (m, 1H) 3.80-3.89 (m, 0.5H) 3.93 (d, J=3.52 Hz, 3H) 3.95-4.03 (m, 1H) 4.48-4.58 (m, 0.5H) 4.64-4.72 (m, 0.5H) 6.58-6.71 (m, 2H) 7.14 (br d, J=7.83 Hz, 1H) 7.24-7.39 (m, 2H) 7.48 (brt, J=7.43 Hz, 2H) 7.54-7.73 (m, 4H) 7.89 (br d, J=13.30 Hz, 1H) 8.04 (br d, J=12.91 Hz, 1H) 8.22 (br d, J=14.87 Hz, 1H) 8.60-8.74 (m, 1H); MS (ESI, m/z): 621.2 [M+H]+
Using Example 770, the title compound was obtained as described in general method Y 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.05-2.21 (m, 1H) 2.25-2.41 (m, 1H) 3.55 (br dd, J=11.15, 5.28 Hz, 0.5H) 3.62-3.69 (m, 1H) 3.69-3.77 (m, 1H) 3.79-3.83 (m, 0.5H) 3.88-4.00 (m, 1H) 3.93 (s, 3H) 4.49-4.54 (m, 0.5H) 4.64-4.71 (m, 0.5H) 5.22 (d, J=5.87 Hz, 2H) 7.07 (br t, J=8.51 Hz, 2H) 7.35 (br d, J=4.11 Hz, 1H) 7.51 (br s, 1H) 7.52-7.61 (m, 4H) 7.89 (d, J=14.09 Hz, 1H) 8.05 (d, J=12.33 Hz, 1H) 8.23 (dd, J=13.79, 2.05 Hz, 1H) 8.61-8.73 (m, 1H); MS (ESI, m/z): 512.2 [M+H]+
A mixture of Example 689 (30 mg, 0.05 mmol) in 0.5 mL of 2N NaOH/tetrahydrofuran/methanol (2/2/1) was stirred at rt for 6 hrs. The mixture was neutralized with 2N HCl and partitioned between ethyl acetate and water. The organic layer was separated and washed with water, brine dried over MgSO4 and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 20 mg of the title compound. 1H NMR (600 MHz, METHANOL-d4) δ ppm 2.26 (dt, J=13.06, 6.68 Hz, 1H) 2.80 (ddd, J=13.06, 8.66, 6.46 Hz, 1H) 3.73 (dd, J=10.86, 6.16 Hz, 1H) 3.94 (s, 3H) 4.04 (dd, J=10.86, 6.16 Hz, 1H) 4.60 (t, J=6.46 Hz, 1H) 4.75 (dd, J=8.80, 6.46 Hz, 1H) 7.17 (td, J=8.51, 2.35 Hz, 1H) 7.35 (dd, J=8.80, 2.93 Hz, 1H) 7.41 (dd, J=8.51, 6.16 Hz, 1H) 7.52 (d, J=8.80 Hz, 2H) 7.70 (d, J=8.22 Hz, 2H) 7.91 (s, 1H) 8.05 (s, 1H) 8.21-8.28 (m, 1H) 8.51-8.65 (m, 1H); MS (ESI, m/z): 563.1 [M+H]+
Using Example 842, the title compound was obtained as described in general method Z. MS (ESI, m/z): 485.2 [M+H]+
4-Bromophenol (0.5 mmol) and K2CO3 (1.5 mmol) were added to 3-fluoropyridine (0.5 mmol) in N,N-dimethylformamide (2 mL). The mixture was stirred at 100° C., and after the end of the process the reaction mixture was cooled to room temperature. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate/hexanes) to yield product.
A mixture of 1-bromo-4-iodobenzene (0.5 mmol), 4-nitroaniline (0.5 mmol), Cs2CO3 (1.5 mmol), Pd(OAc)2 (3 mol %) and 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (4.5 mol %) in toluene was heated to reflux for 6 h. After the completion of the reaction, the solvent was removed under reduced pressure, and the residue was extracted with ethyl acetate/water. The collected organic layer was dried over MgSO4 overnight and then filtered to remove MgSO4. After removing the solvent from the filtrate, the residue was purified by silica gel column chromatography (ethyl acetate/hexanes). MeI (1 mmol) was added to 4-bromo-N-(4-nitrophenyl)aniline (0.5 mmol) and K2CO3 (1.5 mmol) in N,N-dimethylformamide (2 mL). The mixture was stirred at 100° C., and after the end of the process the reaction mixture was cooled to room temperature. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate/hexanes) to yield product.
To a mixture of hydroquinone (2 mmol), KOtBu (2 mmol) and 18-crown-6 ether (2 mmol) in dimethyl sulfoxide (2 mL) was added 1-bromo-4-fluorobenzene (0.5 mmol). The mixture was stirred at 100° C. for 24 hr and then water was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate/hexanes) to yield product.
A mixture of 4-bromophenol (0.5 mmol), diisopropyl azodicarboxylate (0.65 mmol) and triphenylphosphine (0.65 mmol) in tetrahydrofuran (2.5 mL) was added 1-methylpiperidin-4-ol (0.6 mmol). The mixture was stirred at rt for 4 hr and then water was added. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified by flash column chromatography (ethyl acetate/hexanes) to yield product.
To a mixture of tert-butyl (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate (1 mol) in tetrahydrofuran (30 mL) was added KOtBu (1M in tetrahydrofuran, 4 mol). The mixture was stirred for 30 min at 50° C. To a stirred mixture was added benzyl bromide (1.1 mol) and stirred for 2 hrs at 50° C. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated in vacuo. The crude product was used for the next step without further purification.
To a mixture of [1,1′-biphenyl]-4-carboxylic acid (1 mol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.1 mol) and triethylamine (3 mol) in N,N-dimethylformamide (30 mL) was added tert-butyl (R)-pyrrolidin-3-ylcarbamate (1 mol). The mixture was stirred for 2 hrs at room temperature. The crude product was purified through silicagel column chromatography (5% methanol/CH2Cl2) to give an off-white solid. To a mixture of product in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL) and stirred at room temperature for overnight. After removing volatiles, the crude product was used for the next step without further purification.
The following compounds were obtained by methods disclosed herein and/or by methods known to one skilled in the art.
Abbreviations: ATP for adenosine triphosphate; EDTA for ethylenediaminetetraacetic acid; DMEM for Dulbecco's Modified Eagle's Medium; FBS for fetal bovine serum; GI50 for half-maximal growth inhibitory concentration; GT for glutamate-tyrosine; HEPES for (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); HTRF for homogeneous time-resolved fluorescence; IC50 for half maximal inhibitory concentration; RPMI for Roswell Park Memorial Institute; and SAR for structure-activity relationship.
For the SAR (structure-activity relationship) and compound screening, LanthaScreen™ TR-FRET (Time-Resolved fluorescence energy transfer) assay was employed using the phospho-tyrosine specific Terbium (Tb)-labelded antibody with a fluorescein labeled poly-GT (glutamate-tyrosine) as a substrate. Upon excitation at 340 nm by UV, the energy from Tb donor of the antibody is transferred to the fluorescein of the phosphorylated poly GT substrate, and fluorescein emits light at 520 nm. The ratio between the intensity of primary emission at 495 nm and that of secondary emission at 520 nm was used to quantify the level of kinase activity. The recombinant proteins of human c-MER and AXL catalytic domains, Fluorescein-labeled poly-GT substrate, Tb-labeled anti-phosphorylated tyrosine antibodies, the kinase assay buffer, and 0.5M EDTA solution were purchased (Life technologies, USA). The TR-FRET assays were carried out in the white low volume 384-well plate (Corning, USA). To measure the compound mediated inhibition of kinase activity, the recombinant kinases were pre-incubated with test compounds for 20 minutes prior to the addition of 200 nM fluorescein labeled poly-GT substrates and 10 uM ATP, and then the reaction was carried out for 1 hour at room temperature. 10 mM EDTA was added to terminate the enzyme reaction, and the level of phosphorylation of poly-GT substrate was determined following 30 min incubation with 2 nM Tb-labeled antibody. The fluorescence intensity was measured with Envision™ plate reader (PerkinElmer, USA).
a++++ for IC50 < 10; +++ for 10 ≤ IC50 < 100; ++ for 100 ≤ IC50 < 1000; + for IC50 ≥ 1000 nM.
For the SAR (structure-activity relationship) and compound screening, HTRF (Homogeneous Time Resolved Fluorescence) kinase activity assay was employed for all MER, AXL and TYRO3 kinases using Cisbio HTRF® KinEASE™-TK kit (Cisbio, USA). The kit includes biotin-labeled TK substrate, streptavidin-XL665, Eu3+-cryptate-labeled TK antibody and HTRF® Detection buffer. There are two main steps in the kinase assay: kinase reaction and detection of phosphorylated substrate. The reaction was carried out in white low volume 384-well plate (Corning, USA) with 25 nL compound in dimethyl sulfoxide in each well. To measure the compound mediated inhibition of kinase activity, 2.5 uL the recombinant kinases were pre-incubated with test compounds for 30 minutes in the kinase reaction buffer (20 mM HEPES pH7.4, 2 mM MnCl2, 10 mM MgCl2, 100 uM Na3VO4, 0.0075% Triton X 100, 0.005% BSA and 1 mM DTT) prior to the addition of 2.5 uL of 1 uM biotin-labeled TK substrates and 10 uM ATP. Then the reaction was stopped after 1 hour incubation at room temperature by adding 5 uL of HTRF® Detection buffer which also contains 0.375 nM Eu3+-cryptate-labeled TK antibody and 0.062 uM streptavidin-XL665(SA-XL665) to allow for detection of the phosphorylated peptide product. After 1h incubation at room temperature, the fluorescence intensity was measured with Envision™ plate reader (PerkinElmer, USA). Upon excitation at 340 nm by UV, the energy from Eu3+ donor of the antibody is transferred to the FRET acceptor XL665, and XL655 emits light at 665 nm. The level of kinase activity was quantified by the HTRF ratio that calculated from the intensity of emission at 665 nm and emission at 620 nm (fluorescence intensity @ 665 nm/fluorescence intensity @ 620 nm×10,000). The recombinant protein of human MER (528-end) was purchased from Carnabio, Japan. The recombinant human AXL (473-end) and TYRO3 (455-end) were purchased from SignalChem, Canada.
a++++ for IC50 < 10; +++ for 10 ≤ IC50 < 100; ++ for 100 ≤ IC50 < 1000; + for IC50 ≥ 1000 nM.
CD8-MerTK is a chimeric fusion protein consisting of the extracellular and transmembrane domains of the human CD8u (amino acids 1 to 209) at its N-terminus and the kinase domain and intracellular parts of MerTK (amino acids 521-994) at its C-terminus. To establish an in cell kinase assay for MerTK kinase, the IL-3 dependent Ba/F3 cells of murine lymphoid origin was transfected with CD8-MerTK. The resulting Ba/F3-CDM line was then validated that Ba/F3-CDM cell proliferation is completely dependent on the activity of MerTK kinase activity when growing in the absence of IL-3. For a routine cellular assay, Ba/F3-CDM cells were seeded at 2,000 cells per well in 384-well cell culture plate containing DMEM/10% FBS culture media and incubated for 24 hours before addition of compounds pre-diluted in culture media. Following compound treatment, cells were further incubated for 48 hours and the proliferation was measured. To discriminate a Ba/F3 growth inhibition by a specific inhibition of MerTK kinase following compound treatment vs growth inhibition due to a non-specific unintended cytotoxicity of compounds, we routinely carried out control sets of Ba/F3 cells in parallel that grown in IL3-supplemented growth media. In the presence of IL-3, the proliferation of Ba/F3 is no longer dependent on the MerTK activity. Cell growth and proliferation was measured with Celltiter-Glo™ system (Promega, USA) according to the manufacturer's instruction. The half-maximal growth inhibitory concentration (GI50) value was calculated with Prism6.0 software (GraphPad, USA).
a++++ for IC50 < 100; +++ for 100 ≤ IC50 < 500; ++ for 500 ≤ IC50 < 1000; + for IC50 ≥ 1000 nM.
Three Ba/F3 cell lines (a murine IL-3 dependent pro-B cell line) expressing BCR fusions to the kinase domains of either MerTK (Ba/F3-MerTK), Axl (Ba/F3-Axl), or Tyro3 (Ba/F3-Tyro3) were purchased from Advanced Cellular Dynamics. The IL-3 independence of all 3 cell lines was confirmed. After thawing, the 3 Ba/F3 cell lines were split and maintained in cell culture media, which consisted of RPMI-1640-HEPES (Thermo-Cat#22400-089) with 1× Glutamax (Thermo-Cat#35050-061) and 10% FBS (Sigma-Cat# F4135 (500 ml), at a cell density range of 0.05×106−1×106 cells/mL 4 days before used in the routine screen. Compound plates were prepared using Nunc™ white 384-well optical bottom plates (ThermoFisher, USA) with compound in 25 nL dimethyl sulfoxide in each well. For routine assays, each of the 3 Ba/F3 cell lines was seeded at 1,000 cells per well with 25 μL of cell culture media directly into 384-well compound plates and incubated for 72 hours. Cell proliferation was then measured by adding 25 μL of Cell Titer Glo 2.0 (Promega, USA). After incubating with Cell Titer Glo at room temperature for 30 mins, the luminescence intensity, which quantifies the cell viability, was measured using an Envision™ plate reader (PerkinElmer, USA). To discriminate a Ba/F3 growth inhibition by specific inhibition of each of the 3 kinases following compound treatment vs growth inhibition due to a non-specific cytotoxicity of compounds, control sets of Ba/F3-Tyro3 cells were routinely carried out in parallel that were grown in IL3-supplemented (0.1 μg/mL) growth media. In the presence of IL-3, the proliferation of the Ba/F3-Tyro3 cells is no longer dependent on the Tyro3 kinase activity.
a++++ for IC50 < 100; +++ for 100 ≤ IC50 < 500; ++ for 500 ≤ IC50 < 1000; + for IC50 ≥ 1000 nM.
Based on the studies conducted and the results obtained so far, it is believed that the following compounds (numbered 1 to 383), including isomers, mixtures of isomer as well as pharmaceutically acceptable salts and solvates thereof, are particularly interesting.
It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the present disclosure, which is defined by the appended claims and their equivalents. Various changes and modifications to the described embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations, or methods, or any combination of such changes and modifications of use of the present disclosure, may be made without departing from the spirit and scope thereof.
This application claims priority to U.S. provisional application Ser. No. 62/406,015 filed Oct. 10, 2016. The disclosure of this priority application is incorporated herein in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/055793 | 10/9/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62406015 | Oct 2016 | US |
